Protein-encoding RNA

By employing an mRNA with a signal peptide having specific N-terminal modifications, the efficiency of protein secretion is enhanced, addressing the limitations of existing expression systems and achieving higher yields and safer therapeutic applications.

JP2024156665APending Publication Date: 2024-11-06VERSAMEB AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024106599
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-11-08
Filing Date
2024-07-02
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Existing methods for increasing the expression and secretion of encoded proteins in cell-free systems, cells, or organisms are inefficient, particularly due to limitations in current expression systems that require adaptation for different cell lines and often result in suboptimal protein yield and secretion.

Method used

The use of an mRNA encoding a protein with a signal peptide, where the N-terminal amino acids 1 to 9 have an average hydrophobicity score greater than 2, and the signal peptide is either heterologous or homologous to the protein, modified by insertions, deletions, and/or substitutions, enhancing protein secretion efficiency.

Benefits of technology

This approach leads to significantly higher protein secretion, up to six times more than with natural homologous signal peptides, reducing the required therapeutic dose and minimizing mRNA-related side effects, making it suitable for controlled release formulations and difficult-to-process tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156665000009
    Figure 2024156665000009
  • Figure 2024156665000010
    Figure 2024156665000010
  • Figure 2024156665000011
    Figure 2024156665000011
Patent Text Reader

Abstract

To provide an mRNA comprising a nucleic acid sequence encoding a protein and signal peptide, as well as a transcription unit, an expression vector or vector for gene therapy comprising the nucleic acid encoding the protein and signal peptide.SOLUTION: Provided herein is an mRNA comprising: from 5' to 3' direction, i) a signal peptide and ii) a nucleic acid sequence encoding a protein, where the N-terminal amino acids from positions 1 to 9 of the signal peptide of an amino acid sequence have an average hydrophobic score of 2.2 or higher calculated according to the Kyte-Doolittle scale; the signal peptide is heterologous to the protein; the signal peptide comprises an amino acid sequence of from 16 to 40 amino acids in length; with the proviso that the protein is not an oxidoreductase.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an mRNA comprising a nucleic acid sequence encoding a protein and a signal peptide, wherein amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide is i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. The present invention relates to an mRNA selected from the group consisting of:

[0002] The invention further relates to an mRNA comprising a nucleic acid sequence encoding i) a protein; and ii) a signal peptide heterologous to said protein, wherein the signal peptide heterologous to said protein is a signal peptide of brain-derived neurotrophic factor (BDNF), and said protein is not an oxidoreductase. The invention also relates to a transcription unit or expression vector comprising a nucleic acid sequence encoding a protein and a signal peptide, wherein amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of more than 2, and the signal peptide is i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. The present invention also relates to a transcription unit or expression vector selected from the group consisting of: a nucleic acid sequence encoding a protein and a signal peptide heterologous to said protein, said signal peptide being the signal peptide of brain-derived neurotrophic factor (BDNF). The present invention also relates to therapeutic compositions and kits comprising the mRNA, and / or the transcription unit or expression vector. The present invention also relates to an mRNA, a transcription unit or expression vector, a therapeutic composition and / or kit for use as a medicament, in particular an mRNA comprising a nucleic acid sequence encoding i) IGF1; and ii) the signal peptide of brain-derived neurotrophic factor (BDNF) for use as a medicament. The present invention also relates to an mRNA and a therapeutic composition thereof for use in a method for treating skeletal muscle injury. [Background technology]

[0003] Up to now, various attempts have been made to increase the yield of expression and secretion of encoded proteins, in particular by using improved expression systems both in vitro and / or in vivo. The methods for increasing expression and secretion generally described in the prior art are conventionally based on the use of expression vectors or cassettes containing specific promoters and corresponding regulatory elements. These expression vectors or cassettes are typically limited to a specific cell system, so these expression systems need to be adapted when used in different cell systems. Such adapted expression vectors or cassettes are then usually transfected into cells, typically treated according to a specific cell line. Therefore, nucleic acid molecules such as mRNAs are selected that can express the encoded protein in target cells mainly by a cell-specific system independent of promoters and regulatory elements specific to a specific cell type. In this context, a distinction can be made between elements that stabilize mRNA and elements that increase the translation efficiency of mRNA. For example, WO02 / 098443 describes mRNAs that are stabilized in a general form and optimized for translation in their coding region. WO02 / 098443 further discloses a method for determining sequence modifications. WO02 / 098443 additionally describes the possibility of substituting adenine and uracil nucleotides in mRNA sequences to increase the guanine / cytosine (G / C) content of the sequence. In this context, WO02 / 098443 generally refers to sequences as base sequences for such modifications, and the modified mRNA encodes at least one biologically active peptide or polypeptide that is translated in the patient to be treated, for example, either without errors, poorly, or with some errors. In a further approach to increase the expression of the encoded protein, WO2007 / 036366 application describes the positive effect of a long poly(A) sequence (especially longer than 120 bp) and the combination of at least two 3' untranslated regions of the beta globin gene on mRNA stability and translation activity.Despite all the advances in the art, efficient expression, and especially efficient secretion, of encoded proteins in cell-free systems, cells or organisms (recombinant expression) remains a challenging task. Summary of the Invention

[0004] The present invention relates to an mRNA comprising a nucleic acid sequence encoding a protein and a signal peptide, wherein amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide is i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. The present invention provides an mRNA selected from the group consisting of:

[0005] The present invention further comprises: i) a protein; and ii) a signal peptide heterologous to said protein An mRNA comprising a nucleic acid sequence encoding The signal peptide heterologous to the protein is a signal peptide of brain-derived neurotrophic factor (BDNF), and the protein is not an oxidoreductase. In particular, the present invention provides an mRNA comprising: i) a protein; and ii) a signal peptide heterologous to said protein An mRNA comprising a nucleic acid sequence encoding The signal peptide heterologous to the protein is the signal peptide of brain-derived neurotrophic factor (BDNF), and the protein is selected from the group consisting of carboxypeptidases; cytokines; extracellular ligands and transporters; extracellular matrix proteins; glucosidases; glycosyltransferases; growth factors; growth factor binding proteins; heparin binding proteins; hormones; hydrolases; immunoglobulins; isomerases; kinases; lyases; metalloenzyme inhibitors; metalloproteases; milk proteins; neuroactive proteins; proteases; protease inhibitors; protein phosphatases; esterases; transferases; and vasoactive proteins.

[0006] The present invention further relates to a transcription unit or expression vector comprising a nucleic acid sequence encoding a protein and a signal peptide, wherein the amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. The present invention provides a transcription unit or expression vector selected from the group consisting of:

[0007] The invention further provides a transcription unit or expression vector comprising a nucleic acid sequence encoding a protein and a signal peptide heterologous to said protein, wherein the signal peptide heterologous to said protein is the signal peptide of brain-derived neurotrophic factor (BDNF), and said protein is not an oxidoreductase.The invention further provides a transcription unit or expression vector comprising a nucleic acid sequence encoding a protein and a signal peptide heterologous to said protein, wherein the signal peptide heterologous to said protein is the signal peptide of brain-derived neurotrophic factor (BDNF), and said protein is selected from the group consisting of carboxypeptidases; cytokines; extracellular ligands and transporters; extracellular matrix proteins; glucosidases; glycosyltransferases; growth factors; growth factor binding proteins; heparin binding proteins; hormones; hydrolases; immunoglobulins; isomerases; kinases; lyases; metalloenzyme inhibitors; metalloproteases; milk proteins; neurostimulatory proteins; proteases; protease inhibitors; protein phosphatases; esterases; transferases; and vasoactive proteins. The present invention further provides a therapeutic composition comprising the above-mentioned mRNA and / or transcription unit or expression vector. The present invention further provides a kit comprising the above-mentioned mRNA, transcription unit or expression vector and / or therapeutic composition, as well as instructions for use, optionally a vector map, optionally a host cell, optionally a medium for culturing the host cell, and / or optionally a selection medium for selecting and culturing the transfected host cell. The present invention further provides the above-mentioned mRNA, transcription unit or expression vector, therapeutic composition or kit for use as a medicament. The present invention further provides an mRNA comprising a nucleic acid sequence encoding i) IGF1; and ii) a signal peptide of brain-derived neurotrophic factor (BDNF) for use as a medicament. The present invention further provides an mRNA or a therapeutic composition containing the mRNA for use in a method for treating skeletal muscle injury.

[0008] The present inventors have surprisingly discovered an mRNA comprising a nucleic acid sequence encoding a protein and a signal peptide, wherein the amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. It has been found that an mRNA selected from the group consisting of: provides more efficient secretion of a protein by cells transfected with this mRNA compared to secretion of the protein by cells transfected with an mRNA encoding the protein and its native homologous signal peptide. In particular, the inventors have surprisingly found that an mRNA comprising a nucleic acid sequence encoding i) a protein; and ii) a BDNF signal peptide heterologous to said protein provides more efficient secretion of a protein by cells transfected with this mRNA compared to the native homologous signal peptide of the protein. The amount of secreted protein is up to 6 times higher compared to an mRNA comprising the same protein and the native homologous signal peptide of the protein. This unexpected discovery is very useful for effectively delivering and expressing an mRNA encoding a desired protein in cells, and obtaining a higher amount of secreted protein than that having the native homologous signal peptide of the protein. The higher amount of secreted protein obtained with the same amount of mRNA provided by the present invention is extremely useful for reducing the therapeutic dose to a dose required for local application to tissues, thereby increasing its safety window against possible mRNA-related side effects. This further makes the application more suitable for formulations and coating of devices for controlled release. This further reduces the risk of mRNA-related immunogenicity, making the application more suitable for tissues that can only be injected in limited volumes or that are previously difficult to treat. The inventors have also found that it allows the effective delivery and expression of mRNA, particularly mRNA encoding human IGF-1, to skeletal muscle, thereby allowing the expression of desired polypeptides in skeletal muscle, providing meaningful functional benefits to the muscle. The mRNA is preferably present in a liquid composition, preferably in naked form. This liquid composition can be delivered directly to skeletal muscle, for example by injection, without the need for any gene transfer vector or carrier for the mRNA, or any method to enhance transfer to the tissue, such as electrotransfer or ultrasound.Furthermore, it has been shown that injection of mRNA into damaged skeletal muscles accelerates the recovery process and results in increased skeletal muscle function. Surprisingly, animals treated with mRNA encoding IGF-1 reached a functional level in the healthy range by 16 days. In contrast, vehicle-treated control animals did not achieve full functional recovery even by day 28. [Brief description of the drawings]

[0009] [Figure 1] 1 DNA and RNA sequences of Cpd.1. (A) shows the DNA sequence of human codon-optimized IGF1 (SEQ ID NO:1) containing its predomain, prodomain and coding domain. The sequence of the predomain (signaling peptide) is shown in italics, the sequence of the prodomain is underlined, the IGF-I coding domain is shown in bold, and the stop codon is shown in bold. (B) illustrates the RNA sequence of the predomain, prodomain and coding domain of human IGF1 (SEQ ID NO:2), in which the uridine is N1-methylpseudouridine. The predomain and prodomain are cleaved upon secretion. [Diagram 2] Figure 2 shows the DNA and RNA sequences of Cpd.2. (A) shows the DNA sequence of human codon-optimized IGF1 (SEQ ID NO:3) containing the IGF2 predomain and the IGF1 prodomain and coding domain. The sequence of the predomain (signaling peptide) is shown in italics, the sequence of the prodomain is underlined, the IGF1 coding domain is shown in bold, and the stop codon is shown in bold. (B) illustrates the RNA sequence of the IGF2 predomain and IGF1 prodomain and coding domain, in which the uridine is N1-methylpseudouridine (SEQ ID NO:4). The predomain and prodomain are cleaved upon secretion. [Diagram 3]Figure 3 shows the DNA and RNA sequences of Cpd.3. (A) shows the DNA sequence of human codon-optimized IGF1 (SEQ ID NO:5) containing the ALB predomain and the IGF1 prodomain and coding domain. The sequence of the predomain (signaling peptide) is shown in italics, the sequence of the prodomain is underlined, the IGF1 coding domain is shown in bold, and the stop codon is shown in bold. (B) illustrates the RNA sequence of the ALB predomain and IGF1 prodomain and coding domain, in which the uridine is N1-methylpseudouridine (SEQ ID NO:6). The predomain and prodomain are cleaved upon secretion. [Figure 4] Figure 2 shows the DNA and RNA sequences of Cpd.4. (A) shows the DNA sequence of human codon-optimized IGF1 (SEQ ID NO: 7) containing the BDNF predomain and the IGF1 prodomain and coding domain. The sequence of the predomain (signaling peptide) is shown in italics, the sequence of the prodomain is underlined, the IGF1 coding domain is shown in bold, and the stop codon is shown in bold. (B) illustrates the RNA sequence of the BDNF predomain and the IGF1 prodomain and coding domain, in which the uridine is N1-methylpseudouridine (SEQ ID NO: 8). The predomain and prodomain are cleaved upon secretion. [Diagram 5] 5 DNA and RNA sequences. (A) shows the DNA sequence of human codon-optimized IGF1 (SEQ ID NO: 9) containing the CXCL12 predomain and the IGF1 prodomain and coding domain. The sequence of the predomain (signaling peptide) is in italics, the sequence of the prodomain is underlined, the IGF1 coding domain is in bold, and the stop codon is in bold. (B) illustrates the RNA sequence of the CXCL12 predomain and the IGF1 prodomain and coding domain (SEQ ID NO: 10), in which the uridine is N1-methylpseudouridine. The predomain and prodomain are cleaved upon secretion. [Figure 6]Figure 1 shows the DNA and RNA sequences of Cpd.6. (A) shows the DNA sequence of human codon-optimized IGF1 (SEQ ID NO: 11) containing a synthetic signaling peptide 1 predomain and an IGF1 prodomain and coding domain. The sequence of the predomain (signaling peptide) is in italics, the sequence of the prodomain is underlined, the IGF1 coding domain is in bold, and the stop codon is in bold. (B) illustrates the RNA sequence of the synthetic signaling peptide 1 predomain and IGF1 prodomain and coding domain (SEQ ID NO: 12) in which the uridine is N1-methylpseudouridine. The predomain and prodomain are cleaved upon secretion. [Figure 7] Figure 1 shows the DNA and RNA sequences of Cpd.7. (A) shows the DNA sequence of human codon-optimized IGF1 (SEQ ID NO: 13) containing the synthetic signaling peptide 2 predomain and the IGF1 prodomain and coding domain. The sequence of the predomain (signaling peptide) is in italics, the sequence of the prodomain is underlined, the IGF1 coding domain is in bold, and the stop codon is in bold. (B) illustrates the RNA sequence of the synthetic signaling peptide 2 predomain and the IGF1 prodomain and coding domain (SEQ ID NO: 14) in which the uridine is N1-methylpseudouridine. The predomain and prodomain are cleaved upon secretion. [Figure 8] Figure 15 shows the DNA sequence of vector pVAX.A120 containing the Cpd.1 insert marked in bold (SEQ ID NO: 15). The Cpd.1 ORF was digested from its original plasmid and subcloned into the vector. [Figure 9] Figure 16 shows the DNA sequence of vector pMA-T containing the Cpd.2 insert marked in bold (SEQ ID NO: 16). The Cpd.2 ORF was digested from its original plasmid and subcloned into the vector. [Figure 10]Figure 17 shows the DNA sequence of vector pMA-T containing the Cpd.3 insert marked in bold (SEQ ID NO: 17). The Cpd.3 ORF was digested from its original plasmid and subcloned into the vector. [Figure 11] Figure 18 shows the DNA sequence of vector pMA-T containing the Cpd.4 insert marked in bold (SEQ ID NO: 18). The Cpd.4 ORF was digested from its original plasmid and subcloned into the vector. [Figure 12] Figure 19 shows the DNA sequence of vector pMA-T containing the Cpd.5 insert marked in bold (SEQ ID NO: 19). The Cpd.5 ORF was digested from its original plasmid and subcloned into the vector. [Figure 13] Figure 2 shows the DNA sequence of vector pMA-RQ containing Cpd.6 marked in bold (SEQ ID NO: 20). The ORF of Cpd.6 was digested from its original plasmid and subcloned into the vector. [Figure 14] Figure 2 shows the DNA sequence of vector pMA-RQ containing Cpd.7 marked in bold (SEQ ID NO: 21). The ORF of Cpd.7 was digested from its original plasmid and subcloned into the vector. [Figure 15] FIG. 2 shows the forward (SEQ ID NO: 22) and reverse primer (SEQ ID NO: 23) sequences used to amplify pMA-T and pMA-RQ plasmids for IVT of mRNA. [Figure 16] Figure 2 shows the gene names, UniProt numbers, codon-optimized DNA and amino acid sequences of the signal peptides of Cpd.1 to Cpd.7, and vectors (SEQ ID NOs: 24 to 37). Note that the signal peptides of Cpd.6 and Cpd.7 are synthetic peptides with no matching known protein sequences in public databases. [Figure 17]Figure 1. Induction of IGF1 secretion from human embryonic kidney cells (HEK293T) by mRNA transfection of Cpd.1–Cpd.7. HEK293T cells were transfected with 2 µg each of Cpd.1–Cpd.7, and secreted IGF1 was measured in cell culture supernatants 24 h later using a specific ELISA. Cpd.4 induced significantly higher IGF1 secretion than Cpd.1 (3.3-fold). Data represent the mean ± standard error of the mean of four replicates. Significance (***, <0.001) was assessed by one-way ANOVA followed by Dunnett's multiple comparison test. [Figure 18] Figure 1 shows the concentration dependence of induction of IGF1 secretion in HEK293T cells after Cpd.1 or Cpd.4 mRNA transfection. Cells were transfected with Cpd.1 or Cpd.4 at various concentrations (0, 0.02, 0.06, 0.2, 0.6 or 2 μg) and secreted IGF1 was measured in cell culture supernatants after 24 h using a specific ELISA. Cpd.4-induced IGF1 secretion was significantly more potent (EC50 0.134 μg) than Cpd.1 (EC50 0.889 μg). Data represent the mean ± standard error of the mean of two replicates. Significance (***, <0.001) was assessed by two-way ANOVA of two curves. [Figure 19] Figure 1. Induction of IGF1 secretion from mouse skeletal muscle cells (C2C12) by mRNA transfection of Cpd.1–Cpd.7. C2C12 cells were transfected with 2 μg each of Cpd.1–Cpd.7, and secreted IGF1 was measured in cell culture supernatants 24 h later using a specific ELISA. Cpd.4 induced significantly higher IGF1 secretion than Cpd.1 (6.1-fold). Data represent the mean ± standard error of the mean of four replicates. Significance (***, <0.001) was assessed by one-way ANOVA followed by Dunnett's multiple comparison test. [Figure 20]Figure 1. Induction of IGF1 secretion from human primary skeletal muscle cells (HSkMCs) by mRNA transfection of Cpd.1 and Cpd.4. HSkMC cells were transfected with 2 μg Cp.1 or Cpd.4 each, and secreted IGF1 was measured in cell culture supernatants after 24 h using a specific ELISA. Cpd.4 induced significantly higher IGF1 secretion than Cpd.1 (3.1-fold). Data represent the mean ± standard error of the mean of three replicates. Significance (**, p<0.01) was assessed by one-way ANOVA followed by Dunnett's multiple comparison test. [Figure 21] Figure 1. Functional recovery of the tibialis anterior (TA) muscle after notexin injury. After notexin injury by intramuscular injection (day 0), two IGF-I mRNA treatments (Cpd.4 (1 μg)) were applied by intramuscular injection on days 1 and 4 (see arrow heads). The control group received vehicle solution. Muscle function was assessed on days 1, 4, 7, 10, 14, 21 and 28 after injury. Data represent the mean ± standard error of the mean (SEM) of 5 mice per group and time point. Asterisks indicate significant differences (p<0.05) between Cpd.4-treated and control groups as assessed by Student's t-test. [Figure 22]Figure 1. Induction of IGF1 secretion from human embryonic kidney cells (HEK293T) by mRNA transfection of Cpd.1 as a control and Cpd.8-Cpd.26. HEK293T cells were transfected with 0.3 µg each Cpd.1 and Cpd.8-Cpd.26 and secreted IGF1 was measured in cell culture supernatants after 24 h using a specific ELISA. IGF1 secretion was normalized to Cpd.1 IGF1 secretion. Cpd.8, 9, 10, 11, 12 and 13 showed reduced IGF1 secretion, whereas Cpd.14, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25 and 26 induced higher IGF1 secretion than Cpd.1 (up to 2.6-fold). Data represent the mean ± standard error of the mean of 2-11 replicates per Cpd. Significance (*, p<0.05; **, p<0.001; ***, <0.001) was assessed by Student's t test for individual Cpd. compared with Cpd.1. [Figure 23] Figure 1. Induction of IGF1 secretion from human hepatocytes (HepG2) by mRNA transfection of Cpd.1 as a control and Cpd.4-Cpd.26. HepG2 cells were transfected with 0.3 µg each Cpd.1 and Cpd.4-Cpd.26 and secreted IGF1 was measured in cell culture supernatants after 24 h using a specific ELISA. IGF1 secretion was normalized to Cpd.1. Cpd.8, 9 and 12 showed a decrease in IGF1 secretion, whereas Cpd.4, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 and 26 induced higher IGF1 secretion than Cpd.1 (up to 8.3-fold). Data represent the mean ± standard error of the mean of 2-4 replicates per Cpd. Significance (**, p<0.01; ***, <0.001) was assessed by Student's t test of individual Cpd. compared with Cpd.1. [Figure 24]Figure 1. Induction of IGF1 secretion from human neuronal cells (IMR32) by mRNA transfection of Cpd.1 as a control and Cpd.4-Cpd.24. IMR32 cells were transfected with 0.3 µg each Cpd.1 and Cpd.4-Cpd.24 and secreted IGF1 was measured in cell culture supernatants after 24 h using a specific ELISA. IGF1 secretion was normalized to Cpd.1. Cpd.4, 14, 15, 16, 17, 20, 22, 23 and 24 induced higher IGF1 secretion than Cpd.1 (up to 2.6-fold). Data represent the mean ± standard error of the mean of two to six replicates per Cpd. Significance (*, p<0.05; ***, <0.001) was assessed by Student's t-test for individual Cpd. compared to Cpd.1. [Diagram 25] Figure 1. Induction of IGF1 secretion from human primary chondrocytes by mRNA transfection of Cpd.1 as a control and Cpd.4-Cpd.25. Chondrocytes were transfected with 0.6 µg each Cpd.1 and Cpd.4-Cpd.25 and secreted IGF1 was measured in cell culture supernatants after 24 h using a specific ELISA. IGF1 secretion was normalized to Cpd.1. Cpd.4, 14, 15, 16, 20, 21, 22, 24 and 25 induced higher IGF1 secretion than Cpd.1 (up to 1.9-fold). Data represent the mean ± standard error of the mean of one to two replicates per Cpd. Significance (*, p<0.05; ***, <0.001) was assessed by Student's t-test for individual Cpd. compared to Cpd.1. [Figure 26]Induction of IGF1 secretion from rat wild-type (A) or SOD1GS93A (B) primary motor neurons by mRNA transfection of Cpd.1 as a control and Cpd.4-Cpd.17. Rat wild-type primary motor neurons were transfected with 0.3 μg each of Cp.1, Cpd.4, Cpd.14 and Cpd.17, and rat SOD1GS93A primary motor neurons were transfected with 0.3 μg each of Cp.1, Cpd.14 and Cpd.17, and secreted IGF1 was measured in cell culture supernatants after 48 h using a specific ELISA. IGF1 secretion was normalized to Cpd.1. Cpd.4, 14 and 17 induced higher IGF1 secretion than Cpd.1 (up to 4.3-fold in wild-type or 9.3-fold in SOD1S93A). Data represent the mean ± standard error of the mean of two replicates per Cpd. Significance was assessed by Student's t-test of individual Cpd. compared to Cpd.1, revealing no statistical difference. [Figure 27] Figure 1. Induction of EPO secretion from human embryonic kidney cells (HEK293T, A), human hepatocytes (HepG2, B) and human lung cancer cells (A549, C) by mRNA transfection of Cpd.27, Cpd.28 or Cpd.29. Cells were transfected with 0.3-0.9 µg Cpd.27, Cpd.28 or Cpd.29 each and secreted EPO was measured in cell culture supernatants after 24 h using specific ELISA. EPO secretion was normalized to Cpd.27. Cpd.28 and 29 induced higher EPO secretion than Cpd.27 in all three cell types analyzed (up to 1.8-fold). Data represent the mean ± standard error of the mean of three to eight replicates per Cpd. Significance (*, p<0.05; ***, <0.001) was assessed by Student's t-test of individual Cpd. compared with Cpd.27. [Figure 28]Figure 1. Induction of INS secretion from human embryonic kidney cells (HEK293T) by mRNA transfection of Cpd.30, Cpd.31 or Cpd.32. Cells were transfected with 0.6 μg Cpd.30, Cpd.31 or Cpd.32 each and secreted INS was measured in cell culture supernatants after 24 h using specific ELISA. INS secretion was normalized to Cpd.30. Cpd.31 and 32 induced higher INS secretion than Cpd.30 (up to 3.9-fold). Data represent the mean ± standard error of the mean of three to five replicates per Cpd. Significance (*, p<0.05; ***, <0.001) was assessed by Student's t-test for individual Cpd. compared to Cpd.30. [Figure 29] Induction of IL4 secretion from human embryonic kidney cells (HEK293T, A), human hepatocytes (HepG2, B), human monocytes (THP-1, C) and human lung cancer cells (A549, D) by mRNA transfection of Cpd.33, Cpd.34 or Cpd.35. Cells were transfected with 0.5-0.6 µg Cpd.33, Cpd.34 or Cpd.35 each and secreted IL4 was measured in cell culture supernatants after 24 h using specific ELISA. IL4 secretion was normalized to Cpd.33. Cpd.34 and 35 induced higher IL4 secretion than Cpd.33 in all three cell types analyzed (up to 2.2-fold). Data represent the mean ± standard error of the mean of three to eight replicates per Cpd. Significance (*, p<0.05; ***, <0.001) was assessed by Student's t-test for individual Cpd. compared with Cpd.33. [Diagram 30]Induction of IL10 secretion from human embryonic kidney cells (HEK293T, A), human hepatocytes (HepG2, B) or human monocytes (THP-1, C) by mRNA transfection of Cpd.36, Cpd.37 or Cpd.38. Cells were transfected with 0.3-0.6 µg Cpd.36, Cpd.37 or Cpd.38 each and secreted IL10 was measured in cell culture supernatants after 24 h using specific ELISA. IL10 secretion was normalized to Cpd.36. Cpd.37 and 38 induced higher IL10 secretion than Cpd.36 in all three cell types analyzed (up to 2.2-fold). Data represent the mean ± standard error of the mean of 4-8 replicates per Cpd. Significance (**, p<0.01; ***, <0.001) was assessed by Student's t-test for individual Cpd. compared with Cpd.36. [Diagram 31] Induction of IGF-1 secretion from human hepatocytes (HepG2, A) and human primary chondrocytes (B) by mRNA transfection of Cpd.39. Cells were transfected with 0.3–0.6 µg Cp.39 each, and secreted IGF1 was measured in cell culture supernatants after 24 h using a specific ELISA. IGF1 secretion was normalized to Cpd.1. Cpd.39 induced higher IGF1 secretion than Cpd.1 in all two cell types analyzed (up to 1.4-fold). Data represent the mean ± standard error of the mean of 4–7 replicates. Significance (**, p<0.01; ***, <0.001) was assessed by Student's t-test for individual Cpd.1 compared to Cpd.39. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The term "RNA" as used herein includes RNA that codes for an amino acid sequence as well as RNA that does not code for an amino acid sequence. Typically, RNA as used herein is coding RNA, i.e., RNA that codes for an amino acid sequence. Such RNA molecules are also referred to as mRNA (messenger RNA) and are single-stranded RNA molecules. Thus, the term "RNA" as used herein preferably refers to mRNA. RNA may be produced by chemical and enzymatic synthetic techniques known to those skilled in the art or by using recombinant technology, or may be isolated from natural sources, or a combination thereof. RNA may optionally contain non-naturally occurring and naturally occurring nucleoside modifications, such as N-terminal nucleotides, also referred to herein as methylpseudouridine. 1 -methylpseudouridine and the like.

[0011] The term "mRNA" (i.e. messenger RNA), as used herein, refers to a polymer constructed from nucleoside phosphate building blocks, mainly including adenosine, cytidine, uridine and guanosine as nucleosides, and containing a coding region that codes for a protein. In the context of the present invention, mRNA shall be understood to mean any polyribonucleotide molecule that, upon entry into a cell, is suitable for the expression of a protein or a fragment thereof or that can be translated into a protein or a fragment thereof. The mRNA of the present invention, comprising a nucleic acid sequence encoding a protein and a signal peptide, shall be understood to mean a polyribonucleotide molecule that, upon entry into a cell, is suitable for inducing the expression and secretion of said protein or a fragment thereof. The mRNA of the present invention is an artificial nucleic acid molecule, i.e. an artificial mRNA. An artificial nucleic acid molecule, e.g. an artificial mRNA, may typically be understood to be a nucleic acid molecule that does not occur in nature, such as a recombinant mRNA. A recombinant mRNA is a preferred mRNA of the present invention. The mRNA contains a ribonucleotide sequence that encodes a protein or a fragment thereof, whose function in or near a cell is generally necessary or beneficial, particularly in the context of healing skeletal muscle injury. The mRNA may contain the sequence of the complete protein or a functional variant thereof. Thus, the nucleic acid sequence of the mRNA of the complete protein usually includes a nucleic acid sequence encoding a signal peptide and a nucleic acid sequence encoding the protein. The mRNA of the present invention includes a nucleic acid sequence encoding the protein and a signal peptide. The nucleic acid sequence encoding the protein may optionally include a pro-domain of the protein, the pro-domain usually being located at the N-terminus of the protein. The protein and the signal peptide are usually encoded by the nucleic acid sequence of the mRNA of the present invention in the order of i) signal peptide and ii) protein from 5' to 3', i.e. the last nucleoside of the coding region of the signal peptide is followed by the first nucleoside of the coding region of the protein, or in the case of a protein containing a pro-domain, the first nucleoside of the coding region of the precursor protein form of the protein.The ribonucleotide sequence may code for a protein or a functional fragment thereof that acts as a factor, inducer, regulator, stimulator or enzyme, where the protein is usually one whose function is required to improve the disorder, in particular skeletal muscle damage. Here, functional variants are understood to mean fragments that may take on the function of a protein in a cell whose function in the cell is required. In addition, the mRNA may also have further functional regions and / or 3' or 5' non-coding regions. The 3' and / or 5' non-coding regions may be regions that naturally flank the protein-coding sequence or an artificial sequence, such as a cap at the 5' end and / or a polyA tail at the 3' end, which contribute to the stabilization of the RNA. The skilled person can determine suitable sequences for this by routine experimentation in each case. The mRNA or DNA used to transcribe the mRNA may be codon-optimized. Preferably, the DNA used in the present invention for transcribing the mRNA of the present invention and the mRNA of the present invention are codon-optimized. Generally, codon optimization refers to the process of modifying a nucleic acid sequence for expression in a host cell of interest by replacing at least one codon (e.g., more than one, more than two, more than three, more than four, more than five, more than ten, more than fifteen, more than twenty, more than twenty-five, more than fifty, or more than one codon) of the native sequence with a codon that is more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Codon frequency tables are readily available, for example, in "codon frequency databases," and these tables can be adapted in a variety of ways. Computer algorithms for codon-optimizing a particular sequence for expression in a particular host cell, such as Gene Forge® (Aptagen, PA) and GeneOptimizer® (ThermoFischer, MA), are also available and are preferred.

[0012] The term "naked RNA" as used herein refers to RNA that is not complexed to any kind of other compound, particularly proteins, peptides, polymers such as cationic polymers, lipids, liposomes, viral vectors, etc. Thus, "naked RNA" means that the RNA is present in a free, uncomplexed form, dispersed molecularly in a solution, for example in a liquid composition. For example, it is not envisaged that "naked RNA" is complexed with lipid and / or polymer carrier systems (e.g., lipid nanoparticles and micelles) / transfection reagents, such as DreamFect™ Gold or (branched) PEI. Thus, compositions that include mRNA, such as the therapeutic compositions of the present invention, do not contain lipid and / or polymer carrier system transfection reagents, such as DreamFect™ Gold or (branched) PEI, for example.

[0013] The terms "nucleic acid sequence", "nucleotide sequence" and "nucleotide acid sequence" are used synonymously herein and have the same meaning herein, preferably referring to DNA or RNA. The terms "nucleic acid sequence", "nucleotide sequence" and "nucleotide acid sequence" are preferably used synonymously with the term "polynucleotide sequence". Preferably, a nucleic acid sequence is a polymer that comprises or consists of nucleotide monomers covalently linked to each other by sugar / phosphate-backbone phosphate diester bonds. The term "nucleic acid sequence" also encompasses modified nucleic acid sequences, such as base-modified, sugar-modified or backbone-modified DNA or RNA.

[0014] The term "open reading frame" as used herein refers to a triplet sequence of several nucleotides that can be translated into a peptide or protein. An open reading frame (ORF) preferably contains at its 5' end an initiation codon, i.e. a combination of three consecutive nucleotides that usually codes for the amino acid methionine (ATG), followed by a region that usually represents a length of a number of three nucleotides. The ORF preferably ends with a stop codon (e.g., TAA, TAG, TGA). This is typically the only stop codon of the open reading frame. Thus, an open reading frame, in the context of the present invention, is a nucleic acid sequence that preferably consists of a number of nucleotides divisible by three, starts with an initiation codon (e.g., ATG) and preferably ends with a stop codon (e.g., TAA, TGA, or TAG). An open reading frame may be isolated or incorporated into a longer nucleic acid sequence, for example in a vector or mRNA. An open reading frame may also be called a "(protein) coding region" or, preferably, a "coding sequence".

[0015] The term "signal peptide", also referred to herein as signal transduction peptide, predomain, signal sequence, targeting signal, localization signal, localization sequence, transit peptide, leader sequence or leader peptide, is a short peptide (usually 16-40 amino acids in length) present at the N-terminus of newly synthesized proteins destined for the secretory pathway. Signal peptides of the invention are preferably 10-50, more preferably 11-45, even more preferably 12-45, most preferably 13-45, particularly 14-45, more particularly 15-45, even more particularly 16-40 amino acids in length. Signal peptides according to the invention are located at the N-terminus of a protein of interest or at the N-terminus of a precursor protein form of the protein of interest. Using a signal peptide according to the invention, a protein of interest can be secreted in an amount at least equal to, and preferably greater than, the amount of said protein secreted using its native (homologous) signal peptide. The signal peptide according to the present invention is usually of eukaryotic origin, e.g. a signal peptide of a eukaryotic protein, preferably of mammalian origin, e.g. a signal peptide of a mammalian protein, more preferably of human origin, e.g. a signal peptide of a mammalian protein. In some embodiments, the heterologous and / or homologous signal peptide to be modified is a naturally occurring signal peptide of a eukaryotic protein, preferably a naturally occurring signal peptide of a mammalian protein, more preferably a naturally occurring signal peptide of a human protein.

[0016] The term "protein" as used herein typically refers to a molecule that includes one or more peptides or polypeptides. A peptide or polypeptide is typically a chain of amino acid residues linked by peptide bonds. A peptide typically includes 2-50 amino acid residues. A polypeptide typically includes more than 50 amino acid residues. A protein typically folds into a three-dimensional form, which may be necessary for the protein to perform its biological function. The term "protein" as used herein includes fragments of proteins and fusion proteins. Preferably, the protein is of mammalian origin, more preferably of human origin, i.e., a human protein. Preferably, the protein is a protein that is normally secreted from cells, i.e., a protein that is secreted from cells in the natural state. The proteins referred to herein are typically selected from the group consisting of carboxypeptidases; cytokines; extracellular ligands and transporters; extracellular matrix proteins; glucosidases; glycosyltransferases; growth factors; growth factor binding proteins; heparin binding proteins; hormones; hydrolases; immunoglobulins; isomerases; kinases; lyases; metalloenzyme inhibitors; metalloproteases; milk proteins; neuroactive proteins; proteases; protease inhibitors; protein phosphatases; esterases; transferases; and vasoactive proteins.

[0017] Carboxypeptidases are proteins that are protease enzymes that hydrolyze (cleave) peptide bonds at the carboxy terminus (C-terminus) of proteins; cytokines are proteins that are secreted and act either locally or systemically as modulators of target cell signaling through receptors on their surface, often involved in immunological responses; extracellular ligands and transporters are proteins that are secreted and act through binding to other proteins or that carry other proteins or other molecules to exert a specific biological function; extracellular matrix proteins are a group of proteins secreted by supporting cells that provide structural and biochemical support to surrounding cells; glucosidases are enzymes involved in breaking down complex carbohydrates such as starch and glycogen into their monomers; glycosyltransferases are enzymes that give rise to natural glycosidic bonds; growth factors are proteins that act as modulators of target cell signaling through receptors on their surface, often involved in trophic responses and survival or cell homeostasis signaling. act either locally or systemically as modulators, secreted proteins capable of stimulating cell growth, proliferation, healing, and cell differentiation; growth factor binding proteins are secreted proteins that bind to growth factors and thereby modulate their biological activity; heparin binding proteins are secreted proteins that interact with heparin to modulate its biological function, often in concert with separate binding to growth factors or hormones; hormones are members of a class of signaling molecules produced by glands in multicellular organisms, secreted and transported by the circulatory system to target distant organs to control physiological functions and behaviors through binding to specific receptors on their target cells; hydrolases are a class of enzymes that biochemically catalyze molecular cleavage by utilizing water to break chemical bonds, resulting in the splitting of larger molecules into smaller molecules; immunoglobulins are large Y-shaped secreted proteins produced primarily by plasma cells and used by the immune system to neutralize pathogens such as bacteria and viruses;Isomerases are a general class of enzymes that convert molecules from one isomer to another, thereby facilitating rearrangements within molecules that break and form bonds;kinases are enzymes that catalyze the transfer of phosphate groups from high-energy phosphate donor molecules to specific substrates;lyases are enzymes that catalyze the breaking of various chemical bonds by means other than hydrolysis and oxidation, often forming new double bonds or new ring structures;metalloenzyme inhibitors are cellular inhibitors of matrix metalloproteases (MMPs);metalloproteases are protease enzymes whose catalytic mechanism involves metal ions;milk proteins are proteins secreted into milk;neurotropic proteins are proteins that act either locally or over a distance to maintain neuronal function, survival, and physiology proteases (also called peptidases or proteinases) are enzymes that carry out protein degradation by hydrolysis of peptide bonds; protease inhibitors are proteins that inhibit the function of proteases; protein phosphatases are enzymes that remove phosphate groups from phosphorylated amino acid residues of their substrate proteins; esterases are enzymes that split esters into acids and alcohols in a chemical reaction with water at amino acid residues; transferases are a class of enzymes that catalyze the transfer of specific functional groups (e.g., methyl or glycosyl groups) from one molecule (called the donor) to another (called the acceptor); vasoactive proteins are secreted proteins that have a biological effect on the function of blood vessels. The carboxypeptidases; cytokines; extracellular ligands and transporters; extracellular matrix proteins; glucosidases; glycosyltransferases; growth factors; growth factor binding proteins; heparin binding proteins; hormones; hydrolases; immunoglobulins; isomerases; kinases; lyases; metalloenzyme inhibitors; metalloproteases; milk proteins; neuroactive proteins; proteases; protease inhibitors; protein phosphatases; esterases; transferases; and vasoactive proteins referred to herein may be found in the UniProt database.

[0018] The terms "fragment" or "fragment of a sequence" have the same meaning herein and are shorter portions of the full-length sequence of a nucleic acid molecule, such as DNA or RNA, or a protein. Thus, a fragment typically comprises or consists of a sequence identical to the corresponding stretch in the full-length sequence. A preferred fragment of a sequence in the context of the present invention comprises or consists of a consecutive stretch of entities, such as nucleotides or amino acids, that correspond to a consecutive stretch of entities in the molecule from which the fragment is derived, and represents at least 5%, usually at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, and most preferably at least 80% of the total (i.e. full-length) molecule from which the fragment is derived.

[0019] The term "heterologous signal peptide to said protein" as used herein refers to a naturally occurring signal peptide that is different from the naturally occurring signal peptide of the protein, i.e. the signal peptide is not from the same gene of the protein. Usually, a heterologous signal peptide to a given protein is a signal peptide from another protein, which is not related to the given protein, i.e. has a different amino acid sequence from the signal peptide of the given protein, for example, a signal peptide from another protein that has a different amino acid sequence from the signal peptide of the given protein by more than 50%, preferably more than 60%, more preferably more than 70%, even more preferably more than 80%, most preferably more than 90%, and especially more than 95%. Preferably, a heterologous signal peptide to a given protein has less than 95%, preferably less than 90%, more preferably less than 80%, even more preferably less than 70%, most preferably less than 60%, and especially less than 50% sequence identity with the amino acid sequence of the naturally occurring (homologous) signal peptide of the given protein. Heterologous sequences may be derived from the same organism, but they do not naturally occur in the same nucleic acid molecule, for example in the same mRNA. The signal peptide heterologous to the protein and the protein to which the signal peptide is heterologous may be from the same or different origins, usually from the same origin, preferably from eukaryotic origin, more preferably from eukaryotic origin of the same eukaryote, even more preferably from mammalian origin, particularly from mammalian origin of the same mammalian organism, even more particularly from human origin. In Example 1, an mRNA is disclosed that comprises a nucleic acid sequence encoding human BDNF signal peptide and human IGF1, i.e., a signal peptide heterologous to the protein, where the signal peptide and the protein are from the same origin, i.e., from human origin.

[0020] The term "signal peptide homologous to said protein" as used herein refers to the naturally occurring signal peptide of the protein. A signal peptide homologous to a protein is a signal peptide encoded by the gene of the protein as it exists in nature. A signal peptide homologous to a protein is usually of eukaryotic origin, e.g. a naturally occurring signal peptide of a eukaryotic protein, preferably of mammalian origin, e.g. a naturally occurring signal peptide of a mammalian protein, more preferably of human origin, e.g. a naturally occurring signal peptide of a human protein.

[0021] The term "naturally occurring amino acid sequence that does not have a function of a signal peptide in nature" as used herein refers to an amino acid sequence that exists in nature and is not identical to the amino acid sequence of any signal peptide that exists in nature. The naturally occurring amino acid sequence that does not have a function of a signal peptide in nature referred to in the present invention is preferably 10 to 50, more preferably 11 to 45, even more preferably 12 to 45, most preferably 13 to 45, particularly 14 to 45, more particularly 15 to 45, even more particularly 16 to 40 amino acids in length. Preferably, the naturally occurring amino acid sequence that does not have a function of a signal peptide in nature according to the present invention is from a eukaryotic source and is not identical to any signal peptide of eukaryotic source, more preferably from a mammalian source and is not identical to any signal peptide of mammalian source, more preferably from a human source and is not identical to any signal peptide of human source that exists in nature. The naturally occurring amino acid sequence that does not have a function of a signal peptide in nature is usually an amino acid sequence of a coding sequence for a protein. A naturally occurring amino acid sequence which does not have the function of a signal peptide in nature according to the present invention is usually of eukaryotic origin, preferably of mammalian origin, more preferably of human origin.

[0022] The terms "naturally occurring," "natural," and "in the natural state" have equivalent meanings as used herein.

[0023] The term "amino acids 1-9 at the N-terminus of a signal peptide amino acid sequence" as used herein refers to the first nine amino acids at the N-terminus of a signal peptide amino acid sequence. Similarly, the term "amino acids 1-7 at the N-terminus of a signal peptide amino acid sequence" as used herein refers to the first seven amino acids at the N-terminus of a signal peptide amino acid sequence, and the term "amino acids 1-5 at the N-terminus of a signal peptide amino acid sequence" as used herein refers to the first five amino acids at the N-terminus of a signal peptide amino acid sequence.

[0024] The term "an amino acid sequence modified by at least one amino acid insertion, deletion and / or substitution" as used herein refers to an amino acid sequence that comprises an amino acid substitution, insertion and / or deletion of at least one amino acid within the amino acid sequence. The term "a signal peptide heterologous to said protein modified by at least one amino acid insertion, deletion and / or substitution" as used herein refers to an amino acid sequence of a naturally occurring signal peptide heterologous to a protein that comprises an amino acid substitution, insertion and / or deletion of at least one amino acid within its naturally occurring amino acid sequence. The term "a signal peptide homologous to said protein modified by at least one amino acid insertion, deletion and / or substitution" as used herein refers to a naturally occurring signal peptide homologous to a protein that comprises an amino acid substitution, insertion and / or deletion of at least one amino acid within its naturally occurring amino acid sequence. The term "naturally occurring amino acid sequence modified by at least one amino acid insertion, deletion and / or substitution" refers to a naturally occurring amino acid sequence that includes an amino acid substitution, insertion and / or deletion of at least one amino acid within its naturally occurring amino acid sequence. "Amino acid substitution" or "substitution" as used herein refers to the replacement of an amino acid with another amino acid at a particular position in a parent protein sequence. For example, the substitution R34K refers to a polypeptide in which an arginine at position 34 is replaced with a lysine. For the aforementioned example, 34K indicates a substitution with a lysine at position 34. For purposes described herein, multiple substitutions are typically separated by a slash. For example, R34K / L78V refers to a double mutant containing the substitutions R34K and L38V. "Amino acid insertion" or "insertion" as used herein refers to the addition of an amino acid at a particular position in a parent protein sequence. For example, insertion-34 represents an insertion at position 34. "Amino acid deletion" or "deletion" as used herein refers to the removal of an amino acid at a particular position in a parent protein sequence. For example, R34- represents a deletion of the arginine at position 34.

[0025] Preferably, the deleted amino acid is an amino acid having a hydrophobicity score of less than -0.8, preferably less than 1.9. Preferably, the replacement amino acid is an amino acid having a hydrophobicity score higher than the hydrophobicity score of the replaced amino acid, more preferably, the replacement amino acid is an amino acid having a hydrophobicity score of 2.8 or more, more preferably, a hydrophobicity score of 3.8 or more. Preferably, the inserted amino acid is an amino acid having a hydrophobicity score of 2.8 or more, more preferably, a hydrophobicity score of 3.8 or more.

[0026] Of a given amino acid sequence, typically 1 to 15, preferably 1 to 11 amino acids, more preferably 1 to 10 amino acids, even more preferably 1 to 9 amino acids, particularly 1 to 8 amino acids, even more particularly 1 to 7 amino acids, even more particularly 1 to 6 amino acids, particularly preferably 1 to 5 amino acids, even more particularly preferably 1 to 4 amino acids, and even more particularly preferably 1 to 2 amino acids have been inserted, deleted and / or substituted. Of a given amino acid sequence, usually 1 to 15, preferably 1 to 11 amino acids, more preferably 1 to 10 amino acids, even more preferably 1 to 9 amino acids, particularly 1 to 8 amino acids, more particularly 1 to 7 amino acids, even more particularly 1 to 6 amino acids, particularly preferably 1 to 5 amino acids, even more particularly preferably 1 to 4 amino acids, and even more particularly preferably 1 to 2 amino acids are inserted, deleted and / or substituted at the N-terminus of the amino acid sequence of the signal peptide, usually within the range of 1 to 11 amino acids, preferably within the range of 1 to 10 amino acids, more preferably within the range of 1 to 9 amino acids, even more preferably within the range of 1 to 8 amino acids, particularly within the range of 1 to 7 amino acids, more particularly within the range of 1 to 6 amino acids, even more particularly within the range of 1 to 5 amino acids, particularly preferably within the range of 1 to 4 amino acids, even more particularly preferably within the range of 1 to 3 amino acids, and even more particularly preferably within the range of 1 to 2 amino acids.

[0027] Preferably, the amino acid sequence is optionally modified by deletion and / or substitution of at least one amino acid.

[0028] Preferably, the average hydrophobicity score of the first 9 N-terminal amino acids of the amino acid sequence of the modified signal peptide is increased by 1.0 unit or more compared to the signal peptide not containing the modification.

[0029] The term "insulin-like growth factor 1", "insulin-like growth factor 1 (IGF1)" or "IGF1" as used herein generally refers to the native sequence of IGF1 protein without signaling peptide and may include propeptide and / or E peptide, preferably without signaling peptide and without E peptide. The term "human insulin-like growth factor 1 (IGF1)" as used herein refers to the native sequence of human IGF1 (pro-IGF1), referred to as UniProtKB-P05019 in the Uniprot database and NM_000618.4, NM_001111285.2 and NM_001111283.2 in the Genbank database, or fragments thereof. The native DNA sequence encoding human insulin-like growth factor 1 may be codon-optimized. The native sequence of human IGF1 comprises or consists of a human signaling peptide having 21 amino acids (nucleotides 1-63), a human propeptide (also called prodomain) having 27 amino acids (nucleotides 64-144), mature human IGF1 having 70 amino acids (nucleotides 145-354) and a C-terminal domain of human IGF1, the so-called E peptide (or E domain). The C-terminal domain of human IGF1 (the so-called E peptide or E domain) comprises the Ea, Eb or Ec domains, which are generated by alternative splicing events. The Ea domain comprises or consists of 35 amino acids (105 nucleotides), the Eb domain comprises or consists of 77 amino acids (231 nucleotides), and the Ec domain comprises or consists of 40 amino acids (120 nucleotides) (see, e.g., Wallis M (2009) New insulin-like growth factor (IGF)-precursor sequences from mammalian genomes: the molecular evolution of IGFs and associated peptides in primates. Growth Horm IGF Res 19(1):12-23. doi:10.1016 / j.ghir.2008.05.001).The term "human insulin-like growth factor 1 (IGF)" as used herein generally refers to the native sequence of human IGF1 protein without signaling peptide and may include propeptide and / or E peptide, preferably without signaling peptide and without E peptide. The term "human insulin-like growth factor 1 (IGF)" as used herein generally includes mature human IGF1. The term "mature protein" refers to a protein that is synthesized in the endoplasmic reticulum and secreted via the Golgi apparatus in cells that express and secrete the protein. The term "mature IGF1" refers to a protein that is synthesized in the endoplasmic reticulum and secreted via the Golgi apparatus in cells that express and secrete IGF1. The term "mature human IGFI" refers to a protein that is synthesized in the endoplasmic reticulum and secreted via the Golgi apparatus in human cells that express and secrete human IGF1, and generally contains the amino acid sequence encoded by the nucleotide sequence shown in SEQ ID NO: 39.

[0030] The term "insulin" or "INS" as used herein generally refers to the native sequence of insulin without signaling peptide. The term "human insulin" or "human INS" as used herein refers to the native sequence of human insulin, which is referred to as UniProtKB-P01308 in the Uniprot database and NM_000207.2, NM_001185097.1, NM_001185098.1 and NM_001291897.1 in the Genbank database, or fragments thereof. The native DNA sequence encoding human insulin may be codon-optimized. The native sequence of human insulin comprises or consists of a human signaling peptide having 24 amino acids (nucleotides 1-72), a human insulin B chain having 30 amino acids (nucleotides 73-163), a human insulin propeptide (also called the connecting peptide or C-peptide) having 31 amino acids (nucleotides 64-144), and a C-terminal domain of the human insulin A chain comprising or consisting of 21 amino acids (nucleotides 64-144). The term "human insulin" as used herein generally includes human insulin without the signaling peptide.

[0031] The term "erythropoietin", "EPO" or "Epo" as used herein generally refers to the native sequence of EPO without the signaling peptide. The term "human erythropoietin", "human EPO" or "human Epo" as used herein generally refers to the native sequence of human erythropoietin, referred to in the Uniprot database as UniProtKB-P01588 and in the Genbank database as NM_000799.2, or fragments thereof. The native DNA sequence encoding human erythropoietin may be codon-optimized. The native sequence of human erythropoietin comprises or consists of a chain encoding a human signaling peptide having 27 amino acids (nucleotides 1-81), a human Epo having 166 amino acids (nucleotides 82-579). The term "human erythropoietin" as used herein generally includes human EPO without the signaling peptide.

[0032] The term "interleukin-4" or "IL4" as used herein generally refers to the native sequence of IL4 without the signaling peptide. The term "human interleukin-4" or "human IL4" as used herein generally refers to the native sequence of human IL4, referred to in the Uniprot database as UniProtKB-P05112, and in the Genbank database as NM_000589.3 and NM_172348.2, or fragments thereof. The native DNA sequence encoding human IL4 may be codon-optimized. The native sequence of human IL4 comprises or consists of a chain encoding a human signaling peptide having 24 amino acids (nucleotides 1-72), a human IL4 having 129 amino acids (nucleotides 73-387). The term "human IL4" as used herein generally includes human IL4 without the signaling peptide.

[0033] The term "interleukin-10" or "IL10" as used herein generally refers to the native sequence of IL10 without the signaling peptide. The term "human interleukin-10" or "human IL10" as used herein generally refers to the native sequence of human IL10, referred to in the Uniprot database as UniProtKB-P22301 and in the Genbank database as NM_000572.2, or fragments thereof. The native DNA sequence encoding human IL10 may be codon-optimized. The native sequence of human IL10 comprises or consists of a chain encoding a human signaling peptide having 18 amino acids (nucleotides 1-54), a human IL10 having 160 amino acids (nucleotides 55-534). The term "human IL10" as used herein generally includes human IL10 without the signaling peptide.

[0034] The term "insulin growth factor 1 (IGF1) signal peptide" or "IGF1 signal peptide", as used herein, refers to the native signal peptide of IGF1, referred to in the Uniprot database as P05019, and in the Genbank database as NM_000618.4, NM_001111284.1 and NM_001111285.2, preferably having the amino acid sequence set forth in SEQ ID NO: 24, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 25.

[0035] The term "insulin growth factor 2 (IGF2) signal peptide" or "IGF2 signal peptide", as used herein, refers to the native signal peptide of IGF2, referred to in the Uniprot database as P01344, and in the Genbank database as NM_000612.5, NM_001007139.5, NM_001127598.2, NM_001291861.2 and NM_001291862.2, preferably having the amino acid sequence set forth in SEQ ID NO: 26 and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 27.

[0036] The term "serum albumin (ALB) signal peptide" or "ALB signal peptide" as used herein refers to the native signal peptide of ALB, referred to in the Uniprot database as P02768 and in the Genbank database as NM_000477.6, preferably having the amino acid sequence set forth in SEQ ID NO: 28 and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 29.

[0037] The term "Brain-derived neurotrophic factor (BDNF)" or "signal peptide of BDNF", as used herein, refers to the native signal peptide of BDNF, referred to in the Uniprot database as P23560, and in the Genbank database as NM_001143805.1, NM_170731.4, NM_170734.3, NM_001143810.1 and NM_001143809.1, preferably having the amino acid sequence set forth in SEQ ID NO: 30, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 31.

[0038] The term "signal peptide of stromal cell-derived factor-1 (CXCL12)" or "signal peptide of CXCL12", as used herein, refers to the native signal peptide of CXCL12, referred to in the Uniprot database as P48061, and in the Genbank database as NM_000609.6, NM_001033886.2, NM_001178134.1, NM_001277990.1 and NM_199168.3, preferably having the amino acid sequence set forth in SEQ ID NO: 32, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 33.

[0039] The term "synthetic signaling peptide 1 (synthetic seq1) signal peptide" or "synthetic seq1 signal peptide" as used herein refers to synthetic signal peptide 1 having the amino acid sequence set forth in SEQ ID NO:34 and / or encoded by the DNA sequence set forth in SEQ ID NO:35.

[0040] The term "synthetic signaling peptide 2 (synthetic seq2) signal peptide" or "synthetic seq1 signal peptide" as used herein refers to synthetic signal peptide 1 having the amino acid sequence set forth in SEQ ID NO:36 and / or encoded by the DNA sequence set forth in SEQ ID NO:37.

[0041] The term "signal peptide of latent transforming growth factor beta binding protein 2 (LTBP2)" or "signal peptide of LTBP2" as used herein refers to the native signal peptide of LTBP2, which is referred to in the Uniprot database as Q14767 and in the Genbank database as NM_000428.2, preferably having the amino acid sequence set forth in SEQ ID NO: 41, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 42.

[0042] The term "signal peptide of the acid-labile subunit of the insulin-like growth factor binding protein complex (IGFALS)" or "IGFALS signal peptide" as used herein refers to the native signal peptide of IGFALS, referred to in the Uniprot database as P35858, and in the Genbank database as NM_001146006.1 and NM_004970.2, preferably having the amino acid sequence set forth in SEQ ID NO: 46, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 47.

[0043] The term "insulin (INS) signal peptide" or "INS signal peptide", as used herein, refers to the native signal peptide of INS, referred to in the Uniprot database as P1308, and in the Genbank database as NM_001185097.1, NM_000207.2, NM_001185098.1 and NM_001291897.1, preferably having the amino acid sequence set forth in SEQ ID NO: 51, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 52.

[0044] The term "erythropoietin (Epo) signal peptide" or "Epo signal peptide" as used herein refers to the native signal peptide of Epo, referred to in the Uniprot database as P01588 and in the Genbank database as NM_000799.2, preferably having the amino acid sequence set forth in SEQ ID NO: 56 and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 57.

[0045] The term "signal peptide of granulocyte colony stimulating factor (CSF3)" or "signal peptide of CSF3" as used herein refers to the native signal peptide of CSF3, referred to in the Uniprot database as P09919, and in the Genbank database as NM_000759.3, NM_001178147.1, NM_172219.2 and NM_172220.2, preferably having the amino acid sequence set forth in SEQ ID NO: 61, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 62.

[0046] The term "beta-nerve growth factor (NGF) signal peptide" or "NGF signal peptide" as used herein refers to the native signal peptide of NGF, referred to in the Uniprot database as P01138, and in the Genbank database as NM_002506.2 and XM_006710663.3, preferably having the amino acid sequence set forth in SEQ ID NO: 66, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 67.

[0047] The term "interleukin-4 (IL4) signal peptide" or "IL4 signal peptide" as used herein refers to the native signal peptide of IL4, referred to in the Uniprot database as P05112, and in the Genbank database as NM_000589.3 and NM_172348.2, preferably having the amino acid sequence set forth in SEQ ID NO: 77, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 78.

[0048] The term "signal peptide of Interleukin-10 (IL10)" or "signal peptide of IL10" as used herein refers to the native signal peptide of IL10, referred to in the Uniprot database as P22301 and in the Genbank database as NM_000572.2, preferably having the amino acid sequence set forth in SEQ ID NO: 82, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 83.

[0049] The term "fibroblast growth factor 5 (FGF5) signal peptide" or "FGF5 signal peptide", as used herein, refers to the native signal peptide of FGF5, referred to in the Uniprot database as P12034, and in the Genbank database as NM_004464.3 and NM_033143.2, preferably having the amino acid sequence set forth in SEQ ID NO: 87, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 88 or SEQ ID NO: 183.

[0050] The term "signal peptide of Complement Factor H-related protein 2 (FHR2)" or "signal peptide of FHR2", as used herein, refers to the native signal peptide of FHR2, referred to in the Uniprot database as P36980, and in the Genbank database as NM_001312672.1 and NM_005666.3, preferably having the amino acid sequence set forth in SEQ ID NO: 92, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 93.

[0051] The term "insulin-like growth factor binding protein 5 (IBP5) signal peptide" or "IBP5 signal peptide", as used herein, refers to the native signal peptide of IBP5, referred to in the Uniprot database as P24593, and in the Genbank database as NM_001312672.1 and NM_000599.3, preferably having the amino acid sequence set forth in SEQ ID NO: 97, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 98.

[0052] The term "signal peptide of neurotrophin-3 (NTF3)" or "signal peptide of NTF3", as used herein, refers to the native signal peptide of NTF3, referred to in the Uniprot database as P20783, and in the Genbank database as NM_002527.4, XM_011520963.2 and NM_001102654.1, preferably having the amino acid sequence set forth in SEQ ID NO: 102, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 103.

[0053] The term "prostate and testis expressed protein 2 (PATE2) signal peptide" or "PATE2 signal peptide" as used herein refers to the native signal peptide of PATE2, referred to in the Uniprot database as Q6UY27 and in the Genbank database as NM_212555.2, preferably having the amino acid sequence set forth in SEQ ID NO: 107, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 108.

[0054] The term "signal peptide of extracellular superoxide dismutase (SOD3)" or "signal peptide of SOD3" as used herein refers to the native signal peptide of SOD3, referred to in the Uniprot database as P08294 and in the Genbank database as NM_003102.2, preferably having the amino acid sequence set forth in SEQ ID NO: 112, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 113.

[0055] The term "glucagon receptor (GL-R) coding sequence" or "GL-R coding sequence" as used herein refers to the coding strand of GL-R, which is a naturally occurring amino acid sequence that does not have a signal peptide function in nature, and which is designated as P47871 in the Uniprot database and as NM_000160.4 and XM_006722277.1 in the Genbank database, and which has the amino acid sequence preferably as set forth in SEQ ID NO: 117 and / or is preferably encoded by the DNA sequence as set forth in SEQ ID NO: 118.

[0056] The term "modified insulin growth factor 1 (IGF1) signal peptide", "modified IGF1 signal peptide" or "modified IGF1 signal peptide", as used herein, refers to the modified signal peptide of IGF1, designated in the Uniprot database as P05019, and in the Genbank database as NM_000618.4, NM_001111284.1 and NM_001111285.2, modified by G2L / S5L / T9L / Q10L substitutions and K3- and C15- deletions, preferably having the amino acid sequence set forth in SEQ ID NO: 122, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 123.

[0057] The term "modified signal peptide of insulin growth factor 2 (IGF2)", "modified signal peptide of IGF2" or "modified signal peptide of IGF2" as used herein refers to the modified signal peptide of IGF2, which is designated in the Uniprot database as P01344, and in the Genbank database as NM_000612.5, NM_001007139.5, NM_001127598.2, NM_001291861.2 and NM_001291862.2, modified by substitutions G2L / G6L / K7L / S8L and deletions P4-, M5-, I23- and A24-, preferably having the amino acid sequence set forth in SEQ ID NO: 127, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 128.

[0058] The term "modified signal peptide of stromal cell-derived factor-1 (CXCL12)", "modified signal peptide of CXCL12" or "modified signal peptide of CXCL12" as used herein refers to the modified signal peptide of CXCL12, designated in the Uniprot database as P48061, and in the Genbank database as NM_000609.6, NM_001033886.2, NM_001178134.1, NM_001277990.1 and NM_199168.3, modified by N3- and K5-deletions, and preferably having the amino acid sequence as set forth in SEQ ID NO: 132 and / or preferably encoded by the DNA sequence as set forth in SEQ ID NO: 133.

[0059] The term "modified signal peptide of Interleukin-4 (IL4)", "modified signal peptide of IL4" or "modified signal peptide of IL4" as used herein refers to the modified signal peptide of IL4, designated in the Uniprot database as P05112 and in the Genbank database as NM_000589.3 and NM_172348.2, modified by G2-, T4-, S5- and Q6-deletions, preferably having the amino acid sequence as set forth in SEQ ID NO: 166 and / or preferably encoded by the DNA sequence as set forth in SEQ ID NO: 167, the native signal peptide of IL4.

[0060] The term "modified signal peptide of Interleukin-10 (IL10)", "modified signal peptide of IL10" or "modified signal peptide of IL10" as used herein refers to the modified signal peptide of IL10, designated in the Uniprot database as P22301 and in the Genbank database as NM_000572.2, modified by substitutions H2V / S3L / S4L and S8L, preferably having the amino acid sequence set forth in SEQ ID NO: 174 and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 175.

[0061] The term "modified form of the insulin (INS) signal peptide", "modified signal peptide of INS" or "modified form of the INS signal peptide" as used herein refers to the modified signal peptide of INS, designated in the Uniprot database as P1308 and in the Genbank database as NM_001185097.1, NM_000207.2, NM_001185098.1 and NM_001291897.1, modified by M5- and R6-deletions, preferably having the amino acid sequence as set forth in SEQ ID NO: 147 and / or preferably encoded by the DNA sequence as set forth in SEQ ID NO: 148 or SEQ ID NO: 182, the native signal peptide of INS.

[0062] The term "modified form of the signal peptide of brain-derived neurotrophic factor (BDNF)", "modified signal peptide of BDNF" or "modified form of the signal peptide of BDNF" as used herein refers to the modified signal peptide of BDNF, designated in the Uniprot database as P23560 and in the Genbank database as NM_001143805.1, NM_170731.4, NM_170734.3, NM_001143810.1 and NM_001143809.1, modified by substitutions T2L / T7L and S11L, preferably having the amino acid sequence set forth in SEQ ID NO: 137 and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 138.

[0063] The term "modified erythropoietin (Epo) signal peptide", "modified Epo signal peptide" or "modified Epo signal peptide", as used herein, refers to the modified Epo signal peptide, designated in the Uniprot database as P01588 and in the Genbank database as NM_000799.2, modified by G2L / P7L / W9L substitutions and H4-, E5-, and W11- deletions, preferably having the amino acid sequence set forth in SEQ ID NO: 152 and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 153.

[0064] The term "modified insulin growth factor 1 (IGF1) prodomain", "modified IGF1 prodomain" or "IGF1-Pro-modified" as used herein refers to the propeptide of IGF1, which is a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, designated in the Uniprot database as P05019, and in the Genbank database as NM_000618.4, NM_001111284.1 and NM_001111285.2, modified by the deletion of ten adjacent amino acid residues 22 to 31 (VKMHTMSSSH) at the N-terminus of the propeptide, preferably having the amino acid sequence set forth in SEQ ID NO: 142, and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 143.

[0065] The term "modified intestinal alkaline phosphatase (ALPI) prodomain", "modified ALPI prodomain", "ALPI-modified" or "ALPI-Pro-modified" as used herein refers to the naturally occurring amino acid sequence having no signal peptide function in nature, designated P09923 in the Uniprot database and NM_001631.4 in the Genbank database, modified by substitutions A504L / A505L / S511L / G517L / T518L and deletions H506-, P507-, A509-, A510- and P513-, preferably having the amino acid sequence set forth in SEQ ID NO: 189 and / or preferably encoded by the DNA sequence set forth in SEQ ID NO: 190.

[0066] The term "mRNA includes a nucleic acid sequence encoding a propeptide of IGF1 and a nucleic acid sequence encoding mature IGF1, but does not include a nucleic acid sequence encoding an E peptide of IGF1" as used herein generally refers to an mRNA that includes a nucleotide sequence encoding a propeptide (also called a prodomain) of human IGF1 having 27 amino acids and a nucleotide sequence encoding a mature human IGF1 having 70 amino acids, but does not include a nucleotide sequence encoding an E peptide (also called an E domain) of human IGF1, i.e., does not include a nucleotide sequence encoding an Ea, Eb or Ec domain. The nucleotide sequence encoding a propeptide (also called a prodomain) of human IGF1 having 27 amino acids and a nucleotide sequence encoding a mature human IGF1 having 70 amino acids may be codon-optimized.

[0067] The term "vector" or "expression vector" as used herein refers to naturally occurring or synthetically produced constructs, such as plasmids, minicircles, phagemids, cosmids, artificial chromosomes / minichromosomes, bacteriophages, viruses, such as baculoviruses, retroviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, bacteriophages, for the uptake, propagation, expression or transfer of nucleic acids in cells. Vectors may either be integrated into the genome of a host cell or remain within the host cell as autonomously replicating constructs. Methods used to construct vectors are well known to those skilled in the art and are described in various publications. In particular, techniques for constructing suitable vectors are known to those skilled in the art, including descriptions of functional and regulatory elements, such as promoters, enhancers, termination and polyadenylation signals, selection markers, origins of replication, and splicing signals. Eukaryotic expression vectors will typically also contain prokaryotic sequences that facilitate the propagation of the vector in bacteria, such as an origin of replication for selection in bacteria and antibiotic resistance genes that can be removed prior to transfection of eukaryotic cells. A variety of eukaryotic expression vectors that contain cloning sites into which a polynucleotide can be operably linked are well known in the art, and some are commercially available from companies such as Agilent Technologies, Santa Clara, Calif.; Invitrogen, Carlsbad, Calif.; Promega, Madison, Wis. or Invivogen, San Diego, Calif.

[0068] The term "gene therapy vector" as used herein refers to any vector that is used to deliver a nucleic acid sequence, e.g., a nucleic acid sequence encoding a gene, to a cell. Gene therapy vectors and gene delivery methods are well known in the art. Non-limiting examples of these methods include viral vector delivery systems, including DNA and RNA viruses with genomes that are either episomal or integrated after delivery to a cell, DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle, non-viral vector delivery systems including transposon systems (for delivery and integration into the host genome; Moriarity et al. (2013) Nucleic Acids Res 41(8), e92; Aronovich et al. (2011) Hum. Mol. Genet. 20(R1), R14-R20), retrovirus-mediated DNA transfer (e.g., retroviruses such as Moloney murine leukemia virus, spleen necrosis virus, Rous sarcoma virus, Harvey sarcoma virus, avian leukemia virus, gibbon ape leukemia virus, human immunodeficiency virus, adenovirus, myeloproliferative sarcoma virus, and mammary cancer virus; see, e.g., Kay et al. (1993) Science 262, 117-119; Anderson (1992) Science 262, 117-119). 256, 808-813), and DNA virus-mediated DNA transfer including adenovirus, herpes virus, parvovirus and adeno-associated virus (e.g., Ali et al. (1994) Gene Therapy 1, 367-384). Viral vectors also include, but are not limited to, adeno-associated virus, adenovirus virus, lentivirus, retrovirus, and herpes simplex virus vectors. Vectors capable of integration into the host genome include, but are not limited to, retrovirus or lentivirus.

[0069] The term "transcription unit", "expression unit" or "expression cassette" as used herein refers to a region within a vector, construct or polynucleotide sequence that contains one or more genes to be transcribed, where the genes contained within the segment are operably linked to each other. They are transcribed from a single promoter, and transcription is terminated by at least one polyadenylation signal. As a result, different genes are at least transcriptionally linked. More than one protein or product can be transcribed and expressed from each transcription unit (polycistronic transcription unit). Each transcription unit is expected to contain the regulatory elements necessary for the transcription and translation of any of the selected sequences contained within that unit, and each transcription unit may contain the same or different regulatory elements. For example, each transcription unit may contain the same terminator. IRES elements or introns can be used for functional linking of genes within a transcription unit. A vector or polynucleotide sequence may contain more than one transcription unit.

[0070] The term "skeletal muscle injury" as used herein refers to any injury and tear of skeletal muscle, preferably tear of skeletal muscle induced by eccentric muscle contraction, stretching and muscle overload. Essentially any skeletal muscle can be affected by such injury or tear. Preferably, the skeletal muscle injury is an injury and tear of skeletal muscle, where the skeletal muscle is selected from the muscle groups of the head, neck, chest, back, abdomen, pelvis, arms, legs and buttocks.

[0071] More preferably, the skeletal muscle injury is caused by a skeletal muscle injury to the following muscles: plantar, temporal, nipple, pectoralis major, tibialis posterior, tibialis anterior, gastrocnemius, coracobrachialis, diaphragm, palmaris longus, rectus abdominis, external anal sphincter, internal anal sphincter, subscapularis, biceps, triceps, quadriceps, calf, groin, popliteal tendon, deltoid, teres major, supraspinatus of rotator cuff, infraspinatus of rotator cuff, teres minor of rotator cuff, subscapularis of rotator cuff, rectus femoris, femoralis, rectus abdominis, external abdominal oblique, masseter, trapezius, latissimus dorsi, pectoralis, erector spinae, iliocostalis, longissimus, spinalis, latissimus dorsi, transversespinalis, semispinalis dorsi, semispinalis cervicis, semispinalis capitis, multifidus, rotator cuff, interspinales, intertransverses, splenius capitis, splenius cervicis, intercostal, subcostales, transverse thoracic, levator costaris, serratus posterior inferior, serratus posterior superior, transverse abdominis, rectus abdominis, pyramis, cremaster, quadratus lumborum, external oblique, internal oblique.

[0072] Even more preferably, the skeletal muscle injury is an injury or tear where the skeletal muscle is selected from the group consisting of: plantaris, temporalis, papilla, pectoralis major, tibialis posterior, tibialis anterior, gastrocnemius, coracobrachialis, diaphragm, palmaris longus, rectus abdominis, external anal sphincter, internal anal sphincter, subscapularis, biceps, triceps, quadriceps, calf, groin, popliteal tendon, deltoid, teres major, supraspinatus of rotator cuff, infraspinatus of rotator cuff, teres minor of rotator cuff, subscapularis of rotator cuff, rectus femoris, rectus abdominis, external oblique abdominal muscle, masseter, trapezius, latissimus dorsi, pectoralis.

[0073] Preferably, any skeletal muscle injury or tear, preferably skeletal muscle tears induced by eccentric muscle contraction, stretching or muscle overload, are treated by the methods of the present invention.

[0074] In a first aspect, the present invention relates to an mRNA comprising a nucleic acid sequence encoding a protein and a signal peptide, wherein the amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. The present invention provides an mRNA selected from the group consisting of:

[0075] In one embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, wherein said protein is not an oxidoreductase, or a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein has been modified by the insertion, deletion and / or substitution of at least one amino acid, wherein said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences that do not naturally have the function of a signal peptide or naturally occurring amino acid sequences that do not naturally have the function of a signal peptide, but which have been modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0076] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0077] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, which naturally occurring amino acid sequences are modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0078] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, which naturally occurring amino acid sequences are modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0079] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; and ii) a signal peptide homologous to said protein, said signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0080] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0081] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0082] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and wherein the signal peptide is a signal peptide heterologous to said protein, and wherein said signal peptide heterologous to said protein is optionally modified by insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase.

[0083] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and wherein the signal peptide is a signal peptide homologous to said protein, and wherein the signal peptide homologous to said protein is modified by the insertion, deletion and / or substitution of at least one amino acid.

[0084] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and wherein the signal peptide is a naturally occurring amino acid sequence that does not have a signal peptide function in nature, and wherein the naturally occurring amino acid sequence is optionally modified by insertion, deletion and / or substitution of at least one amino acid.

[0085] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0086] In one embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide comprises i) a signal peptide heterologous to said protein, wherein said protein is not an oxidoreductase, or a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein has been modified by the insertion, deletion and / or substitution of at least one amino acid, wherein said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences that do not naturally have the function of a signal peptide or naturally occurring amino acid sequences that do not naturally have the function of a signal peptide, but which have been modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0087] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0088] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, which naturally occurring amino acid sequences are modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0089] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, which naturally occurring amino acid sequences are modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0090] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide comprises i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; and ii) a signal peptide homologous to said protein, which signal peptide is modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0091] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide comprises i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0092] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide comprises ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0093] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and wherein the signal peptide is a signal peptide heterologous to said protein, and wherein said signal peptide heterologous to said protein is optionally modified by insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase.

[0094] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 7 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and wherein the signal peptide is a signal peptide homologous to said protein, and wherein the signal peptide homologous to said protein is modified by the insertion, deletion and / or substitution of at least one amino acid.

[0095] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein amino acids 1 to 7 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.5, and the signal peptide is a naturally occurring amino acid sequence that does not have a signal peptide function in nature, and is optionally modified by the insertion, deletion and / or substitution of at least one amino acid.

[0096] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0097] In one embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide comprises i) a signal peptide heterologous to said protein, wherein said protein is not an oxidoreductase, or a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein has been modified by the insertion, deletion and / or substitution of at least one amino acid, wherein said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences that do not naturally have the function of a signal peptide or naturally occurring amino acid sequences that do not naturally have the function of a signal peptide, but which have been modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0098] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0099] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, which naturally occurring amino acid sequences are modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0100] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide comprises i) a signal peptide heterologous to said protein, which signal peptide is modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, which naturally occurring amino acid sequences are modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0101] In one embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide comprises i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; and ii) a signal peptide homologous to said protein, said signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0102] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide comprises i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0103] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide comprises ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0104] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein amino acids 1 to 5 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and wherein the signal peptide is a signal peptide heterologous to said protein, and wherein said signal peptide heterologous to said protein is optionally modified by insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase.

[0105] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and wherein the signal peptide is a signal peptide homologous to said protein, and wherein the signal peptide homologous to said protein is modified by the insertion, deletion and / or substitution of at least one amino acid.

[0106] In a further embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein amino acids 1 to 5 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3, and the signal peptide is a naturally occurring amino acid sequence that does not have a signal peptide function in nature, and is optionally modified by the insertion, deletion and / or substitution of at least one amino acid.

[0107] In a preferred embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, the signal peptide being The signal peptide comprises or consists of an amino acid sequence having a length of 16 to 40 amino acids, the N-terminal amino acids 1 to 9 of which have an average hydrophobicity score of greater than 2, i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0108] In a further preferred embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, the signal peptide comprising or consisting of an amino acid sequence of 16 to 40 amino acids in length, the N-terminal amino acids 1 to 9 of said amino acid sequence having an average hydrophobicity score of greater than 2, and the signal peptide i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; and ii) a signal peptide homologous to said protein, said signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0109] In a further preferred embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, the signal peptide comprising or consisting of an amino acid sequence of 16 to 40 amino acids in length, the N-terminal amino acids 1 to 9 of said amino acid sequence having an average hydrophobicity score of greater than 2, and the signal peptide i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0110] In a further preferred embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, the signal peptide comprising or consisting of an amino acid sequence of 16 to 40 amino acids in length, the N-terminal amino acids 1 to 9 of said amino acid sequence having an average hydrophobicity score of greater than 2, and the signal peptide ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of:

[0111] In a further preferred embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the signal peptide comprises or consists of an amino acid sequence of 16 to 40 amino acids in length, wherein the N-terminal amino acids 1 to 9 of said amino acid sequence have an average hydrophobicity score of greater than 2, and wherein the signal peptide is a signal peptide heterologous to said protein, and wherein said signal peptide heterologous to said protein is optionally modified by insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase.

[0112] In a further preferred embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, wherein the signal peptide comprises or consists of an amino acid sequence of 16 to 40 amino acids in length, wherein amino acids 1 to 9 at the N-terminus of said amino acid sequence have an average hydrophobicity score of greater than 2, and wherein the signal peptide is a signal peptide homologous to said protein, and wherein said signal peptide homologous to said protein is modified by insertion, deletion and / or substitution of at least one amino acid.

[0113] In a further preferred embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, the signal peptide comprising or consisting of an amino acid sequence of 16 to 40 amino acids in length, the N-terminal amino acids 1 to 9 of which have an average hydrophobicity score of greater than 2, and the signal peptide is a naturally occurring amino acid sequence that does not have a signal peptide function in nature, and is optionally modified by insertion, deletion and / or substitution of at least one amino acid.

[0114] In one embodiment, the signal peptide is i) a signal peptide heterologous to said protein, which signal peptide is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. is selected from the group consisting of The modification by insertion, deletion and / or substitution of at least one amino acid is made within amino acids 1 to 11, preferably within amino acids 1 to 10, more preferably within amino acids 1 to 9, even more preferably within amino acids 1 to 8, particularly within amino acids 1 to 7, even more particularly within amino acids 1 to 6, even more particularly within amino acids 1 to 5, particularly preferably within amino acids 1 to 4, even more particularly preferably within amino acids 1 to 3, and even more particularly preferably within amino acids 1 to 2, at the N-terminus of the amino acid sequence of the signal peptide.

[0115] The term "hydrophobic score" or "hydrophobicity score" is used herein synonymously with the term "hydropathy score" and refers to the degree of hydrophobicity of an amino acid calculated according to the Kyte-Durittle scale (Kyte J., Doolittle RF; J. Mol. Biol. 157:105-132 (1982)). Amino acid hydrophobicity scores according to the Kyte-Durittle scale are as follows: TIFF2024156665000001.tif137170

[0116] The "average hydrophobicity score" of an amino acid sequence, e.g., the average hydrophobicity score of amino acids 1 to 9 at the N-terminus of an amino acid sequence of a signal peptide, is calculated by adding the hydrophobicity scores on the Kyte-Duritle scale of each of the amino acids in the amino acid sequence, e.g., the hydrophobicity scores of each of the nine amino acids at the N-terminus, 1 to 9, and dividing by the number of amino acids, e.g., dividing by 9.

[0117] In one embodiment of the invention, amino acids 1 to 9 at the N-terminus of the amino acid sequence have an average hydrophobicity score of equal to or greater than 2.05, preferably equal to or greater than 2.1, more preferably equal to or greater than 2.15, even more preferably equal to or greater than 2.2, in particular equal to or greater than 2.25, more particularly equal to or greater than 2.3, even more particularly equal to or greater than 2.35. In a further embodiment, amino acids 1 to 9 at the N-terminus of the amino acid sequence have an average hydrophobicity score of 2.05 to 4.5, preferably 2.1 to 4.5, more preferably 2.15 to 4.5, even more preferably 2.2 to 4.5, in particular 2.25 to 4.5, more particularly 2.3 to 4.5, even more particularly 2.35 to 4.5. In a further embodiment, amino acids 1 to 9 at the N-terminus of the amino acid sequence have an average hydrophobicity score of 2.05 to 4.0, preferably 2.1 to 4.0, more preferably 2.15 to 4.0, even more preferably 2.2 to 4.0, particularly 2.25 to 4.0, more particularly 2.3 to 4.0, and even more particularly 2.35 to 4.0.

[0118] In one embodiment of the invention, the average hydrophobicity score of the last 9 amino acids at the C-terminus of the signal peptide amino acid sequence is at least 1.0 unit lower, preferably at least 1.1 units lower, more preferably at least 1.2 units lower, even more preferably at least 1.3 units lower, particularly 1.0 to 4 units lower, more particularly 1.1 to 4 units lower, even more particularly 1.2 to 4 units lower, and most particularly 1.3 to 4 units lower than the average hydrophobicity score of amino acids 1 to 9 at the N-terminus of the signal peptide amino acid sequence.

[0119] In one embodiment of the present invention, amino acids 1 to 9, amino acids 2 to 10, amino acids 3 to 11, amino acids 4 to 12 and amino acids 5 to 13 at the N-terminus of the amino acid sequence of the signal peptide each have an average hydrophobicity score of greater than 1.5, preferably an average hydrophobicity score of greater than 1.6, more preferably an average hydrophobicity score of greater than 1.7, even more preferably an average hydrophobicity score of greater than 1.8, even more preferably an average hydrophobicity score of greater than 1.9, particularly an average hydrophobicity score of 1.5 to 4.5, more particularly an average hydrophobicity score of 1.6 to 4.5, even more particularly an average hydrophobicity score of 1.7 to 4.5, even more particularly an average hydrophobicity score of 1.8 to 4.5, and most particularly an average hydrophobicity score of 1.9 to 4.5.

[0120] In one embodiment of the present invention, the average hydrophobicity score of amino acids 8 to 16 at the N-terminus of the amino acid sequence of the signal peptide is at least equal to or lower than the average hydrophobicity score of amino acids 3 to 11 at the N-terminus of the amino acid sequence of the signal peptide, preferably at least 0.4 units lower, and more preferably 0.4 to 2.0 units lower.

[0121] In one embodiment of the present invention, the signal peptide comprises or consists of an amino acid sequence of 18 to 40 amino acids in length, and the average hydrophobicity score of amino acids 10 to 18 at the N-terminus of the amino acid sequence of the signal peptide is at least 0.5 units, preferably 0.5 to 3.0 units, lower than the average hydrophobicity score of amino acids 3 to 11 at the N-terminus of the amino acid sequence of the signal peptide.

[0122] In one embodiment of the present invention, the average hydrophobicity score of the last 9 amino acids at the C-terminus of the amino acid sequence of the signal peptide is at least 1.5 units, preferably 1.5 to 3.5 units, lower than the average hydrophobicity score of amino acids 3 to 11 at the N-terminus of the amino acid sequence of the signal peptide.

[0123] In one embodiment of the invention, the average hydrophobicity score of any 9 consecutive amino acids of the amino acid sequence of the signal peptide does not exceed 4.1.

[0124] In one embodiment of the invention, the last 9 amino acids at the C-terminus of the amino acid sequence of the signal peptide comprise at least one amino acid having a negative hydrophobicity score, preferably the last 9 amino acids at the C-terminus of the amino acid sequence of the signal peptide comprise amino acids selected from the group consisting of G, Q, N, T, S, R, K, H, D, E, P, Y and W.

[0125] In one embodiment of the present invention, the second amino acid among amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide is selected from the group consisting of P, Y, W, S, T, G, A, M, C, F, L, V and I.

[0126] In a preferred embodiment of the present invention, the second amino acid among amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide is selected from the group consisting of A, L, S, T, V and W.

[0127] In one embodiment of the invention, amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average polarity of 6.1 or less, preferably an average polarity of less than 6.1, more preferably an average polarity of less than 4, even more preferably an average polarity of less than 2, particularly an average polarity of 6.1 to 0, more particularly an average polarity of 4 to 0, even more particularly an average polarity of 2 to 0, and most particularly an average polarity of 1 to 0.2.

[0128] In one embodiment of the invention, amino acids 1 to 7 at the N-terminus of the amino acid sequence of the signal peptide have an average polarity of 6.1 or less, preferably an average polarity of less than 6.1, more preferably an average polarity of less than 4, even more preferably an average polarity of less than 2, particularly an average polarity of 6.1 to 0, more particularly an average polarity of 4 to 0, even more particularly an average polarity of 2 to 0, and most particularly an average polarity of 1 to 0.2.

[0129] In one embodiment of the invention, amino acids 1 to 5 at the N-terminus of the signal peptide amino acid sequence have an average polarity of 6.1 or less, preferably an average polarity of less than 6.1, more preferably an average polarity of less than 4, even more preferably an average polarity of less than 2, particularly an average polarity of 6.1 to 0, more particularly an average polarity of 4 to 0, even more particularly an average polarity of 2 to 0, and most particularly an average polarity of 1.1 to 0.2.

[0130] Polarity is calculated according to Zimmerman's polarity index (Zimmerman JM, Eliezer N., Simha R.; J. Theor. Biol. 21:170-201 (1968)). The "average polarity" of an amino acid sequence, e.g., the average polarity of amino acids 1-9 at the N-terminus of an amino acid sequence of a signal peptide, is calculated by adding the calculated polarity values ​​according to the Zimmerman polarity index of each of the amino acids in the amino acid sequence, e.g., the average polarity of each of the nine amino acids at the N-terminus, 1-9, and dividing by the number of amino acids, e.g., by 9. The polarity of an amino acid according to the Zimmerman polarity index is as follows: TIFF2024156665000002.tif142170

[0131] The average hydrophobicity score or average polarity of the amino acid sequence of the signal peptide of the invention described above can be calculated using the publicly available online database ProtScale (http: / / www.expasy.org / tools / protscale.html) mentioned in Gasteiger E. et al. (Gasteiger E., Hoogland C., Gattiker A., ​​Duvaud S., Wilkins MR, Appel RD, Bairoch A.; Protein Identification and Analysis Tools on the ExPASy Server; (In) John M. Walker (ed.): The Proteomics Protocols Handbook, Humana Press (2005). pp. 571-607) with the selection of hydrophobicity on the Kyte and Duritt scale ("Hydrophobicity / Kyte and Duritt") or polarity on the Zimmerman scale ("Polarity / Zimmerman") and the settings corresponding to the specific window size of the signal peptide (e.g. a window size of 9 amino acids), setting the relative weight values ​​of the window ends to 100% and without normalization of the scale. Each numerical data can be retrieved by an open link on the results page under "Numerical format (redundant)".

[0132] In one embodiment of the invention, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, and amino acids 1 to 7 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.7. In one embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, and amino acids 1 to 7 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.7, and the signal peptide comprises or consists of an amino acid sequence 14 to 40 amino acids in length.

[0133] In one embodiment of the invention, amino acids 1 to 7 at the N-terminus of the amino acid sequence have an average hydrophobicity score of equal to or greater than 1.6, preferably equal to or greater than 1.7, more preferably equal to or greater than 1.75, even more preferably equal to or greater than 1.8, in particular equal to or greater than 2.0, more particularly equal to or greater than 2.1, even more particularly equal to or greater than 2.2. In a further embodiment, amino acids 1 to 7 at the N-terminus of the amino acid sequence have an average hydrophobicity score of 1.6 to 4.5, preferably 1.7 to 4.5, more preferably 1.75 to 4.5, even more preferably 1.8 to 4.5, in particular 2.0 to 4.5, more particularly 2.1 to 4.5, even more particularly 2.2 to 4.5. In a further embodiment, amino acids 1 to 7 at the N-terminus of the amino acid sequence have an average hydrophobicity score of 1.6 to 4.0, preferably 1.7 to 4.0, more preferably 1.75 to 4.0, even more preferably 1.8 to 4.0, particularly 2.0 to 4.0, more particularly 2.1 to 4.0, and even more particularly 2.2 to 4.0.

[0134] In one embodiment of the invention, the average hydrophobicity score of the last 7 amino acids at the C-terminus of the signal peptide amino acid sequence is equal to or less than the average hydrophobicity score of amino acids 1 to 7 at the N-terminus of the signal peptide amino acid sequence, preferably at least 0.06 units lower, more preferably at least 1.0 unit lower, even more preferably at least 1.1 units lower, in particular at least 1.2 units lower, more particularly 1.0 to 4 units lower, even more particularly 1.0 to 4 units lower, and most particularly 1.2 to 4 units lower.

[0135] In one embodiment of the present invention, amino acids 1 to 7, amino acids 2 to 8, amino acids 3 to 9, amino acids 4 to 10 and amino acids 5 to 11 at the N-terminus of the amino acid sequence of the signal peptide each have an average hydrophobicity score of greater than 1.4, preferably an average hydrophobicity score of greater than 1.5, more preferably an average hydrophobicity score of greater than 1.6, even more preferably an average hydrophobicity score of greater than 1.7, even more preferably an average hydrophobicity score of greater than 1.75, particularly an average hydrophobicity score of 1.4 to 4.5, more particularly an average hydrophobicity score of 1.5 to 4.5, even more particularly an average hydrophobicity score of 1.6 to 4.5, even more particularly an average hydrophobicity score of 1.7 to 4.5, and most particularly an average hydrophobicity score of 1.75 to 4.5.

[0136] In one embodiment of the present invention, the average hydrophobicity score of the last seven amino acids at the C-terminus of the amino acid sequence of the signal peptide is at least 1.0 unit, preferably 1.0 to 3.6 units, lower than the average hydrophobicity score of amino acids 3 to 9 at the N-terminus of the amino acid sequence of the signal peptide.

[0137] In one embodiment of the invention, the average hydrophobicity score of any seven consecutive amino acids of the amino acid sequence of the signal peptide does not exceed 4.1.

[0138] In one embodiment of the invention, the last seven amino acids at the C-terminus of the amino acid sequence of the signal peptide comprise at least one amino acid having a negative hydrophobicity score, preferably the last seven amino acids at the C-terminus of the amino acid sequence of the signal peptide comprise an amino acid selected from the group consisting of G, Q, N, T, S, R, K, H, D, E, P, Y and W.

[0139] In one embodiment of the present invention, the second amino acid of amino acids 1 to 7 at the N-terminus of the amino acid sequence of the signal peptide is selected from the group consisting of P, Y, W, S, T, G, A, M, C, F, L, V and I.

[0140] In a preferred embodiment of the present invention, the second amino acid among amino acids 1 to 7 at the N-terminus of the amino acid sequence of the signal peptide is selected from the group consisting of A, L, S, T, V and W.

[0141] In one embodiment of the invention, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, and the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3 units. In one embodiment, the mRNA comprises a nucleic acid sequence encoding a protein and a signal peptide, and the N-terminal amino acids 1 to 5 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 1.3 units, and the signal peptide comprises or consists of an amino acid sequence 12 to 40 amino acids in length.

[0142] In one embodiment of the invention, amino acids 1 to 5 at the N-terminus of the amino acid sequence have an average hydrophobicity score of equal to or greater than 1.0, preferably equal to or greater than 1.1, more preferably equal to or greater than 1.2, even more preferably equal to or greater than 1.25, in particular equal to or greater than 1.3, more particularly equal to or greater than 1.35, even more particularly equal to or greater than 1.38. In a further embodiment, amino acids 1 to 5 at the N-terminus of the amino acid sequence have an average hydrophobicity score of 1 to 4.5, preferably 1.1 to 4.5, more preferably 1.2 to 4.5, even more preferably 1.25 to 4.5, in particular 1.3 to 4.5, more particularly 1.35 to 4.5, even more particularly 1.38 to 4.5. In a further embodiment, amino acids 1 to 5 at the N-terminus of the amino acid sequence have an average hydrophobicity score of 1.0 to 4.0, preferably 1.1 to 4.0, more preferably 1.2 to 4.0, even more preferably 1.25 to 4.0, in particular 1.3 to 4.0, more particularly 1.35 to 4.0, and even more particularly 1.38 to 4.0.

[0143] In one embodiment of the present invention, the average hydrophobicity score of the last five amino acids at the C-terminus of the amino acid sequence of the signal peptide is at least 0.2 units lower, preferably at least 0.24 units lower, more preferably at least 1.0 unit lower, even more preferably at least 1.2 units lower, particularly 0.2 to 4 units lower, more particularly 0.24 to 4 units lower, even more particularly 1.0 to 4 units lower, and most particularly 1.2 to 4 units lower than the average hydrophobicity score of amino acids 1 to 5 at the N-terminus of the amino acid sequence of the signal peptide.

[0144] In one embodiment of the present invention, amino acids 1 to 5, amino acids 2 to 6, amino acids 3 to 7, amino acids 4 to 8 and amino acids 5 to 9 at the N-terminus of the amino acid sequence of the signal peptide each have an average hydrophobicity score of greater than 1.0, preferably an average hydrophobicity score of greater than 1.15, more preferably an average hydrophobicity score of greater than 1.2, even more preferably an average hydrophobicity score of greater than 1.21, even more preferably an average hydrophobicity score of greater than 1.23, particularly an average hydrophobicity score of 1.0 to 4.5, more particularly an average hydrophobicity score of 1.15 to 4.5, even more particularly an average hydrophobicity score of 1.2 to 4.5, even more particularly an average hydrophobicity score of 1.21 to 4.5, and most particularly an average hydrophobicity score of 1.23 to 4.5.

[0145] In one embodiment of the present invention, the average hydrophobicity score of the last five amino acids at the C-terminus of the amino acid sequence of the signal peptide is at least 1.2 units, preferably 1.2 to 3.0 units, and more preferably 1.2 to 4.3 units lower than the average hydrophobicity score of amino acids 3 to 7 at the N-terminus of the amino acid sequence of the signal peptide.

[0146] In one embodiment of the invention, the average hydrophobicity score of any five consecutive amino acids of the amino acid sequence of the signal peptide does not exceed 4.2, preferably does not exceed 4.3.

[0147] In one embodiment of the invention, five of the nine amino acids at the C-terminus of the signal peptide amino acid sequence comprise at least one amino acid with a negative hydrophobicity score, and preferably the last five amino acids at the C-terminus of the signal peptide amino acid sequence comprise amino acids selected from the group consisting of G, Q, N, T, S, R, K, H, D, E, P, Y and W.

[0148] In one embodiment of the present invention, the second amino acid among amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide is selected from the group consisting of P, Y, W, S, T, G, A, M, C, F, L, V and I.

[0149] In a preferred embodiment of the present invention, the second amino acid among amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide is selected from the group consisting of A, L, S, T, V and W.

[0150] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, which signal peptide heterologous to said protein is optionally modified by insertion, deletion and / or substitution of less than 50% of the number of amino acids of the amino acid sequence of the signal peptide heterologous to said protein.

[0151] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, which signal peptide heterologous to said protein has, optionally, been modified by the insertion, deletion and / or substitution of at least one amino acid, wherein the modified signal peptide has an amino acid sequence which differs by 1, preferably 2, more preferably 3, even more preferably 4, most preferably 5, particularly 6, more particularly 7, even more particularly 8, most particularly 9 or 10 amino acids from the amino acid sequence of a signal peptide not comprising the modification heterologous to said protein.

[0152] In one embodiment, the modified signal peptide has an amino acid sequence that differs by 1 to 2 amino acids, preferably 1 to 3 amino acids, more preferably 1 to 4 amino acids, even more preferably 1 to 5 amino acids, most preferably 1 to 6 amino acids, particularly 1 to 7 amino acids, more particularly 1 to 10 amino acids, even more particularly 1 to 12 amino acids, and most particularly 1 to 15 amino acids from the amino acid sequence of a signal peptide that does not contain a modification heterologous to the protein.

[0153] In one embodiment, the modified signal peptide has 95% to 50%, preferably 95% to 60%, more preferably 95% to 70%, even more preferably 95% to 80%, and most preferably 95% to 90% sequence identity with the amino acid sequence of a signal peptide that does not contain a modification heterologous to said protein.

[0154] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, which signal peptide heterologous to said protein has been modified by insertion, deletion and / or substitution of at least one amino acid, wherein the modified signal peptide has an amino acid sequence which differs from the amino acid sequence of a naturally occurring (homologous) signal peptide of said protein by at least one, preferably at least two, more preferably at least three, even more preferably at least four, most preferably at least five, particularly at least six, more particularly at least seven, even more particularly at least eight, most particularly at least nine or ten amino acids. In one embodiment, the modified signal peptide heterologous to said protein has less than 95%, preferably less than 90%, more preferably less than 80%, even more preferably less than 70%, most preferably less than 60%, in particular less than 50% sequence identity with the amino acid sequence of a naturally occurring (homologous) signal peptide of said protein.

[0155] In one embodiment of the present invention, the signal peptide is ii) a signal peptide homologous to said protein, wherein the signal peptide homologous to said protein has been modified by insertion, deletion and / or substitution of at least one amino acid, and amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide not containing the modification homologous to said protein have an average hydrophobicity score of 2 and less, preferably less than 2.

[0156] In one embodiment of the invention, the signal peptide is ii) a signal peptide homologous to said protein, which is modified by insertion, deletion and / or substitution of less than 50% of the number of amino acids of the amino acid sequence of the signal peptide homologous to said protein.

[0157] In one embodiment of the invention, the signal peptide is ii) a signal peptide homologous to said protein, which is modified by insertion, deletion and / or substitution of at least one amino acid, and said modified signal peptide homologous to said protein differs from the amino acid sequence of a signal peptide not containing a modification homologous to said protein by 1, preferably 2, more preferably 3, even more preferably 4, most preferably 5, particularly 6, more particularly 7, even more particularly 8 to 12, and most particularly 9 to 15 amino acids. In one embodiment, said modified signal peptide homologous to a protein differs from the amino acid sequence of a signal peptide not containing a modification homologous to said protein by 1 to 2 amino acids, preferably 1 to 3 amino acids, more preferably 1 to 4 amino acids, even more preferably 1 to 5 amino acids, most preferably 1 to 6 amino acids, particularly 1 to 7 amino acids, more particularly 1 to 10 amino acids, even more particularly 1 to 12 amino acids, and most particularly 1 to 15 amino acids.

[0158] In one embodiment, the modified signal peptide homologous to the protein has less than 95%, preferably less than 90%, more preferably less than 80%, even more preferably less than 70%, most preferably less than 60%, especially less than 50% sequence identity with the amino acid sequence of a signal peptide that does not contain a modification homologous to the protein.

[0159] In one embodiment of the invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, and which is optionally modified by insertion, deletion and / or substitution of less than 50% of the number of amino acids of the naturally occurring amino acid sequence.

[0160] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, and the modified naturally occurring amino acid sequence is a naturally occurring amino acid sequence that differs from the amino acid sequence of the naturally occurring amino acid sequence not comprising the modification by one, preferably two, more preferably three, even more preferably four, most preferably five, particularly six, more particularly seven, even more particularly 8 to 12, and most particularly 9 to 15 amino acids.

[0161] In one embodiment, the modified naturally occurring amino acid sequence differs from the amino acid sequence of a naturally occurring amino acid sequence that does not contain the modification by 1 to 2 amino acids, preferably 1 to 3 amino acids, more preferably 1 to 4 amino acids, even more preferably 1 to 5 amino acids, most preferably 1 to 6 amino acids, particularly 1 to 7 amino acids, more particularly 1 to 10 amino acids, even more particularly 1 to 12 amino acids, and most particularly 1 to 15 amino acids.

[0162] In one embodiment, the modified naturally occurring amino acid sequence has a sequence identity of less than 95%, preferably less than 90%, more preferably less than 80%, even more preferably less than 70%, most preferably less than 60%, especially less than 50% with the amino acid sequence of a naturally occurring amino acid sequence without the modification.

[0163] In one embodiment of the invention, the modified naturally occurring amino acid sequence which does not have the function of a signal peptide in nature has an amino acid sequence which differs from the amino acid sequence of a naturally occurring signal peptide by more than 50%, preferably more than 60%, more preferably more than 70%, even more preferably more than 80%, most preferably more than 90%, in particular more than 95%. In one embodiment, the modified naturally occurring amino acid sequence which does not have the function of a signal peptide in nature has a sequence identity with the amino acid sequence of a naturally occurring signal of less than 100%, preferably less than 95%, more preferably less than 90%, even more preferably less than 80%, most preferably less than 70%, in particular less than 60%, more in particular less than 50%.

[0164] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to the protein, and examples of the signal peptide heterologous to the protein include the signal peptide of brain-derived neurotrophic factor (BDNF), the signal peptide of neurotrophin-3 (NTF-3), the signal peptide of fibroblast growth factor 5 (FGF5), the signal peptide of insulin-like growth factor binding protein 5 (IBP5), the signal peptide of prostate and testis expressed protein 2 (PATE2), the signal peptide of extracellular superoxide dismutase (SOD3), and the signal peptide of complement factor H-related protein 2 (FHR2). or i) a signal peptide heterologous to said protein selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12), the signal peptide of insulin growth factor 2 (IGF2), the signal peptide of insulin (INS), and the signal peptide of brain-derived neurotrophic factor (BDNF), modified by at least one amino acid insertion, deletion and / or substitution, wherein said signal peptide heterologous to said protein is a signal peptide heterologous to said protein selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12), the signal peptide of insulin growth factor 2 (IGF2), the signal peptide of insulin (INS), and the signal peptide of brain-derived neurotrophic factor (BDNF).

[0165] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to the protein, and the heterologous signal peptide to the protein is selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 30, the signal peptide of neurotrophin-3 (NTF-3) as set forth in SEQ ID NO: 102, the signal peptide of fibroblast growth factor 5 (FGF5) as set forth in SEQ ID NO: 87, the signal peptide of insulin-like growth factor binding protein 5 (IBP5) as set forth in SEQ ID NO: 97, the signal peptide of prostate and testis expressed protein 2 (PATE2) as set forth in SEQ ID NO: 107, the signal peptide of extracellular superoxide dismutase (SOD3) as set forth in SEQ ID NO: 112, and the signal peptide of complement factor H-related protein 2 (FHR2) as set forth in SEQ ID NO: 92. or i) a signal peptide heterologous to said protein selected from the group consisting of a modified C-X-C motif chemokine ligand 12 (CXCL12) signal peptide set forth in SEQ ID NO: 132, a modified insulin growth factor 2 (IGF2) signal peptide set forth in SEQ ID NO: 127, a modified insulin (INS) signal peptide set forth in SEQ ID NO: 147, and a modified brain-derived neurotrophic factor (BDNF) signal peptide set forth in SEQ ID NO: 137.

[0166] In one embodiment of the invention, the signal peptide is a signal peptide heterologous to said protein selected from the group consisting of: i) the signal peptide of brain-derived neurotrophic factor (BDNF), the signal peptide of neurotrophin-3 (NTF-3), the signal peptide of fibroblast growth factor 5 (FGF5), the signal peptide of insulin-like growth factor binding protein 5 (IBP5), the signal peptide of prostate and testis expressed protein 2 (PATE2), the signal peptide of extracellular superoxide dismutase (SOD3), and the signal peptide of complement factor H-related protein 2 (FHR2). Preferably, the signal peptide heterologous to the protein is selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 30, the signal peptide of neurotrophin-3 (NTF-3) as set forth in SEQ ID NO: 102, the signal peptide of fibroblast growth factor 5 (FGF5) as set forth in SEQ ID NO: 87, the signal peptide of insulin-like growth factor binding protein 5 (IBP5) as set forth in SEQ ID NO: 97, the signal peptide of prostate and testis expressed protein 2 (PATE2) as set forth in SEQ ID NO: 107, the signal peptide of extracellular superoxide dismutase (SOD3) as set forth in SEQ ID NO: 112, and the signal peptide of complement factor H-related protein 2 (FHR2) as set forth in SEQ ID NO: 92.

[0167] In one embodiment of the invention, the signal peptide is i) a heterologous signal peptide to said protein, modified by the insertion, deletion and / or substitution of at least one amino acid, selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12), the signal peptide of insulin growth factor 2 (IGF2), the signal peptide of insulin (INS), and the signal peptide of brain-derived neurotrophic factor (BDNF).

[0168] In a preferred embodiment of the invention, the signal peptide heterologous to said protein modified by the insertion, deletion and / or substitution of at least one amino acid is selected from the group consisting of a modified C-X-C motif chemokine ligand 12 (CXCL12) signal peptide as set forth in SEQ ID NO: 132, a modified insulin growth factor 2 (IGF2) signal peptide as set forth in SEQ ID NO: 127, a modified insulin (INS) signal peptide as set forth in SEQ ID NO: 147, and a modified brain-derived neurotrophic factor (BDNF) signal peptide as set forth in SEQ ID NO: 137.

[0169] In one embodiment of the invention, the signal peptide is ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by insertion, deletion and / or substitution of at least one amino acid, and said signal peptide homologous to said protein and said protein are selected from the group consisting of the signal peptide of insulin growth factor 1 (IGF1) and IGF1, the signal peptide of insulin and INS, the signal peptide of erythropoietin (EPO) and EPO, the signal peptide of interleukin 4 (IL-4) and IL-4, and the signal peptide of interleukin 10 (IL-10) and IL-10. In a preferred embodiment of the invention, the signal peptide homologous to said protein, modified by the insertion, deletion and / or substitution of at least one amino acid, is selected from the group consisting of the modified signal peptide of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 122, the modified signal peptide of insulin as set forth in SEQ ID NO: 147, the modified signal peptide of erythropoietin (EPO) as set forth in SEQ ID NO: 152, the modified signal peptide of interleukin 4 (IL-4) as set forth in SEQ ID NO: 166 and the modified signal peptide of interleukin 10 (IL-10) as set forth in SEQ ID NO: 174.

[0170] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence is modified, if necessary, by insertion, deletion and / or substitution of at least one amino acid, and the naturally occurring amino acid sequence is a naturally occurring amino acid sequence selected from the group consisting of the propeptide of insulin growth factor 1 (IGF1), the coding sequence of the glucagon receptor (GL-R) and the propeptide of intestinal alkaline phosphatase (ALPI).

[0171] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature, which is a coding sequence for the glucagon receptor (GL-R); iii) a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature, which is modified by at least one amino acid insertion, deletion and / or substitution and which is the propeptide of insulin growth factor 1 (IGF1); or iii) a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature, which is modified by at least one amino acid insertion, deletion and / or substitution and which is the propeptide of intestinal alkaline phosphatase (ALPI).

[0172] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature and is a coding sequence for the glucagon receptor (GL-R).

[0173] In one embodiment of the invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, and which naturally occurring amino acid sequence is the propeptide of insulin growth factor 1 (IGF1).

[0174] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, and which naturally occurring amino acid sequence is the propeptide of intestinal alkaline phosphatase (ALPI).

[0175] In a preferred embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature, which is a coding sequence of the glucagon receptor (GL-R) as shown in SEQ ID NO: 117; iii) a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature, which is modified by at least one amino acid insertion, deletion and / or substitution, and the modified naturally occurring amino acid sequence is a modified propeptide of insulin growth factor 1 (IGF1) as shown in SEQ ID NO: 142; or iii) a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature, which is modified by at least one amino acid insertion, deletion and / or substitution, and the modified naturally occurring amino acid sequence is a modified propeptide of intestinal alkaline phosphatase (ALPI) as shown in SEQ ID NO: 189.

[0176] In a preferred embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, and is the coding sequence of the glucagon receptor (GL-R) shown in SEQ ID NO: 117.

[0177] In a preferred embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, and the modified naturally occurring amino acid sequence is a modified propeptide of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 142.

[0178] In a preferred embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, and the modified naturally occurring amino acid sequence is a modified propeptide of intestinal alkaline phosphatase (ALPI) as set forth in SEQ ID NO: 189.

[0179] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, optionally modified by insertion, deletion and / or substitution of at least one amino acid, and wherein the amount of secreted protein using a signal peptide heterologous to said protein is greater than the amount of said secreted protein using a signal peptide homologous to said protein, preferably at least 1.4-fold greater than the amount of said secreted protein using a signal peptide heterologous to said protein.

[0180] In one embodiment of the invention, the signal peptide is ii) a signal peptide homologous to said protein, which signal peptide homologous to said protein is modified by at least one amino acid insertion, deletion and / or substitution, and the amount of secreted protein using the modified signal peptide homologous to said protein is greater than the amount of said secreted protein using a signal peptide not comprising a modification homologous to said protein. Preferably, the amount of secreted protein using the modified signal peptide homologous to said protein is preferably at least 1.4-fold greater than the amount of said secreted protein using an unmodified signal peptide homologous to said protein.

[0181] In one embodiment of the invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence is optionally modified by the insertion, deletion and / or substitution of at least one amino acid, and the amount of secreted protein using the naturally occurring amino acid sequence that does not have a signal peptide function in nature is greater than the amount of said secreted protein using a signal peptide homologous to said protein. Preferably, the amount of secreted protein using the optionally modified naturally occurring amino acid sequence is preferably at least 1.4 times greater than the amount of said secreted protein using a signal peptide homologous to said protein.

[0182] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, which signal peptide heterologous to said protein is optionally modified by insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not thioredoxin, more in particular that said protein is not rod-derived cone viability factor.

[0183] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, said protein being selected from the group consisting of insulin growth factor 1 (IGF1), insulin (INS), erythropoietin (EPO), interleukin-4 (IL-4) and interleukin-10 (IL-10); i) a signal peptide heterologous to said protein, said signal peptide being modified by at least one amino acid insertion, deletion and / or substitution, said protein being IGF1; ii) a signal peptide homologous to said protein, which is modified by at least one amino acid insertion, deletion and / or substitution, and wherein the protein is selected from the group consisting of insulin growth factor 1 (IGF1), insulin (INS), erythropoietin (EPO), interleukin-4 (IL-4) and interleukin-10 (IL-10); iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, the naturally occurring amino acid sequence being the coding sequence for the glucagon receptor (GL-R) and the protein being insulin growth factor 1 (IGF1); and iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, and which is the propeptide of insulin growth factor 1 (IGF1), and the protein is insulin growth factor 1 (IGF1). is selected from.

[0184] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, said protein being selected from the group consisting of insulin growth factor 1 (IGF1), insulin (INS), erythropoietin (EPO), interleukin-4 (IL-4) and interleukin-10 (IL-10).

[0185] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, said protein being selected from the group consisting of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 188, insulin (INS) as set forth in SEQ ID NO: 185, erythropoietin (EPO) as set forth in SEQ ID NO: 184, interleukin-4 (IL-4) as set forth in SEQ ID NO: 186 and interleukin-10 (IL-10) as set forth in SEQ ID NO: 187.

[0186] In one embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein has been modified by the insertion, deletion and / or substitution of at least one amino acid, and said protein is IGF1.

[0187] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by the insertion, deletion and / or substitution of at least one amino acid, said protein being IGF1 as set forth in SEQ ID NO: 188.

[0188] In one embodiment of the invention, the signal peptide is ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by an insertion, deletion and / or substitution of at least one amino acid, and wherein said protein is a signal peptide homologous to said protein selected from the group consisting of insulin growth factor 1 (IGF1), insulin (INS), erythropoietin (EPO), interleukin-4 (IL-4) and interleukin-10 (IL-10).

[0189] In a preferred embodiment of the present invention, the signal peptide is ii) a signal peptide homologous to said protein, which is modified by at least one amino acid insertion, deletion and / or substitution, and the protein is a signal peptide homologous to said protein selected from the group consisting of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 188, insulin (INS) as set forth in SEQ ID NO: 185, erythropoietin (EPO) as set forth in SEQ ID NO: 184, interleukin-4 (IL-4) as set forth in SEQ ID NO: 186 and interleukin-10 (IL-10) as set forth in SEQ ID NO: 187.

[0190] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, the naturally occurring amino acid sequence being the coding sequence for the glucagon receptor (GL-R) and the protein being insulin growth factor 1 (IGF1).

[0191] In one embodiment of the invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, and is a propeptide of insulin growth factor 1 (IGF1), and the protein is insulin growth factor 1 (IGF1).

[0192] In one embodiment of the invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, and is the propeptide of intestinal alkaline phosphatase (ALPI) and the protein is insulin growth factor 1 (IGF1).

[0193] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, the naturally occurring amino acid sequence being the coding sequence for the glucagon receptor (GL-R) and the protein being insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 188.

[0194] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, the modified naturally occurring amino acid sequence being a modified propeptide of insulin growth factor 1 (IGF1), and the protein being insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 188.

[0195] In one embodiment of the present invention, the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, which naturally occurring amino acid sequence has been modified by the insertion, deletion and / or substitution of at least one amino acid, the modified naturally occurring amino acid sequence being a modified propeptide of intestinal alkaline phosphatase (ALPI) and the protein being insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 188.

[0196] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, said signal peptide heterologous to said protein being selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF), the signal peptide of neurotrophin-3 (NTF-3), the signal peptide of fibroblast growth factor 5 (FGF5), the signal peptide of insulin-like growth factor binding protein 5 (IBP5), the signal peptide of prostate- and testis-expressed protein 2 (PATE2), the signal peptide of extracellular superoxide dismutase (SOD3), and the signal peptide of complement factor H-related protein 2 (FHR2), with the proviso that said protein is not an oxidoreductase; i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by an insertion, deletion and / or substitution of at least one amino acid, and wherein said signal peptide heterologous to said protein is selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12), the signal peptide of insulin growth factor 2 (IGF2), the signal peptide of insulin (INS), and the signal peptide of brain-derived neurotrophic factor (BDNF), with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by an insertion, deletion and / or substitution of at least one amino acid, said signal peptide homologous to said protein being selected from the group consisting of the signal peptide of insulin growth factor 1 (IGF1), the signal peptide of insulin (INS), the signal peptide of erythropoietin (EPO), the signal peptide of interleukin 4 (IL-4), and the signal peptide of interleukin 10 (IL-10); iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, the naturally occurring amino acid sequence being the coding sequence for the glucagon receptor (GL-R); iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which is modified by the insertion, deletion and / or substitution of at least one amino acid, and which is the propeptide of insulin growth factor 1 (IGF1); and iii) a naturally occurring amino acid sequence that does not naturally have the function of a signal peptide, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, and which naturally occurring amino acid sequence is the propeptide of intestinal alkaline phosphatase (ALPI). is selected from the group consisting of:

[0197] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, said signal peptide heterologous to said protein being selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF), the signal peptide of neurotrophin-3 (NTF-3), the signal peptide of fibroblast growth factor 5 (FGF5), the signal peptide of insulin-like growth factor binding protein 5 (IBP5), the signal peptide of prostate- and testis-expressed protein 2 (PATE2), the signal peptide of extracellular superoxide dismutase (SOD3), and the signal peptide of complement factor H-related protein 2 (FHR2), said protein being selected from the group consisting of cytokines, growth factors, and hormones; i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by insertion, deletion and / or substitution of at least one amino acid, said signal peptide heterologous to said protein being selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12), the signal peptide of insulin growth factor 2 (IGF2), the signal peptide of insulin (INS), and the signal peptide of brain-derived neurotrophic factor (BDNF), said protein being selected from the group consisting of cytokines, growth factors and hormones; ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by at least one amino acid insertion, deletion and / or substitution, said signal peptide homologous to said protein and said protein being selected from the group consisting of the signal peptide of insulin growth factor 1 (IGF1) and IGF1, the signal peptide of insulin and INS, the signal peptide of erythropoietin (EPO) and EPO, the signal peptide of interleukin 4 (IL-4) and IL-4, the signal peptide of interleukin 10 (IL-10) and IL-10; iii) a naturally occurring amino acid sequence that does not naturally have a signal peptide function, wherein the signal peptide is the coding sequence for the glucagon receptor (GL-R), and said protein is selected from the group consisting of cytokines; growth factors; and hormones, preferably a growth factor; iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which is modified by the insertion, deletion and / or substitution of at least one amino acid, the naturally occurring amino acid sequence being the propeptide of insulin growth factor 1 (IGF1), said protein being selected from the group consisting of cytokines, growth factors and hormones, preferably a growth factor; and iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, the naturally occurring amino acid sequence being the propeptide of intestinal alkaline phosphatase (ALPI), said protein being selected from the group consisting of cytokines, growth factors and hormones, preferably a growth factor. is selected from the group consisting of:

[0198] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, said signal peptide heterologous to said protein being selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF), the signal peptide of neurotrophin-3 (NTF-3), the signal peptide of fibroblast growth factor 5 (FGF5), the signal peptide of insulin-like growth factor binding protein 5 (IBP5), the signal peptide of prostate- and testis-expressed protein 2 (PATE2), the signal peptide of extracellular superoxide dismutase (SOD3), and the signal peptide of complement factor H-related protein 2 (FHR2), said protein being selected from the group consisting of insulin growth factor 1 (IGF1), insulin (INS), erythropoietin (EPO), interleukin 4 (IL-4), and interleukin 10 (IL-10); i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by insertion, deletion and / or substitution of at least one amino acid, said signal peptide heterologous to said protein being selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12), the signal peptide of insulin growth factor 2 (IGF2), the signal peptide of insulin (INS), and the signal peptide of brain-derived neurotrophic factor (BDNF), and said protein is insulin growth factor 1 (IGF1); ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by at least one amino acid insertion, deletion and / or substitution, said signal peptide homologous to said protein and said protein being selected from the group consisting of the signal peptide of insulin growth factor 1 (IGF1) and IGF1, the signal peptide of insulin and INS, the signal peptide of erythropoietin (EPO) and EPO, the signal peptide of interleukin 4 (IL-4) and IL-4, the signal peptide of interleukin 10 (IL-10) and IL-10; iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, the naturally occurring amino acid sequence being the coding sequence for the glucagon receptor (GL-R), said protein being insulin growth factor 1 (IGF1); iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which is modified by the insertion, deletion and / or substitution of at least one amino acid, the naturally occurring amino acid sequence being the propeptide of insulin growth factor 1 (IGF1), and the protein being insulin growth factor 1 (IGF1); and iii) a naturally occurring amino acid sequence that does not naturally have the function of a signal peptide, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, the naturally occurring amino acid sequence being the propeptide of intestinal alkaline phosphatase (ALPI), said protein being insulin growth factor 1 (IGF1). is selected from the group consisting of:

[0199] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein and said protein is selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF) and IGF1, insulin, EPO, or IL-10, the signal peptide of neurotrophin-3 (NTF-3) and IGF1, the signal peptide of fibroblast growth factor 5 (FGF5) and IGF1 or IL4, the signal peptide of insulin-like growth factor binding protein 5 (IBP5) and IGF1, the signal peptide of prostate- and testis-expressed protein 2 (PATE2) and IGF1, the signal peptide of extracellular superoxide dismutase (SOD3) and IGF1, and the signal peptide of complement factor H-related protein 2 (FHR2) and IGF1; i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by an insertion, deletion and / or substitution of at least one amino acid, said signal peptide heterologous to said protein and said protein is selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12) and IGF1, the signal peptide of insulin growth factor 2 (IGF2) and IGF1, the signal peptide of insulin (INS) and IGF1, and the signal peptide of brain-derived neurotrophic factor (BDNF) and IGF1; ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by at least one amino acid insertion, deletion and / or substitution, said signal peptide homologous to said protein and said protein being selected from the group consisting of the signal peptide of insulin growth factor 1 (IGF1) and IGF1, the signal peptide of insulin and INS, the signal peptide of erythropoietin (EPO) and EPO, the signal peptide of interleukin 4 (IL-4) and IL-4, the signal peptide of interleukin 10 (IL-10) and IL-10; iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, the naturally occurring amino acid sequence being the coding sequence for the glucagon receptor (GL-R), said protein being insulin growth factor 1 (IGF1); iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which is modified by the insertion, deletion and / or substitution of at least one amino acid, the naturally occurring amino acid sequence being the propeptide of insulin growth factor 1 (IGF1), and the protein being insulin growth factor 1 (IGF1); and iii) a naturally occurring amino acid sequence that does not naturally have the function of a signal peptide, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, the naturally occurring amino acid sequence being the propeptide of intestinal alkaline phosphatase (ALPI), said protein being insulin growth factor 1 (IGF1). is selected from the group consisting of:

[0200] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, said signal peptide heterologous to said protein being selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 30, the signal peptide of neurotrophin-3 (NTF-3) as set forth in SEQ ID NO: 102, the signal peptide of fibroblast growth factor 5 (FGF5) as set forth in SEQ ID NO: 87, the signal peptide of insulin-like growth factor binding protein 5 (IBP5) as set forth in SEQ ID NO: 97, the signal peptide of prostate- and testis-expressed protein 2 (PATE2) as set forth in SEQ ID NO: 107, the signal peptide of extracellular superoxide dismutase (SOD3) as set forth in SEQ ID NO: 112, and the signal peptide of complement factor H-related protein 2 (FHR2) as set forth in SEQ ID NO: 92, with the proviso that said protein is not an oxidoreductase; i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by at least one amino acid insertion, deletion and / or substitution, and said signal peptide heterologous to said protein is selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12) as set forth in SEQ ID NO: 132, the signal peptide of insulin growth factor 2 (IGF2) as set forth in SEQ ID NO: 127, the signal peptide of insulin (INS) as set forth in SEQ ID NO: 147, and the signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 137, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by insertion, deletion and / or substitution of at least one amino acid, said signal peptide homologous to said protein being selected from the group consisting of the modified signal peptide of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 122, the modified signal peptide of insulin (INS) as set forth in SEQ ID NO: 147, the modified signal peptide of erythropoietin (EPO) as set forth in SEQ ID NO: 152, the modified signal peptide of interleukin 4 (IL-4) as set forth in SEQ ID NO: 166, and the modified signal peptide of interleukin 10 (IL-10) as set forth in SEQ ID NO: 174; iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which is the coding sequence of the glucagon receptor (GL-R) shown in SEQ ID NO: 117; iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, and the modified naturally occurring amino acid sequence is a modified propeptide of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 142; and iii) A naturally occurring amino acid sequence that does not naturally have the function of a signal peptide, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, and the modified naturally occurring amino acid sequence is a modified propeptide of intestinal alkaline phosphatase (ALPI) as set forth in SEQ ID NO: 189. is selected from the group consisting of:

[0201] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to said protein, said signal peptide heterologous to said protein being selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 30, the signal peptide of neurotrophin-3 (NTF-3) as set forth in SEQ ID NO: 102, the signal peptide of fibroblast growth factor 5 (FGF5) as set forth in SEQ ID NO: 87, the signal peptide of insulin-like growth factor binding protein 5 (IBP5) as set forth in SEQ ID NO: 97, the signal peptide of prostate- and testis-expressed protein 2 (PATE2) as set forth in SEQ ID NO: 107, the signal peptide of extracellular superoxide dismutase (SOD3) as set forth in SEQ ID NO: 112, and the signal peptide of complement factor H-related protein 2 (FHR2) as set forth in SEQ ID NO: 92, said protein being selected from the group consisting of cytokines, growth factors and hormones; i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by insertion, deletion and / or substitution of at least one amino acid, said modified signal peptide heterologous to said protein being selected from the group consisting of a modified signal peptide of C-X-C motif chemokine ligand 12 (CXCL12) as set forth in SEQ ID NO: 132, a modified signal peptide of insulin growth factor 2 (IGF2) as set forth in SEQ ID NO: 127, a modified signal peptide of insulin (INS) as set forth in SEQ ID NO: 147, and a modified signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 137, said protein being selected from the group consisting of cytokine growth factors and hormones; ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by at least one amino acid insertion, deletion and / or substitution, said modified signal peptide homologous to said protein and said protein being selected from the group consisting of a modified signal peptide of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 122 and IGF1 as set forth in SEQ ID NO: 188, a modified signal peptide of insulin as set forth in SEQ ID NO: 147 and insulin (INS) as set forth in SEQ ID NO: 185, a modified signal peptide of erythropoietin (EPO) as set forth in SEQ ID NO: 152 and EPO as set forth in SEQ ID NO: 184, a modified signal peptide of interleukin 4 (IL-4) as set forth in SEQ ID NO: 166 and IL-4 as set forth in SEQ ID NO: 186, a modified signal peptide of interleukin 10 (IL-10) as set forth in SEQ ID NO: 174 and IL-10 as set forth in SEQ ID NO: 187; iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, the naturally occurring amino acid sequence being the coding sequence for the glucagon receptor (GL-R) shown in SEQ ID NO: 117, said protein being selected from the group consisting of cytokines; growth factors; and hormones, preferably a growth factor; iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, the modified naturally occurring amino acid sequence being a modified propeptide of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 142, said protein being selected from the group consisting of cytokines; growth factors; and hormones, preferably a growth factor; and iii) A naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, the modified naturally occurring amino acid sequence being a modified propeptide of intestinal alkaline phosphatase (ALPI) as set forth in SEQ ID NO: 189, said protein being selected from the group consisting of cytokines; growth factors; and hormones, preferably a growth factor. is selected from the group consisting of:

[0202] In a preferred embodiment of the invention, the signal peptide is i) a signal peptide heterologous to the protein, the signal peptide being heterologous to the protein, and examples of the signal peptide heterologous to the protein include the signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 30, the signal peptide of neurotrophin-3 (NTF-3) as set forth in SEQ ID NO: 102, the signal peptide of fibroblast growth factor 5 (FGF5) as set forth in SEQ ID NO: 87, the signal peptide of insulin-like growth factor binding protein 5 (IBP5) as set forth in SEQ ID NO: 97, the signal peptide of prostate- and testis-expressed protein 2 (PATE2) as set forth in SEQ ID NO: 107, the signal peptide of a signal peptide heterologous to said protein selected from the group consisting of: a signal peptide of extracellular superoxide dismutase (SOD3) as set forth in SEQ ID NO: 188, a signal peptide of complement factor H-related protein 2 (FHR2) as set forth in SEQ ID NO: 92, said protein being selected from the group consisting of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 185, insulin as set forth in SEQ ID NO: 184, erythropoietin (EPO) as set forth in SEQ ID NO: 184, interleukin 4 (IL-4) as set forth in SEQ ID NO: 186, and interleukin 10 (IL-10) as set forth in SEQ ID NO: 187; i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by insertion, deletion and / or substitution of at least one amino acid, said modified signal peptide heterologous to said protein being selected from the group consisting of a modified signal peptide of C-X-C motif chemokine ligand 12 (CXCL12) as set forth in SEQ ID NO: 132, a modified signal peptide of insulin growth factor 2 (IGF2) as set forth in SEQ ID NO: 127, a modified signal peptide of insulin (INS) as set forth in SEQ ID NO: 147, and a modified signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 137, said protein being insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 188; ii) a signal peptide homologous to said protein, wherein said signal peptide homologous to said protein is modified by at least one amino acid insertion, deletion and / or substitution, said modified signal peptide homologous to said protein and said protein being selected from the group consisting of a modified signal peptide of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 122 and IGF1 as set forth in SEQ ID NO: 188, a modified signal peptide of insulin as set forth in SEQ ID NO: 147 and insulin (INS) as set forth in SEQ ID NO: 185, a modified signal peptide of erythropoietin (EPO) as set forth in SEQ ID NO: 152 and EPO as set forth in SEQ ID NO: 184, a modified signal peptide of interleukin 4 (IL-4) as set forth in SEQ ID NO: 166 and IL-4 as set forth in SEQ ID NO: 186, a modified signal peptide of interleukin 10 (IL-10) as set forth in SEQ ID NO: 174 and IL-10 as set forth in SEQ ID NO: 187; iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, the naturally occurring amino acid sequence being the coding sequence for the glucagon receptor (GL-R) shown in SEQ ID NO: 117, and the protein being insulin growth factor 1 (IGF1) shown in SEQ ID NO: 188; iii) naturally occurring amino acid sequences that do not have the function of a signal peptide in nature, which naturally occurring amino acid sequences are modified by the insertion, deletion and / or substitution of at least one amino acid, the modified naturally occurring amino acid sequence being a modified propeptide of insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 142, and the protein being insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 188, and iii) a naturally occurring amino acid sequence that does not naturally have the function of a signal peptide, which naturally occurring amino acid sequence is modified by the insertion, deletion and / or substitution of at least one amino acid, the modified naturally occurring amino acid sequence being a modified propeptide of intestinal alkaline phosphatase (ALPI) as set forth in SEQ ID NO: 189, said protein being insulin growth factor 1 (IGF1) as set forth in SEQ ID NO: 188. is selected from the group consisting of:

[0203] In certain preferred embodiments of the invention, the mRNA comprising the nucleic acid sequence encoding the protein and the signal peptide is selected from the group consisting of the mRNA sequence shown in SEQ ID NO:8, the mRNA sequence shown in SEQ ID NO:105, the mRNA sequence shown in SEQ ID NO:90, the mRNA sequence shown in SEQ ID NO:100, the mRNA sequence shown in SEQ ID NO:110, the mRNA sequence shown in SEQ ID NO:115, the mRNA sequence shown in SEQ ID NO:95, the mRNA sequence shown in SEQ ID NO:135, the mRNA sequence shown in SEQ ID NO:130, the mRNA sequence shown in SEQ ID NO:150, the mRNA sequence shown in SEQ ID NO:140, the mRNA sequence shown in SEQ ID NO:125, the mRNA sequence shown in SEQ ID NO:161, the mRNA sequence shown in SEQ ID NO:155, the mRNA sequence shown in SEQ ID NO:169, the mRNA sequence shown in SEQ ID NO:177, the mRNA sequence shown in SEQ ID NO:120, the mRNA sequence shown in SEQ ID NO:145, and the mRNA sequence shown in SEQ ID NO:192.

[0204] In a further aspect, the present invention provides a method for producing a method for the treatment of a cancer, comprising: i) a protein; and ii) a signal peptide heterologous to said protein, said signal peptide being the signal peptide of brain-derived neurotrophic factor (BDNF), said protein being not an oxidoreductase an mRNA comprising a nucleic acid sequence encoding especially, i) proteins; and ii) a signal peptide heterologous to the protein, wherein the signal peptide heterologous to the protein is the signal peptide of brain-derived neurotrophic factor (BDNF), and the protein is selected from the group consisting of carboxypeptidases; cytokines; extracellular ligands and transporters; extracellular matrix proteins; glucosidases; glycosyltransferases; growth factors; growth factor binding proteins; heparin binding proteins; hormones; hydrolases; immunoglobulins; isomerases; kinases; lyases; metalloenzyme inhibitors; metalloproteases; milk proteins; neuroactive proteins; proteases; protease inhibitors; protein phosphatases; esterases; transferases; and vasoactive proteins. The present invention provides an mRNA comprising a nucleic acid sequence encoding the

[0205] In one embodiment of the present invention, the protein is a therapeutic protein.In a preferred embodiment of the present invention, the protein is of human origin, i.e., is a human protein.In a further preferred embodiment of the present invention, the protein is selected from the group consisting of carboxypeptidase, cytokine, extracellular ligand and transporter, extracellular matrix protein, glucosidase, glycosyltransferase, growth factor, growth factor binding protein, heparin binding protein, hormone, hydrolase, immunoglobulin, isomerase, kinase, lyase, metalloenzyme inhibitor, metalloprotease, milk protein, neurostimulatory protein, protease, protease inhibitor, protein phosphatase, esterase, transferase, and vasoactive protein, all of which are of human origin. In a more preferred embodiment of the invention, the protein of the invention is selected from the group consisting of human carboxypeptidases; human cytokines; human extracellular ligands and transporters; human extracellular matrix proteins; human glucosidases; human glycosyltransferases; human growth factors; human growth factor binding proteins; human heparin binding proteins; human hormones; human hydrolases; human immunoglobulins; human isomerases; human kinases; human lyases; human metalloenzyme inhibitors; human metalloproteases; human milk proteins; human neurostimulatory proteins; human proteases; human protease inhibitors; human protein phosphatases; human esterases; human transferases; and human vasoactive proteins.

[0206] In one embodiment, the protein is a carboxypeptidase selected from the group consisting of ACE, ACE2, CNDP1, CPA1, CPA2, CPA4, CPA5, CPA6, CPB1, CPB2, CPE, CPN1, CPQ, CPXM1, CPZ, and SCPEP1; a cytokine is selected from the group consisting of BMP1, BMP10, BMP15, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8A, BMP8B, C1QTNF4, CCL1, CCL11, CCL13, CCL14, CCL15, CCL16, CCL 17, CCL18, CCL19, CCL2, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L, CCL4L2, CCL5, CCL7, CCL8, CD40L G, CER1, CKLF, CLCF1, CNTF, CSF1, CSF2, CSF3, CTF1, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL17, CXCL2, CXCL3, CXCL5, CX CL8, CXCL9, DKK1, DKK2, DKK3, DKK4, EDA, EBI3, FAM3B, FAM3C, FASLG, FLT3LG, GDF1, GDF10, GDF11, GDF15, GDF2, GDF3, GDF5, GDF6, GDF7, GDF9, GPI, GRE M1, GREM2, GRN, IFNA1, IFNA13, IFNA10, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNG, IFNK, IFNL1, I FNL2, IFNL3, IFNL4, IFNW1, IL10, IL11, IL12A, IL12B, IL13, IL15, IL16, IL17A, IL17B, IL17C, IL17D, IL17F, IL18, IL19, IL1A, IL1B, IL1F10, IL2, IL20 , IL21, IL22, IL23A, IL24, IL25, IL26, IL27, IL3, IL31, IL32, IL33, IL34, IL36A, IL36B, IL36G, IL36RN, IL37, IL4, IL5, IL6, IL7, IL9, LEFTY1, LEFTY2,LIF, LTA, MIF, MSTN, NAMPT, NODAL, OSM, PF4, PF4V1, SCGB3A1, SECTM1, SLURP1, SPP1, THNSL2, THPO, TNF, TNFSF10, TNFSF11, TNFSF12, TNFSF13, TN FSF13B, TNFSF14, TNFSF15, TSLP, VSTM1, WNT1, WNT10A, WNT10B, WNT11, WNT16, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B , WNT8A, WNT8B, WNT9A, WNT9B, XCL1, and XCL2; extracellular ligands and transporters selected from the group consisting of APCS, CHI3L1, CHI3L2, CLEC3B, DMBT1, DMKN, EDDM3A, EDDM3B, EFNA4, EMC10, ENAM, EPYC, ERVH48-1, F13B, FCN1, FCN2, GLDN, GPLD1, HEG1, ITFG1, KAZALD1, KCP, LACRT, LEG1, METRN, NOTCH2NL, NPNT, OLFM1, O LFML3, PRB2, PSAP, PSAPL1, PSG1, PSG6, PSG9, PTX3, PTX4, RBP4, RNASE10, RNASE12, RNASE13, RNASE9, RSPRY1, RTBDN, S100A12, S100A13, S100A7, S100A8, SAA2, SAA4, SCG1, SCG2, SCG3, SCGB1C1, SCGB1C2, SCGB1D1, SCGB1D2, SCGB1D4, SCGB2B2, SCGB3A2, SCGN, SCRG1, SCUBE1, SCUBE2, SCUBE3, S DCBP, SELENOP, SFTA2, SFTA3, SFTPA1, SFTPA2, SFTPC, SFTPD, SHBG, SLURP2, SMOC1, SMOC2, SMR3A, SMR3B, SNCA, SPATA20, SPATA6, SOGA1, SPARC, S PARCL1, SPATA20, SPATA6, SRPX2, SSC4D, STX1A, SUSD4, SVBP, TCN1, TCN2, TCTN1, TF, TULP3, TFF2, TFF3, THSD7A, TINAG, TINAGL1, TMEFF2, TMEM25,and VWC2L; extracellular ligands and transporters selected from the group consisting of ABI3BP, AGRN, CCBE1, CHL1, COL15A1, COL19A1, COLEC11, DMBT1, DRAXIN, EDIL3, ELN, EMID1, EMILIN1, EMILIN2, EMILIN3, EPDR1, FBLN1, FBLN2, FBLN5, FLRT1, FLRT2, FLRT3, FREM1, GLDN, IBSP, KERA, KIAA0100, KIRREL3, KRT10, LAMB2, MGP, RP an extracellular matrix protein selected from the group consisting of TN, SBSPON, SDC1, SDC4, SEMA3A, SEMA3B, SEMA3C, SEMA3D, SEMA3E, SEMA3F, SEMA3G, SIGLEC1, SIGLEC10, SIGLEC6, SLIT1, SLIT2, SLIT3, SLITRK1, SNED1, SNORC, SPACA3, SPACA7, SPON1, SPON2, STATH, SVEP1, TECTA, TECTB, TNC, TNN, TNR, and TNXB; glucosidases selected from the group consisting of MY1C, AMY2A, AMY2B, CEMIP, CHIA, CHIT1, FUCA2, GLB1L, GLB1L2, HPSE, HYAL1, HYAL3, KL, LYG1, LYG2, LYZL1, LYZL2, MAN2B2, SMPD1, SMPDL3B, SPACA5, and SPACA5B; glycosyltransferases selected from the group consisting of ART5, B4GALT1, EXTL2, GALNT1, GALNT2, GLT1D1, MGAT4A, ST3GAL1, ST3GAL2, ST3GAL3, ST3GAL4, ST a glycosyltransferase selected from the group consisting of AMH, ARTN, BTC, CDNF, CFC1, CFC1B, CHRDL1, CHRDL2, CLEC11A, CNMD, EFEMP1, EGF, EGFL6, EGFL7, EGFL8, EPGN, EREG, EYS, FGF1, FGF10, FGF16, FGF17, FGF18, FGF19, FGF2, FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FRZB,GDNF, GFER, GKN1, HBEGF, HGF, IGF1, IGF2, INHA, INHBA, INHBB, INHBC, INHBE, INS, KITLG, MANF, MDK, MIA, NGF, NOV, NRG1, NRG2, NRG3, NRG4, NRTN, NTF3 , NTF4, OGN, PDGFA, PDGFB, PDGFC, PDGFD, PGF, PROK1, PSPN, PTN, SDF1, SDF2, SFRP1, SFRP2, SFRP3, SFRP4, SFRP5, TDGF1, TFF1, TGFA, TGFB1, TGFB2, TGFB 3, a growth factor selected from the group consisting of THBS4, TIMP1, VEGFA, VEGFB, VEGFC, VEGFD, and WISP3; the growth factor binding protein is selected from the group consisting of CHRD, CYR61, ESM1, FGFBP1, FGFBP2, FGFBP3, HTRA1, GHBP, IGFALS, IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP6, IGFBP7, LTBP1, LTBP2, LTBP3, LTBP4, SOSTDC1, NOG, TWSG1, and WIF1. the heparin-binding protein is selected from the group consisting of ADA2, ADAMTSL5, ANGPTL3, APOB, APOE, APOH, COL5A1, COMP, CTGF, FBLN7, FN1, FSTL1, HRG, LAMC2, LIPC, LIPG, LIPH, LIPI, LPL, PCOLCE2, POSTN, RSPO1, RSPO2, RSPO3, RSPO4, SAA1, SLIT2, SOST, THBS1, and VTN; the hormone is ADCYAP1, ADIPOQ, ADM, ADM2, ANGPTL8, AP ELA, APLN, AVP, C1QTNF12, C1QTNF9, CALCA, CALCB, CCK, CGA, CGB1, CGB2, CGB3, CGB5, CGB8, COPA, CORT, CRH, CSH1, CSH2, CSHL1, ENHO, EPO, ERFE, FBN1, F NDC5, FSHB, GAL, GAST, GCG, GH, GH1, GH2, GHRH, GHRL, GIP, GNRH1, GNRH2, GPHA2, GPHB5, IAPP, INS, INSL3, INSL4, INSL5, INSL6, LHB, METRNL, MLN, NPPA,NPPB, NPPC, OSTN, OXT, PMCCH, PPY, PRL, PRLH, PTH, PTHLH, PYY, RETN RETNLB, RLN1, RLN2, RLN3, SCT, SPX, SST, STC1, STC2, TG, TOR2A, T RH, TSHB, TTR, UCN, UCN2, UCN3, UTS2, UTS2B, and VIP are all very interesting AADACL2, ABHD15, ACP7, ACPP, ADA2, ADAMTSL1, AOA H, ARSF, ARSI, ARSJ, ARSK, BTD, CHI3L2, ENPP1, ENPP2, ENPP3, ENPP5, ENTPD5, ENTPD6, GBP1, GGH, GPLD1, HPSE, LIPC, LIPF, LIPG, LIPH LIPI, LIPK, LIPM, LIPN, LPL, PGLYRP2, PLA1A, PLA2G10, PLA2G12A PLA2G1B, PLA2G2A, PLA2G2D, PLA2G2E, PLA2G2F, PLA2G3, PLA2G5 a hydrolase selected from the group consisting of PLA2G7, PNLIP, PNLIPRP2, PNLIPRP3, PON1, PON3, PPT1, SMPDL3A, THEM6, THSD1, and THSD4; an immunoglobulin selected from the group consisting of IGSF10, IGKV1-12, IGKV1-16, IGKV1-33, IGKV1-6, IGKV1D-12, IGKV1D-39, IGKV1D-8, IGKV2-30, IGKV2D-30, IGKV3-11, IGKV3D-20, IGKV5-2, IGLC1, IGLC2 the isomerase is selected from the group consisting of NAXE, PPIA, and PTGDS; the kinase is selected from the group consisting of ADCK1, ADPGK, FAM20C, ICOS, and PKDCC; the lyase is selected from the group consisting of PM20D1, PAM, and CA6; the metalloenzyme inhibitor is selected from the group consisting of FETUB, SPOCK3, TIMP2, TIMP3, TIMP4, WFIKKN1, and WFIKKN2. metalloproteases selected from the group consisting of ADAM12, ADAM28, ADAM9, ADAMDEC1, ADAMTS1, ADAMTS10, ADAMTS12, ADAMTS13, ADAMTS14, ADAMTS15, ADAMTS16, ADAMTS17, ADAMTS18, ADAMTS19, ADAMTS2, ADAMTS20, ADAMTS3, ADAMTS4, ADAMTS5, ADAMTS6, ADAMTS7, ADAMTS8, ADAMTS9, CLCA1, CLCA2 , CLCA4, IDE, MEP1B, MMEL1, MMP1, MMP10, MMP11, MMP12, MMP13, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP24, MMP25, MMP26, MMP28, MMP3, MMP7, MMP8, MMP9, PAPPA, PAPPA2, TLL1, and TLL2; the milk protein is selected from the group consisting of CSN1S1, CSN2, CSN3, and LALBA;the neuroactive protein is selected from the group consisting of CARTPT, NMS, NMU, NPB, NPFF, NPS, NPVF, NPW, NPY, PCSK1N, PDYN, PENK, PNOC, POMC, PROK2, PTH2, PYY2, PYY3, QRFP, TAC1, and TAC3; the protease is selected from the group consisting of ADAMTS6, C1R, C1RL, C2, CASP4, CELA1 , CELA2A, CELA2B, CFB, CFD, CFI, CMA1, CORIN, CTRB1, CTRB2, CTSB, CTSD, DHH, F10, F11, F12, F2, F3, F7, F8, F9 , FAP, FURIN, GZMA, GZMK, GZMM, HABP2, HGFAC, HTRA3, HTRA4, IHH, KLK10, KLK11, KLK12, KLK13, KLK14, KLK15, KLK3, KLK4, KLK5, KLK6, KLK7, KLK8, KLK9, KLKB1, MASP1, MASP2, MST1L, NAPSA, OVCH1, OVCH2, PCSK2, PCSK5, P CSK6, PCSK9, PGA3, PGA4, PGA5, PGC, PLAT, PLAU, PLG, PROC, PRSS1, PRSS12, PRSS2, PRSS22, PRSS23, PRSS27, P A protease selected from the group consisting of RSS29P, PRSS3, PRSS33, PRSS36, PRSS38, PRSS3P2, PRSS42, PRSS44, PRSS47, PRSS48, PRSS53, PRSS57, PRSS58, PRSS8, PRTN3, RELN, REN, TMPRSS11D, TMPRSS11E, TMPRSS2, TPSAB1, TPSB2, and TPSD1;Protease inhibitors include A2M, A2ML1, AMBP, ANOS1, COL28A1, COL6A3, COL7A1, CPAMD8, CST1, CST2, CST3, CST4, CST5, CST6, CST7, CST8, CST9, CST9L, CST9LP1, CSTL1, EPPIN, GPC3, HMSD, ITIH1, ITIH2, ITIH3, ITIH4, ITIH5, ITIH6, KNG1, OPRPN, OVOS1, OVOS2, PAPLN, PI15, PI16, PI3, PZP, and R3HDM. L, SERPINA1, SERPINA10, SERPINA11, SERPINA12, SERPINA13P, SERPINA3, SERPINA4, SERPINA5, SERPINA7, SERPINA9, SERPINB2, SERPINB5, SERPINC1, SERPINE1, SERPINE2, SERPINE3, SERPINF2, SERPING1, SERPINI1, SERPINI2, SPINK1, SPINK13, SPINK14, SPINK2, SPINK4, SPINK5, a protease inhibitor selected from the group consisting of SPINK6, SPINK7, SPINK8, SPINK9, SPINT1, SPINT3, SPINT4, SPOCK1, SPOCK2, SPP2, SSPO, TFPI, TFPI2, WFDC1, WFDC10A, WFDC13, WFDC2, WFDC3, WFDC5, WFDC6, and WFDC8; a protein phosphatase selected from the group consisting of ACP7, ACPP, PTEN, and PTPRZ1; an esterase selected from the group consisting of B the esterase is selected from the group consisting of CHE, CEL, CES4A, CES5A, NOTUM, and SIAE; the transferase is selected from the group consisting of METTL24, FKRP, CHSY1, CHST9, and B3GAT1; and the vasoactive protein is selected from the group consisting of vasoactive proteins selected from the group consisting of AGGF1, AGT, ANGPT1, ANGPT2, ANGPTL4, ANGPTL6, EDN1, EDN2, EDN3, and NTS;

[0207] In preferred embodiments, the protein is selected from the group consisting of: cytokines; growth factors; growth factor binding proteins; heparin binding proteins; hormones; neuroactive proteins; and vasoactive proteins.

[0208] In a more preferred embodiment, the protein is a cytokine selected from the group consisting of BMP1, BMP10, BMP15, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8A, BMP8B, C1QTNF4, CCL1, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L, CCL4L2, CCL5, CCL7, CC L8, CD40LG, CER1, CKLF, CLCF1, CNTF, CSF1, CSF2, CSF3, CTF1, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL17, CXCL2, CXCL3, CXCL5, CXCL8, CXCL9, DKK1, DKK2, DKK3, DKK4, EDA, EBI3, FAM3B, FAM3C, FASLG, FLT3LG, GDF1, GDF10, GDF11, GDF15, GDF2, GDF3, GDF5, GDF6, GDF7, GDF9, GPI, GREM1, GREM2, GRN, IFNA1, IFNA13, IFNA10, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNG, IFNK, IFNL1, IFNL2, IFNL3, IFNL4, IFNW1, IL10, IL11, IL12A, IL12B, IL13, IL15, IL16, IL17A, IL17B, IL17C, IL17D, IL17F, IL18, IL19, IL1A, IL1B, IL1F10, I L2, IL20, IL21, IL22, IL23A, IL24, IL25, IL26, IL27, IL3, IL31, IL32, IL33, IL34, IL36A, IL36B, IL36G, IL36RN, IL37, IL4, IL5, IL6, IL7, IL9, LEFTY1, LEFTY2, LIF, LTA, MIF, MSTN, NAMPT, NODAL, OSM, PF4, PF4V1, SCGB3A1, SECTM1, SLURP1, SPP1, THNSL2, THPO, TNF, TNFSF10, TNFSF11, TNFSF12, TNFSF13,a cytokine selected from the group consisting of TNFSF13B, TNFSF14, TNFSF15, TSLP, VSTM1, WNT1, WNT10A, WNT10B, WNT11, WNT16, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, XCL1, and XCL2; a growth factor selected from the group consisting of AMH, ARTN, BTC, CDNF, CFC1, CFC1B, CHRDL1, CHRDL2, CLEC11A, CNMD, EFEMP1, EGFR1, EGFR2, EGFR3, EGFR4, EGFR5, EGFR6, EGFR7, EGFR8, EGFR9, EGFR11A, EGFR12, EGFR13, EGFR14, EGFR15, EGFR16, EGFR17, EGFR18, EGFR19, EGFR20, EGFR21, EGFR22, EGFR23, EGFR24, EGFR25, EGFR26, EGFR27, EGFR28, EGFR29, EGFR30, EGFR31, EGFR32, EGFR33, EGFR40, EGFR41, EGFR42, EGFR42, EGFR50, EGFR51, EGFR52, EGFR53, EGFR54, EGFR55, EGFR56, EGFR57, EGFR58, EGFR59, EGFR60, EGFR61, EGFR62, EGFR73, EGFR74, EGFR75, EGFR76, EGFR77, F, EGFL6, EGFL7, EGFL8, EPGN, EREG, EYS, FGF1, FGF10, FGF16, FGF17, FGF18, FGF19, FGF2, FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, F GF8, FGF9, FRZB, GDNF, GFER, GKN1, HBEGF, HGF, IGF1, IGF2, INHA, INHBA, INHBB, INHBC, INHBE, INS, KITLG, MANF, MDK, MIA, NGF, NOV, NRG1, NRG2, NRG3, N a growth factor selected from the group consisting of RG4, NRTN, NTF3, NTF4, OGN, PDGFA, PDGFB, PDGFC, PDGFD, PGF, PROK1, PSPN, PTN, SDF1, SDF2, SFRP1, SFRP2, SFRP3, SFRP4, SFRP5, TDGF1, TFF1, TGFA, TGFB1, TGFB2, TGFB3, THBS4, TIMP1, VEGFA, VEGFB, VEGFC, VEGFD, and WISP3; a growth factor binding protein selected from the group consisting of CHRD, CYR61, ESM1, FGFBP1, FGFBP2, FGFBP 3, a growth factor binding protein selected from the group consisting of HTRA1, GHBP, IGFALS, IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP6, IGFBP7, LTBP1, LTBP2, LTBP3, LTBP4, SOSTDC1, NOG, TWSG1, and WIF1; a heparin binding protein selected from the group consisting of ADA2, ADAMTSL5, ANGPTL3, APOB, APOE, APOH, COL5A1, COMP, CTGF, FBLN7, FN1, FSTL1, HRG, LAMC2, LIPC, LIPG, LIPH,heparin-binding proteins selected from the group consisting of LIPI, LPL, PCOLCE2, POSTN, RSPO1, RSPO2, RSPO3, RSPO4, SAA1, SLIT2, SOST, THBS1, and VTN; hormones selected from the group consisting of ADCYAP1, ADIPOQ, ADM, ADM2, ANGPTL8, APELA, APLN, AVP, C1QTNF12, C1QTNF9, CALCA, CALCB, CCK, CGA, CGB1, CGB2, CGB3 , CGB5, CGB8, COPA, CORT, CRH, CSH1, CSH2, CSHL1, ENHO, EPO, ERFE, FBN1, FNDC5, FSHB, GAL, GAST, GCG, GH, GH1, GH2, GHRH, G HRL, GIP, GNRH1, GNRH2, GPHA2, GPHB5, IAPP, INS, INSL3, INSL4, INSL5, INSL6, LHB, METRNL, MLN, NPPA, NPPB, NPPC, OSTN, OX a hormone selected from the group consisting of T, PMCH, PPY, PRL, PRLH, PTH, PTHLH, PYY, RETN, RETNLB, RLN1, RLN2, RLN3, SCT, SPX, SST, STC1, STC2, TG, TOR2A, TRH, TSHB, TTR, UCN, UCN2, UCN3, UTS2, UTS2B, and VIP; a neuroactive protein selected from the group consisting of CARTPT, NMS, NMU, NPB, NPFF, NPS, NPVF, NPW, N The neuroactive protein is selected from the group consisting of PY, PCSK1N, PDYN, PENK, PNOC, POMC, PROK2, PTH2, PYY2, PYY3, QRFP, TAC1, and TAC3; and the vasoactive protein is selected from the group consisting of AGGF1, AGT, ANGPT1, ANGPT2, ANGPTL4, ANGPTL6, EDN1, EDN2, EDN3, and NTS.

[0209] In an even more preferred embodiment, the protein is selected from the group consisting of: a cytokine; a growth factor; a hormone; and a neurostimulatory protein.

[0210] In certain embodiments of the invention, the protein is a cytokine selected from the group consisting of BMP1, BMP10, BMP15, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8A, BMP8B, C1QTNF4, CCL1, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L, CCL4L2, CCL5, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL3L3, CCL4, CCL4L, CCL4L2, CCL5, CCL7, CCL8, CCL8L ... CL8, CD40LG, CER1, CKLF, CLCF1, CNTF, CSF1, CSF2, CSF3, CTF1, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL17, CXCL2, CXCL3 , CXCL5, CXCL8, CXCL9, DKK1, DKK2, DKK3, DKK4, EDA, EBI3, FAM3B, FAM3C, FASLG, FLT3LG, GDF1, GDF10, GDF11, GDF15, GDF2, GDF3, GDF5, GDF6, GDF7, GDF9 , GPI, GREM1, GREM2, GRN, IFNA1, IFNA13, IFNA10, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNB1, IFNE, IFNG, IFNK , IFNL1, IFNL2, IFNL3, IFNL4, IFNW1, IL10, IL11, IL12A, IL12B, IL13, IL15, IL16, IL17A, IL17B, IL17C, IL17D, IL17F, IL18, IL19, IL1A, IL1B, IL1F10, IL2, IL20, IL21, IL22, IL23A, IL24, IL25, IL26, IL27, IL3, IL31, IL32, IL33, IL34, IL36A, IL36B, IL36G, IL36RN, IL37, IL4, IL5, IL6, IL7, IL9, LEFTY1 , LEFTY2, LIF, LTA, MIF, MSTN, NAMPT, NODAL, OSM, PF4, PF4V1, SCGB3A1, SECTM1, SLURP1, SPP1, THNSL2, THPO, TNF, TNFSF10, TNFSF11, TNFSF12, TNFSF13,a cytokine selected from the group consisting of TNFSF13B, TNFSF14, TNFSF15, TSLP, VSTM1, WNT1, WNT10A, WNT10B, WNT11, WNT16, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, XCL1, and XCL2; a growth factor selected from the group consisting of AMH, ARTN, BTC, CDNF, CFC1, CFC1B, CHRDL1, CHRDL2, CLEC11A, CNMD, EFEMP1, EGFR1, EGFR2, EGFR3, EGFR4, EGFR5, EGFR6, EGFR7, EGFR8, EGFR9, EGFR11A, EGFR12, EGFR13, EGFR14, EGFR15, EGFR16, EGFR17, EGFR18, EGFR19, EGFR20, EGFR21, EGFR22, EGFR23, EGFR24, EGFR25, EGFR26, EGFR27, EGFR28, EGFR29, EGFR30, EGFR31, EGFR32, EGFR33, EGFR40, EGFR41, EGFR42, EGFR42, EGFR50, EGFR51, EGFR52, EGFR53, EGFR54, EGFR55, EGFR56, EGFR57, EGFR58, EGFR59, EGFR60, EGFR61, EGFR62, EGFR73, EGFR74, EGFR75, EGFR76, EGFR77, F, EGFL6, EGFL7, EGFL8, EPGN, EREG, EYS, FGF1, FGF10, FGF16, FGF17, FGF18, FGF19, FGF2, FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FG F8, FGF9, FRZB, GDNF, GFER, GKN1, HBEGF, HGF, IGF1, IGF2, INHA, INHBA, INHBB, INHBC, INHBE, INS, KITLG, MANF, MDK, MIA, NGF, NOV, NRG1, NRG2, NRG3, NR a growth factor selected from the group consisting of G4, NRTN, NTF3, NTF4, OGN, PDGFA, PDGFB, PDGFC, PDGFD, PGF, PROK1, PSPN, PTN, SDF1, SDF2, SFRP1, SFRP2, SFRP3, SFRP4, SFRP5, TDGF1, TFF1, TGFA, TGFB1, TGFB2, TGFB3, THBS4, TIMP1, VEGFA, VEGFB, VEGFC, VEGFD, and WISP3; a hormone selected from the group consisting of ADCYAP1, ADIPOQ, ADM, ADM2, ANGPTL8, APELA, APLN, A VP, C1QTNF12, C1QTNF9, CALCA, CALCB, CCK, CGA, CGB1, CGB2, CGB3, CGB5, CGB8, COPA, CORT, CRH, CSH1, CSH2, CSHL1, ENHO, EPO, ERFE, FBN1, FNDC5, FSHB, GAL, GAST, GCG, GH, GH1, GH2, GHRH, GHRL, GIP, GNRH1, GNRH2, GPHA2, GPHB5, IAPP, INS, INSL3, INSL4, INSL5, INSL6, LHB, METRNL, MLN, NPPA, NPPB, NPPC,Hormones selected from the group consisting of OSTN, OXT, PMCH, PPY, PRL, PRLH, PTH, PTHLH, PYY, RETN, RETNLB, RLN1, RLN2, RLN3, SCT, SPX, SST, STC1, STC2, TG, TOR2A, TRH, TSHB, TTR, UCN, UCN2, UCN3, UTS2, UTS2B, and VIP; and neuroactive proteins selected from the group consisting of neuroactive proteins selected from the group consisting of CARTPT, NMS, NMU, NPB, NPFF, NPS, NPVF, NPW, NPY, PCSK1N, PDYN, PENK, PNOC, POMC, PROK2, PTH2, PYY2, PYY3, QRFP, TAC1, and TAC3.

[0211] In another specific embodiment of the invention, the protein is selected from the group consisting of: cytokines selected from the group consisting of BMP-2, BMP-4, CNTF, MSTN, IFNG, IL6, SPP1; growth factors selected from the group consisting of EGF, FGF1, GDNF, IGF1, IGF2, NTF3, TGFB1; hormones selected from the group consisting of EPO, FBN1, GH, GHRH, OSTN, UCN; and neurostimulatory proteins selected from the group consisting of NPFF, NPY, PNOC, POMC.

[0212] In another specific embodiment of the invention, the protein is selected from the group consisting of: cytokines selected from the group consisting of BMP-2, BMP-4, CNTF, MSTN, IFNG, IL4, IL6, IL10, SPP1; growth factors selected from the group consisting of EGF, FGF1, GDNF, IGF1, IGF2, NTF3, TGFB1; hormones selected from the group consisting of EPO, FBN1, GH, GHRH, OSTN, UCN, INS; and neurostimulatory proteins selected from the group consisting of NPFF, NPY, PNOC, POMC.

[0213] In a more particular embodiment of the invention, the protein is selected from the group consisting of growth factors. In an even more particular embodiment of the invention, the protein is selected from the group consisting of growth factors, the growth factors being AMH, ARTN, BDNF, BTC, CDNF, CFC1, CFC1B, CHRDL1, CHRDL2, CLEC11A, CNMD, EFEMP1, EGF, EGFL6, EGFL7, EGFL8, EPGN, EREG, EYS, FGF1, FGF10, FGF16, FGF17, FGF18, FGF19, FGF2, FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FRZB, GDNF, GFER, GKN1, HBEGF, HGF, I GF1, IGF2, INHA, INHBA, INHBB, INHBC, INHBE, INS, KITLG, MANF, MDK, MIA, NGF, NOV, NRG1, NRG2, NRG3, NRG4, NRTN, NTF3, NTF4, OGN, PDGFA, PDGFB, PDGFC, PDGFD, PGF, PROK1, PSPN, PTN, SDF1, SDF2, SFRP1, SFRP2, SFRP3, SFRP4, SFRP5, TDGF1, TFF1, TGFA, TGFB1, TGFB2, TGFB3, THBS4, TIMP1, VEGFA, VEGFB, VEGFC, VEGFD, and WISP3.

[0214] In another even more particular embodiment of the invention, the protein is selected from the group consisting of growth factors, the growth factors being selected from the group consisting of EGF, FGF1, GDNF, IGF1, IGF2, NTF3, TGFB1. Most particularly, the protein is IGF1, preferably human IGF1.

[0215] In an even more particular embodiment of the invention, the protein is selected from the group consisting of a cytokine; a growth factor; and a hormone, preferably the cytokine is selected from the group consisting of BMP-2, BMP-4, CNTF, MSTN, IFNG, IL4, IL6, IL10, SPP1; the growth factor is selected from the group consisting of EGF, FGF1, GDNF, IGF1, IGF2, NTF3, TGFB1; and the hormone is selected from the group consisting of EPO, FBN1, GH, GHRH, OSTN, UCN, INS. Most particularly, the protein is selected from the group consisting of insulin growth factor 1 (IGF1), insulin (INS), erythropoietin (EPO), interleukin-4 (IL-4) and interleukin-10 (IL-10).

[0216] In one embodiment of the present invention, the mRNA is naked mRNA. In a preferred embodiment, the mRNA comprises m7G(5')G, anti-reverse CAP analogues such as m7GpppG cap, internal ribosome entry site (IRES) and / or poly A tail at the 3' end, in particular to improve translation. The mRNA can have additional regions that promote translation known to those skilled in the art.

[0217] In a preferred embodiment of the invention, the mRNA contains a combination of modified and unmodified nucleotides. In a more preferred embodiment, in such modified mRNA, 1-100%, preferably 10-100%, more preferably 50-100%, even more preferably 90-100%, most preferably 100% of the uridine nucleotides are modified. The adenosine, guanosine, and cytidine-containing nucleotides may be unmodified or partially modified, and they are preferably present in unmodified form. Preferably, the content of modified uridine nucleotides in the mRNA is in the range of 5-25%. In a particularly preferred embodiment of the invention, the modified uridine nucleotides are N 1In a more particularly preferred embodiment of the invention, the mRNA contains a combination of modified and unmodified nucleotides, and in such modified mRNA 1-100%, preferably 10-100%, more preferably 50-100%, even more preferably 90-100%, and most preferably 100% of the uridine nucleotides are N-methylpseudouridine. 1 -Methylpseudouridine.

[0218] In a more preferred embodiment of the present invention, the mRNA is codon-optimized and contains a combination of modified and unmodified nucleotides. In a more preferred embodiment, in such modified mRNA, 1-100%, preferably 10-100%, more preferably 50-100%, even more preferably 90-100%, most preferably 100% of the uridine nucleotides are modified. The adenosine, guanosine, and cytidine-containing nucleotides may be unmodified or partially modified, and they are preferably present in unmodified form. Preferably, the content of modified uridine nucleotides in the mRNA is in the range of 5-25%. In a particularly preferred embodiment of the present invention, the modified uridine nucleotides are N 1 In a more particularly preferred embodiment of the invention, the RNA is an mRNA containing a combination of modified and unmodified nucleotides, and in such modified mRNA 1-100%, preferably 10-100%, more preferably 50-100%, even more preferably 90-100%, most preferably 100% of the uridine nucleotides are N-methylpseudouridine. 1 -Methylpseudouridine.

[0219] In a preferred embodiment of the invention, the mRNA comprises a nucleic acid sequence encoding human insulin-like growth factor 1 (IGF1) as a protein, more preferably the mRNA is naked mRNA comprising a nucleic acid sequence encoding human insulin-like growth factor 1 (IGF1) as a protein. In this preferred embodiment of the invention, the mRNA comprises a nucleic acid sequence encoding mature human IGF-1. In a more preferred embodiment of the invention, the mRNA comprises a nucleic acid sequence encoding the propeptide of IGF1, preferably the propeptide of human IGF1, and a nucleic acid sequence encoding the mature protein of IGF1, preferably the mature protein of human IGF1, and does not comprise a nucleic acid sequence encoding the E peptide of IGF1, preferably does not comprise a nucleic acid sequence encoding the human E peptide of IGF1. In an even more preferred embodiment of the present invention, the mRNA comprises a nucleic acid sequence encoding a propeptide of IGF1, preferably a propeptide of human IGF1, a nucleic acid sequence encoding a mature protein of IGF1, preferably a mature protein of human IGF1. Preferably, the mRNA does not comprise a nucleic acid sequence encoding an E peptide of IGF1, more preferably does not comprise a nucleic acid sequence encoding a human E peptide of IGF1. In an even more preferred embodiment of the present invention, the mRNA comprises a nucleic acid sequence encoding a propeptide of IGF1, preferably a propeptide of human IGF1, a nucleic acid sequence encoding a mature protein of IGF1, preferably a mature protein of human IGF1, and a nucleic acid sequence encoding a signal peptide of brain-derived neurotrophic factor (BDNF). Preferably, the mRNA does not comprise a nucleic acid sequence encoding an E peptide of IGF1, more preferably does not comprise a nucleic acid sequence encoding a human E peptide of IGF1.

[0220] In an even more preferred embodiment of the invention, the mRNA comprises a nucleotide sequence encoding the propeptide (also called the prodomain) of IGF1, preferably human IGF1 having 27 amino acids, and a nucleotide sequence encoding mature IGF1, preferably mature human IGF1 having 70 amino acids, and preferably does not comprise a nucleotide sequence encoding the E peptide of IGF1, and preferably does not comprise a nucleic acid sequence encoding the human E peptide of IGF1. In an even more preferred embodiment of the invention, the mRNA comprises a nucleotide sequence encoding the propeptide (also called the prodomain) of IGF1, preferably human IGF1 having 27 amino acids, a nucleotide sequence encoding mature IGF1, preferably mature human IGF1 having 70 amino acids, and a nucleic acid sequence encoding the signal peptide of brain-derived neurotrophic factor (BDNF). Preferably, the mRNA does not comprise a nucleotide sequence encoding the E peptide of IGF1, more preferably does not comprise a nucleic acid sequence encoding the human E peptide of IGF1.

[0221] In a particular preferred embodiment of the invention, the mRNA comprises a nucleic acid sequence encoding the propeptide (also called prodomain) of human IGF1 having 27 amino acids and a nucleotide sequence encoding mature human IGF1 having 70 amino acids, preferably not comprising a nucleotide sequence encoding the E peptide (also called E domain) of human IGF1, the nucleotide sequence encoding the propeptide (also called prodomain) of human IGF1 having 27 amino acids and the nucleotide sequence encoding mature human IGF1 having 70 amino acids and the nucleotide sequence encoding the E peptide being referred to in the Uniprot database as UniProtKB-P05019 and in the Genbank database as NM_000618.4, NM_001111285.2 and NM_001111283.2, respectively.

[0222] In an even more particular preferred embodiment of the invention, the mRNA comprises a nucleic acid sequence encoding the propeptide (also called the prodomain) of human IGF1 having 27 amino acids as set forth in SEQ ID NO:38, and a nucleotide sequence encoding mature human IGF1 having 70 amino acids as set forth in SEQ ID NO:39, and preferably does not include a nucleotide sequence encoding the E peptide (also called the E domain) of human IGF1.

[0223] In an even more particular preferred embodiment of the invention, the mRNA comprises a nucleic acid sequence encoding the propeptide (also called the prodomain) of human IGF1 having 27 amino acids as set forth in SEQ ID NO: 38, a nucleotide sequence encoding mature human IGF1 having 70 amino acids as set forth in SEQ ID NO: 39, and a nucleic acid sequence encoding the signal peptide of brain-derived neurotrophic factor (BDNF), preferably a nucleotide sequence encoding the signal peptide of brain-derived neurotrophic factor (BDNF) as set forth in SEQ ID NO: 30. Preferably, the mRNA does not comprise a nucleotide sequence encoding the E peptide (also called the E domain) of human IGF1.

[0224] In a particular preferred embodiment of the invention, the mRNA comprising a nucleic acid sequence encoding the signal peptides of human insulin-like growth factor 1 (IGF1) and brain-derived neurotrophic factor (BDNF) comprises the nucleic acid sequence shown in SEQ ID NO:8.

[0225] In a further particular preferred embodiment of the invention, the mRNA comprising a nucleic acid sequence encoding the signal peptides of human insulin-like growth factor 1 (IGF1) and brain-derived neurotrophic factor (BDNF) comprises a nucleic acid sequence transcribed from the DNA sequence shown in SEQ ID NO: 7. Preferably, the nucleic acid sequence is transcribed in vitro from the DNA sequence shown in SEQ ID NO: 7.

[0226] In a more specific preferred embodiment of the present invention, the mRNA comprising a nucleic acid sequence encoding the signal peptide of human insulin-like growth factor 1 (IGF1) and brain-derived neurotrophic factor (BDNF) is preferably 1 to 100%, more preferably 50 to 100%, even more preferably 90 to 100%, and most preferably 100% of the uridine nucleotides are N-type. 1 -methylpseudouridine, comprising the nucleic acid sequence set forth in SEQ ID NO:8.

[0227] In an even more specific preferred embodiment of the present invention, the mRNA comprising a nucleic acid sequence encoding the signal peptide of human insulin-like growth factor 1 (IGF1) and brain-derived neurotrophic factor (BDNF) is preferably 1 to 100%, more preferably 50 to 100%, even more preferably 90 to 100%, and most preferably 100% of the uridine nucleotides are N-type. 1 In this embodiment, the nucleotide sequence is preferably transcribed in vitro from the DNA sequence shown in SEQ ID NO: 7, whereas the uridine nucleotide is N-methylpseudouridine. 1 -Methylpseudouridine-5'-triphosphate (N 1 -methylpseudo-UTP), i.e. 100% N 1 Only -methyl pseudo-UTP is used for transcription from the DNA sequence shown in SEQ ID NO:7.

[0228] In a preferred embodiment of the invention, the signal peptide of brain-derived neurotrophic factor (BDNF) is the signal peptide of human BDNF, more preferably the signal peptide shown in SEQ ID NO: 31, in particular the signal peptide of human BDNF encoded by the nucleic acid sequence shown in SEQ ID NO: 30.

[0229] In a more preferred embodiment of the invention, the mRNA comprises the following sequences from 5' to 3': i) the signal peptide of brain-derived neurotrophic factor (BDNF); ii) optionally a prodomain of the protein; and iii) Mature Protein The nucleic acid sequence encoding the

[0230] In an even more preferred embodiment of the invention, the mRNA comprises the following sequences from 5' to 3': i) the signal peptide of brain-derived neurotrophic factor (BDNF); ii) optionally the prodomain of a human IGF; and iii) mature human IGF The nucleic acid sequence encoding the

[0231] In a preferred embodiment of the invention, the signal peptide of brain-derived neurotrophic factor (BDNF) replaces the protein's natural signal peptide.

[0232] In a further aspect, the invention relates to a transcription unit, expression vector or gene therapy vector comprising a nucleic acid encoding a protein and a signal peptide, wherein the amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, and which are optionally modified by the insertion, deletion and / or substitution of at least one amino acid. The present invention provides a transcription unit, expression vector or gene therapy vector selected from the group consisting of:

[0233] In a further aspect, the present invention provides a transcription unit, expression vector or gene therapy vector comprising a nucleic acid sequence encoding a protein and a signal peptide heterologous to said protein, wherein the signal peptide heterologous to said protein is the signal peptide of Brain-Derived Neurotrophic Factor (BDNF), and the protein is not an oxidoreductase, preferably is not a thioredoxin, more preferably is not a rod-derived cone survival factor. The same applies as described elsewhere herein with respect to the signal peptide of Brain-Derived Neurotrophic Factor (BDNF) and the protein.

[0234] In a further aspect, the present invention provides a transcription unit, expression vector or gene therapy vector comprising a nucleic acid sequence encoding a protein and a signal peptide heterologous to said protein, said signal peptide being the signal peptide of brain-derived neurotrophic factor (BDNF), said protein being selected from the group consisting of carboxypeptidases; cytokines; extracellular ligands and transporters; extracellular matrix proteins; glucosidases; glycosyltransferases; growth factors; growth factor binding proteins; heparin binding proteins; hormones; hydrolases; immunoglobulins; isomerases; kinases; lyases; metalloenzyme inhibitors; metalloproteases; milk proteins; neurostimulatory proteins; proteases; protease inhibitors; protein phosphatases; esterases; transferases; and vasoactive proteins. The same applies as described elsewhere herein with respect to the signal peptide and protein of brain-derived neurotrophic factor (BDNF).

[0235] In a further aspect, the present invention provides a therapeutic composition comprising the mRNA and / or transcription unit, expression vector or gene therapy vector described above. The same applies as described elsewhere herein with respect to the signal peptide and protein of brain-derived neurotrophic factor (BDNF). Usually, the mRNA of the present invention is provided as a therapeutic composition, which is preferably a liquid composition. A liquid composition is any composition in which the mRNA is present in a liquid solution. In one embodiment of the present invention, the mRNA is dissolved in water, or a buffered or unbuffered aqueous solution. The solution is preferably an aqueous solution. Thus, the liquid may be water, preferably sterile water, more preferably "water for injection" (WFI) or any other buffered or unbuffered aqueous solution. In one embodiment of the present invention, the liquid composition is an unbuffered solution, preferably a saline solution, more preferably a saline solution of a pharma- ceutically acceptable salt, even more preferably a NaCl solution, i.e. saline. Preferably, the saline solution is isotonic, and even more preferably, the saline solution exhibits a physiological pH value. In a preferred embodiment of the present invention, the solution in which the mRNA is contained is a buffered solution. Preferably, such a solution is isotonic with blood. In principle, any buffer that effectively buffers in the physiological range, in particular in the range of pH 3.0 to 10.5, more preferably in the range of pH 4.0 to 9.0, may be used. Preferred buffers are acetate buffer, phosphate buffer, phosphate buffered saline (PBS), carbonate buffer, lactate buffer and citrate buffer or Ringer's solution, preferably phosphate buffered saline (PBS). Thus, in a more preferred embodiment of the present invention, the solution in which the mRNA is contained is phosphate buffered saline (PBS).

[0236] The concentration of mRNA in the therapeutic composition is not particularly important and can be adjusted as necessary. Preferably, the concentration is in the range of 0.05 to 20.0 μg / μl, more preferably in the range of 0.1 to 10.0 μg / μl, even more preferably in the range of 0.2 to 5 μg / μl, particularly in the range of 0.4 to 2.0 μg / μl, more particularly in the range of 0.6 to 1.5 μg / μl, even more particularly in the range of 0.80 to 1.20 μg / μl. Particularly preferred is the range of 0.01 μg to 0.1 g, preferably 0.1 μg to 0.01 g, more preferably 0.5 μg to 1 mg, even more preferably 0.5 μg to 10 μg.

[0237] In a further aspect, the present invention provides a kit comprising the above-described mRNA and / or transcription unit, expression vector or gene therapy vector or therapeutic composition, as well as instructions for use, optionally a vector map, optionally a host cell, optionally a culture medium for culturing the host cell, and / or optionally a selection medium for selecting and culturing the transfected host cell. The kit of the present invention may be provided as a kit-of-contents (or in the form of the kit). The kit may further comprise one or more of the components of the therapeutic composition of the present invention, for example in one or more separate containers. For example, the kit may comprise the mRNA (e.g. in dry form), a solubilizing agent and an aqueous solution (buffered or unbuffered), for example in one, two or three (or more) separate containers, respectively. The kit may also comprise an instruction manual or instruction leaflet.

[0238] In a further aspect, the present invention provides an mRNA, a transcription unit, an expression vector or a gene therapy vector, a therapeutic composition or a kit as described above for use as a medicament. With respect to signal peptides, such as the signal peptide of brain-derived neurotrophic factor (BDNF) and proteins, the same applies as described elsewhere herein.

[0239] In a further aspect, the invention provides mRNA or a therapeutic composition comprising or containing the mRNA for use in a method of treating skeletal muscle injury. The invention also provides the use of mRNA or a therapeutic composition comprising or containing the mRNA for the manufacture of a medicament for treating skeletal muscle injury in a subject. The present invention also provides a method of treating skeletal muscle injury in a subject comprising administering to the subject mRNA or a therapeutic composition that comprises or contains mRNA.

[0240] Skeletal muscle injuries, such as muscle ruptures, are one of the most common injuries occurring in sports, with a frequency ranging from 10 to 55% of all sustained injuries. Muscle injuries can be caused by eccentric contractions, stretching and muscle overload. More than 90% of all sports-related injuries are caused by either eccentric contractions, stretching or muscle overload. Skeletal muscle injuries occur when muscles are subjected to sudden, large compressive forces, such as direct impact. In muscle tears, the muscle is subjected to excessive, eccentric tension, leading to excessive tension of the muscle fibers, resulting in the rupture of the muscle fibers near the muscular-tendon junction (MTJ). Muscle tears are one of the most common complaints treated by physicians and account for the majority of all sports-related injuries. Injuries to the hamstring muscle complex (HMC) often affect athletes involved in sports that necessitate rapid acceleration and deceleration while running and require eccentric muscle contractions. Mild injuries can be easily addressed by conservative treatment, while more severe injuries are complete tears of the hamstring muscle. Hamstring muscle tears are treated conservatively or surgically depending on how they are classified. There are mild, moderate, or severe tears. Mild to moderate tears can be treated conservatively, while severe tears are clear indications for surgical treatment. Conservative treatment is determined by clinical symptoms and begins immediately with nonsteroidal, anti-inflammatory drugs before cryotherapy, compression bandaging, immobilization, and elastic bandaging, and physical therapy begins once the patient is stabilized. Ultrasound therapy has been widely discussed as a treatment option, but no significant effect on the final outcome of regeneration was found.Within two weeks, there should be a clear reduction in pain, and physical therapy can be increased to include active exercises as described above.However, it is recognized in the field that surgical procedures are not without risk and candidates must be carefully selected (Jarvinen TA, Jarvinen TL, Kaariainen M, Aarimaa V, Vaittinen S, Kalimo H, Jarvinen M (2007) Muscle injuries: optimizing recovery. Best Pract Res Clin Rheumatol 21(2):317-331. DOI:10.1016 / j.berh.2006.12.004; Horst K, Dienstknecht T, Sellei RM, Pape HC (2014) Partial rupture of the hamstring muscle complex: a literature review on treatment options. Eur J Orthop Surg Traumatol 24(3):285-9. DOI:10.1007 / s00590-013-1315-x). Current treatment options offer little beyond the body's own healing process, and in fact nonsteroidal anti-inflammatory drugs (NSAIDs) can impair the healing process. Today, there is a high unmet medical need due to the lack of effective pharmaceutical treatments available. In particular, there is a need to provide an effective method for treating skeletal muscle injuries that accelerates the recovery process and results in increased function of the damaged muscles.

[0241] In a preferred embodiment of the present invention, the mRNA for use in the method of treating skeletal muscle injury is an mRNA encoding a growth factor, preferably an mRNA encoding human insulin-like growth factor 1 (IGF1). The mRNA encoding a growth factor usually comprises a nuclear sequence encoding a signaling peptide, optionally a nuclear sequence encoding a propeptide of the growth factor, and a nuclear sequence encoding a mature growth factor. The mRNA encoding human IGF1 preferably comprises a nuclear sequence encoding a signaling peptide, optionally a nuclear sequence encoding a propeptide of human IGF1, and a nuclear sequence encoding a mature human IGF1, even more preferably a nuclear sequence encoding a signaling peptide, a nuclear sequence encoding a propeptide of human IGF1, and a nuclear sequence encoding a mature human IGF1, but does not comprise a nuclear sequence encoding an E peptide of human IGF1. The signaling peptide contained by the mRNA encoding a growth factor may be a signaling peptide homologous to the growth factor, i.e., a signaling peptide of the growth factor, or may be a signaling peptide heterologous to the growth factor, preferably a signaling peptide heterologous to the growth factor, more preferably a signaling peptide of brain-derived neurotrophic factor (BDNF), in particular a signal peptide of human BDNF. The signaling peptide contained by the mRNA encoding human IGF1 may be a signaling peptide homologous to human IGF1, i.e., the signaling peptide of human IGF1, or it may be a signaling peptide heterologous to human IGF1, preferably a signaling peptide heterologous to human IGF1, more preferably the signal peptide of brain-derived neurotrophic factor (BDNF), in particular the signal peptide of human BDNF.

[0242] Thus, in a more preferred embodiment of the present invention, the mRNA for use in the method of treating skeletal muscle injury is an mRNA encoding human insulin-like growth factor 1 (IGF1), comprising a nuclear sequence encoding the signal peptide of brain-derived neurotrophic factor (BDNF), particularly the signal peptide of human BDNF, optionally a nuclear sequence encoding the propeptide of human IGF1, and a nuclear sequence encoding mature human IGF-1. In an even more preferred embodiment of the present invention, the mRNA for use in the method of treating skeletal muscle injury is an mRNA encoding human insulin-like growth factor 1 (IGF1), comprising a nuclear sequence encoding the signal peptide of brain-derived neurotrophic factor (BDNF), particularly the signal peptide of human BDNF, optionally a nuclear sequence encoding the propeptide of human IGF1, and a sequence encoding mature human IGF-1, but not including a nuclear sequence encoding the E peptide of human IGF1.

[0243] Thus in a further aspect the present invention provides a method for treating skeletal muscle injury comprising: i) IGF1, preferably human IGF1; and ii) the signal peptide of brain-derived neurotrophic factor (BDNF), preferably the signal peptide of human BDNF The present invention provides an mRNA comprising a nucleic acid sequence encoding the The present invention also provides a method for the manufacture of a medicament for treating skeletal muscle injury in a subject, comprising: i) IGF1, preferably human IGF1; and ii) the signal peptide of brain-derived neurotrophic factor (BDNF), preferably the signal peptide of human BDNF Use of an mRNA comprising a nucleic acid sequence encoding the

[0244] The present invention also provides i) IGF1, preferably human IGF1; and ii) the signal peptide of brain-derived neurotrophic factor (BDNF), preferably the signal peptide of human BDNF Also provided is a method of treating skeletal muscle injury in a subject, comprising administering to the subject an mRNA comprising a nucleic acid sequence encoding Preferably, the present invention relates to a method for treating skeletal muscle injury comprising: i) mature IGF1, preferably mature human IGF1; ii) optionally the prodomain of IGF1, preferably human IGF1; iii) the signal peptide of brain-derived neurotrophic factor (BDNF), preferably the signal peptide of human BDNF The present invention provides an mRNA comprising a nucleic acid sequence encoding the The present invention also provides a method for the manufacture of a medicament for treating skeletal muscle injury in a subject, comprising: i) mature IGF1, preferably mature human IGF1; ii) optionally the prodomain of IGF1, preferably human IGF1; iii) the signal peptide of brain-derived neurotrophic factor (BDNF), preferably the signal peptide of human BDNF Use of an mRNA comprising a nucleic acid sequence encoding the

[0245] The present invention also provides i) mature IGF1, preferably mature human IGF1; ii) optionally the prodomain of IGF1, preferably human IGF1; iii) the signal peptide of brain-derived neurotrophic factor (BDNF), preferably the signal peptide of human BDNF Also provided is a method of treating skeletal muscle injury in a subject, comprising administering to the subject an mRNA comprising a nucleic acid sequence encoding

[0246] The same applies as described elsewhere herein with respect to the mRNA comprising a nucleic acid sequence encoding the signal peptides of human insulin-like growth factor 1 (IGF1) and brain-derived neurotrophic factor (BDNF) for use in a method for treating skeletal muscle injury. In a particular preferred embodiment of the present invention, the mRNA comprising a nucleic acid sequence encoding the signal peptides of human insulin-like growth factor 1 (IGF1) and brain-derived neurotrophic factor (BDNF) comprises the nucleic acid sequence shown in SEQ ID NO: 8. In a further particular preferred embodiment of the present invention, the mRNA comprising a nucleic acid sequence encoding the signal peptides of human insulin-like growth factor 1 (IGF1) and brain-derived neurotrophic factor (BDNF) comprises the nucleic acid sequence transcribed from the DNA sequence shown in SEQ ID NO: 7. Preferably, the nucleic acid sequence is transcribed in vitro from the DNA sequence shown in SEQ ID NO: 7.

[0247] The mRNA and / or therapeutic composition can be applied to cells and tissues, e.g., skeletal muscle, by means known to those skilled in the art, preferably by injection, more preferably intramuscular injection, typically using a syringe equipped with a needle. In principle, any commercially available syringe combined with a needle can be used for this purpose. Preference is given to hypodermic needles. The diameter of the needle is indicated by the needle gauge (G; according to the needle gauge of the stub). Typically, needles in the medical range of 7G (maximum) to 33G (minimum) can be used.

[0248] In some embodiments, the mRNA and / or therapeutic composition may be delivered to the cell by direct DNA transfer (Wolff et al. (1990) Science 247, 1465-1468). The mRNA and / or therapeutic composition may be delivered to the cell after gentle mechanical disruption of the cell membrane and transient permeabilization of the cell. Such gentle mechanical disruption of the membrane can be achieved by gently passing the cell through a small opening (Sharei et al. PLOS ONE (2015) 10(4), e0118803). In another embodiment, the mRNA and / or therapeutic composition may be delivered to the cell by liposome-mediated DNA transfer (e.g., Gao and Huang (1991) Biochem. Ciophys. Res. Comm. 179, 280-285; Crystal (1995) Nature Med. 1, 15-17; Caplen et al. (1995) Nature Med. 3, 39-46). The term "liposome" can encompass a variety of unilamellar and multilamellar vesicular lipid vehicles formed by the formation of enclosed lipid bilayers or aggregates. The mRNA can be encapsulated in the aqueous interior of the liposome, dispersed within the lipid bilayer of the liposome, bound to the liposome via a linking molecule associated with both the liposome and the oligonucleotide, enclosed in the liposome, or complexed with the liposome.

[0249] In one embodiment of the present invention, RNA or therapeutic composition is administered directly (preferably by injection) to skeletal muscle in the form of therapeutic composition, i.e. liquid composition, in which RNA is contained as naked RNA. The same applies as described elsewhere herein with respect to the administration method and characteristics of the composition and the RNA contained therein. In a preferred embodiment, the liquid composition and mRNA of the present invention, respectively, are administered directly to skeletal muscle. In this context, the most preferred administration method is injection, i.e. intramuscular injection.

[0250] In principle, it is envisaged in the context of the present invention to administer the mRNA and the therapeutic composition, respectively, as early as possible, i.e., as early as possible after skeletal muscle damage.For example, this stage is the time when the first symptom(s) is observed (e.g., pain).However, any time after diagnosis is possible and meaningful, and therefore envisaged by the present invention.For example, if there is a surgical procedure (e.g., after muscle rupture), the mRNA and the therapeutic composition, respectively, may be administered during the surgical procedure, but at least immediately after the surgical procedure.

[0251] In one embodiment, the mRNA and the therapeutic composition are administered during or even before the inflammatory and early proliferative phases of skeletal muscle regeneration, respectively. For example, administration may be between days 0 and 10, preferably between days 0 and 7, after injury. More specifically, administration may be on days 0, 1, 2, 3, 4, 5, 6 or 7 after injury. Preferably, administration is on day 1 after injury, even more preferably on day 0. In a preferred embodiment, the therapeutic composition is administered before the inflammatory phase following said skeletal muscle injury. Particularly preferred is administration on day 1 after injury and repeated on day 4 after injury.

[0252] The administration of the mRNA and the therapeutic composition according to the present invention, respectively, can be repeated at least once, but preferably several times (e.g., 3 to 5 times), for example depending on the course of the injury to be treated. Repeated administration may be after 1, 2, 3, 4, 5, 6, 7, 8, or 9 days, preferably after 2, 3, 4, 5, 6, 7 days, more preferably after 3, 4 or 5 days. Repeated administration may be every few weeks (e.g., every 1, 2, 3, or 4 weeks), up to every few days (e.g., every 1, 2, 3, 4, 5, or 6 days), preferably every 2 or 3 days.

[0253] The mRNA or therapeutic composition of the present invention can be administered to the patient in an appropriate dose. The administration regimen can be determined by the attending physician, for example based on clinical factors. As is well known in the medical field, the dosage for any one patient depends on many factors, including the patient's size, body surface area, age, the specific compound administered, sex, timing and route of administration, general health, and other drugs administered at the same time. However, the skilled person / attending physician is in a position to easily estimate the (therapeutically) effective concentration and / or dosage of the active substance administered, for example in vivo or ex vivo. A corresponding sample can be taken, for example from skeletal muscle (for example by a suitable probe), the active compound (naked RNA) can be detected in said sample, and its corresponding concentration can be determined in said sample, for example by HPLC.

[0254] A typical dose of an active substance (e.g., mRNA) may be, for example, in the range of 1 ng to several grams, preferably in the range of 0.1 μg to 1 g, preferably in the range of 1 μg to 0.1 g, more preferably in the range of 10 μg to 1 mg, even more preferably in the range of 15 μg to 0.5 mg, and most preferably in the range of 20 μg to 100 μg. Particularly preferred is the range of 0.01 μg to 0.1 g, preferably 0.1 μg to 0.01 g, more preferably 0.5 μg to 1 mg, even more preferably 0.5 μg to 10 μg. This is particularly true for human patients. When applied to (m)RNA therapy, the dosage of (m)RNA for expression should correspond to this range; however, doses below or above this exemplary range are also envisaged in principle, especially taking into account the factors mentioned above. In general, the regime for regular administration of the therapeutic composition should be in the range of 0.1 μg to 10 mg units per kilogram of body weight per day, preferably in the range of 1 μg to 1 mg units, more preferably in the range of 10 μg to 0.1 mg units. Again, this applies especially to human patients. Progress can be monitored by regular evaluation. Although dosages can vary, a preferred dosage for administration by injection of (m)RNA as a constituent of the liquid composition of the invention is about 10 (m)RNA molecules per injection. 5 ~1015 Again, this is especially true for human patients.

[0255] In particular, it is envisaged that the therapeutic compositions of the invention will be administered to a patient, preferably a human patient / person. However, the skeletal muscle damage described herein can also be treated (or prevented) in non-human animal subjects / patients, such as, for example, pets (e.g., dogs, cats, rabbits, rats and mice), livestock (e.g., cattle, pigs, sheep), horses (e.g., race horses) or ponies, camels (e.g., racing camels), or birds (e.g., chickens, turkeys, parrots).

[0256] In particular, therapeutic compositions comprising mRNA are therapeutically active in the healing process of injuries, disorders and / or diseases, such as skeletal muscle injuries.

[0257] In a more particular preferred embodiment of the invention, the mRNA encoding insulin-like growth factor 1 (IGF1) for use as a medicament comprises the nucleic acid sequence transcribed from the DNA sequence of SEQ ID NO: 7. In an even more particular preferred embodiment of the invention, the mRNA encoding insulin-like growth factor 1 (IGF1) for use as a medicament comprises the nucleic acid sequence of SEQ ID NO: 8.

[0258] Any of the therapeutic compositions of the present invention may be provided together with an instruction manual or instruction leaflet. The instruction manual / leaflet may include guidance for the skilled person / attending physician on how to treat (or prevent) the disease or disorder (skeletal muscle injury) described herein with the present invention. In particular, the instruction manual / leaflet may include guidance on the delivery / administration method and delivery / administration regimen (e.g., route of delivery / administration, administration regimen, timing of delivery / administration, frequency of delivery / administration) described herein, respectively. In particular, the instruction manual / leaflet may include instructions that the mRNA is injected into skeletal muscle and / or prepared for injection into skeletal muscle, respectively. The instruction manual / leaflet may further include instructions that the mRNA is adjusted for administration during the inflammatory phase following skeletal muscle injury, respectively. In principle, what is stated elsewhere in this specification regarding the delivery / administration method and delivery / administration regimen, respectively, may be included in the instruction manual / leaflet as respective instructions. EXAMPLES

[0259] Example 1 Methods and Materials Cloning of IGF1 and exchange of signaling peptides IGF1 is a 70 amino acid polypeptide that is synthesized in the endoplasmic reticulum and secreted via the Golgi apparatus to act autocrine and paracrine as an extracellular growth factor. To ensure proper expression and secretion of mRNA-induced IGF1 from transfected cells, the mRNA sequence contained the native N-terminal pre-pro sequence of human IGF1 (pre-pro-IGF1). This sequence consisted of a sequence encoding the predomain (signaling peptide) of human IGF1 with 21 amino acids (nucleotides 1-63) and a sequence encoding the human prodomain with 27 amino acids (nucleotides 64-144). In addition, the construct contained a sequence encoding the complete coding sequence of mature human IGF1 with 70 amino acids (nucleotides 145-354). In Cpd.2-7, the predomain (signaling peptide, nucleotides 1-63) was exchanged for the predomain of IGF2, ALB, BDNF, CXCL12, respectively, or synthetic signaling peptide 1 or 2. The C-terminal E domain was not added to the construct. In summary, the cloning vector contained a copy of human pre-pro-IGF1 DNA without E peptide information and was defined as Cpd.1, whereas Cpd.2-7 contained alternative predomains (signaling peptides). Figure 1 illustrates the DNA and RNA sequences of IGF1 encoded by its predomain, prodomain and coding domain. Figure 2 illustrates the DNA and RNA sequences of IGF1 and its prodomain and coding domain encoded by the IGF2 predomain. Figure 3 illustrates the DNA and RNA sequences of IGF1 and its prodomain and coding domain encoded by the ALB predomain. Figure 4 illustrates the DNA and RNA sequences of IGF1 and its prodomain and coding domain encoded by the BDNF predomain. Figure 5 illustrates the DNA and RNA sequences of IGF1 and its prodomain and coding domain encoded by the CXCL12 predomain. Figure 6 illustrates the DNA and RNA sequences of IGF1 and its prodomain and coding domain encoded by the synthetic signaling peptide 1 predomain.FIG. 7 illustrates the DNA and RNA sequences of IGF1 and its pro and coding domains encoded by the synthetic signaling peptide 2 predomain. FIG. 8 illustrates the pVAX.A120 vector (www.thermofisher.com) containing a Cpd.1 insert. FIG. 9 illustrates the pMA-T vector (www.thermofisher.com) containing a Cpd.2 insert. FIG. 10 illustrates the pMA-T vector containing a Cpd.3 insert. FIG. 11 illustrates the pMA-T vector containing a Cpd.4 insert. FIG. 12 illustrates the pMA-T vector containing a Cpd.5 insert. FIG. 13 illustrates the pMA-RQ vector (www.thermofisher.com) containing a Cpd.6 insert. FIG. 14 illustrates the pMA-RQ vector (www.thermofisher.com) containing a Cpd.6 insert. FIG. 15 illustrates the primers utilized to amplify Cpd.2-7. Figure 16 summarizes the identification of the various predomains, showing the gene name, UniProt number, DNA and amino acid sequences of the predomain, and vector. For Cpd.6 and Cpd.7, there are no gene names as these were artificial predomains. Codon optimization of the DNA and mRNA sequences of Cpd.1-7 was performed using GeneOptimizer® (ThermoFischer, MA).

[0260] The open reading frame of the pre-pro-IGF1 DNA sequence was synthesized from GeneArt (www.thermofisher.com, ThermoFischer, MA) containing BamHI and EcoRI restriction enzyme recognition sites and subcloned into the pVAX1.A120 vector using the same restriction enzymes. The DNA sequence of the entire vector is shown in Figure 8. The orientation and base sequence of the cloned insert were confirmed by Sanger sequencing of several clones. Successful clones were selected as templates for in vitro transcribed (IVT) mRNA production. For the alternative predomain variants Cpd.2 to Cpd.7, the pMA-T (Figures 9-12) and pMA-RQ (Figures 13-14) vectors were used as templates for IVT. All IVT reactions resulted in mRNA containing identical polyA120 tails.

[0261] Exchange of signaling peptides in Cpd.8–Cpd.39 mRNA In Cpd.8–26 and Cpd.39, the predomain (signaling peptide, nucleotides 1–63) of IGF1 (i.e., Cpd.1) was expressed in the IL-1 domain of LTBP2 (Cpd.8; Uniprot ID:Q14767), IGFALS (Cpd.9; Uniprot ID:P35858), INS (Cpd.10; Uniprot ID:P01308), Epo (Cpd.11; Uniprot ID:P01588), CSF3 (Cpd.12; Uniprot ID:P09919), NGF (Cpd.13; Uniprot ID:P01138), FGF5 (Cpd.14; Uniprot ID:P12034), FHR2 (Cpd.15; Uniprot ID:P012036), and IL-1 domain of IL-2 (Cpd.16; Uniprot ID:P01170). ID:P36980), IBP5 (Cpd.16; Uniprot ID:P24593), NTF3 (Cpd.17; Uniprot ID:P20783), PATE2 (Cpd.18; Uniprot ID:Q6UY27), SOD3 (Cpd.19; Uniprot ID:P08294), part of the coding sequence of GLR (Cpd.20; Uniprot ID:P47871), modified predomain sequence of IGF1 (Cpd.21; Uniprot ID:P05019), modified predomain sequence of IGF2 (Cpd.22; Uniprot ID:P01344), modified predomain sequence of CXCL12 (Cpd.23; Uniprot ID:P48061), modified predomain sequence of BDNF (Cpd.24; Uniprot ID:P48062), and modified predomain sequence of BDNF (Cpd.25; Uniprot ID:P48063). The predomains of Cpd.8-26 and Cpd.39 were replaced with the respective predomains of IGF1 (Cpd.25; Uniprot ID:P05019), ALPI (Cpd.39; Uniprot ID:P09923) and INS (Cpd.26; Uniprot ID:P01308). As with Cpd.1, all above-specified compounds lacked the E peptide. Codon optimization of DNA and mRNA sequences for Cpd.8-26 and Cpd.39 was performed using GeneOptimizer® (ThermoFischer, MA).

[0262] Cpd.27 consisted of a sequence encoding the predomain (signaling peptide) of human erythropoietin (Epo; Uniprot ID: P01588) with 27 amino acids (nucleotides 1-81), and a sequence encoding the coding chain of human erythropoietin with 166 amino acids (nucleotides 82-498). In Cpd.28 and Cpd.29, the predomain (signaling peptide, nucleotides 1-81) of Epo was exchanged for a modified predomain sequence of Epo (Uniprot ID: P01588) and the predomain sequence of BDNF (Uniprot ID: P23560). Codon optimization of the DNA and mRNA sequences of Cpd.27-29 was performed using GeneOptimizer® (ThermoFischer, MA).

[0263] Cpd.30 consisted of a sequence encoding the predomain (signaling peptide) of human insulin (INS; Uniprot ID: P01308) with 24 amino acids (nucleotides 1-72), a sequence encoding the B-chain domain with 30 amino acids (nucleotides 73-162), a sequence encoding the connecting peptide (C-peptide) domain with 31 amino acids (nucleotides 163-255), and a sequence encoding the A-chain domain with 21 amino acids (nucleotides 256-330). In Cpd.31 and Cpd.32, the predomain (signaling peptide, nucleotides 1-72) of INS was exchanged for a modified predomain sequence of INS (Uniprot ID: P01308) and the predomain sequence of BDNF (Uniprot ID: P23560). Codon optimization of the DNA and mRNA sequences of Cpd.30-32 was performed using GeneOptimizer® (ThermoFischer, MA).

[0264] Cpd.33 consisted of a sequence encoding the predomain (signaling peptide) of human interleukin-4 (IL-4; Uniprot ID: P05112) with 24 amino acids (nucleotides 1-72) and a sequence encoding the coding strand domain with 129 amino acids (nucleotides 73-387). In Cpd.34 and Cpd.35, the predomain (signaling peptide, nucleotides 1-72) of IL-4 was exchanged for a modified predomain sequence of IL-4 (Uniprot ID: P05112) and the predomain sequence of FGF5 (Uniprot ID: P01308). Codon optimization of the DNA and mRNA sequences of Cpd.33-35 was performed using GeneOptimizer® (ThermoFischer, MA).

[0265] Cpd.36 consisted of a sequence encoding the predomain (signaling peptide) of human interleukin-10 (IL-10; Uniprot ID: P22301) with 24 amino acids (nucleotides 1-54), and a sequence encoding the coding strand domain with 160 amino acids (nucleotides 55-534). In Cpd.37 and Cpd.38, the predomain (signaling peptide, nucleotides 1-54) of IL-10 was exchanged for a modified predomain sequence of IL-10 (Uniprot ID: P22301) and the predomain sequence of BDNF (Uniprot ID: P23560). Codon optimization of the DNA and mRNA sequences of Cpd.36-38 was performed using GeneOptimizer® (ThermoFischer, MA).

[0266] The amino acid sequences and DNA sequences of the signal peptides of Cpd.1 to 39, as well as the RNA and DNA sequences and vectors for each of Cpd.1 to 39, are shown in Table 1 below. TIFF2024156665000003.tif254170TIFF2024156665000004.tif163170

[0267] In vitro transcription (IVT) of Cpd.1–Cpd.7 mRNA The pVAX.A120 vector (SEQ ID NO: 15) containing Cpd.1 also has a T7 promoter and a 120 bp long polyA tail, and the vector was linearized using XhoI enzyme downstream of the polyA tail before mRNA production using in vitro transcription (IVT). For pMA-T and pMA-RQ vectors, a homologous primer pair (SEQ ID NO: 22 and 23) was used for PCR-based IVT-mRNA production (Figure 15). The reverse primer contained a 120 bp polyA to include the polyA tail in the mature mRNA. Both the linearized plasmid and the PCR amplicon were used as templates for IVT performed by T7 RNA polymerase from the MEGAscript T7 kit (www.ambion.com). All mRNAs were produced with an anti-reverse CAP analog (ARCA; [m7G(5')G]) at the 5' end and chemically modified with 100% N1-methylpseudo-UTP (www.trilink.com). In vitro transcribed mRNA was purified using the MEGAclear kit (www.ambion.com) and analyzed for quality and concentration using the RNA 6000 Nano kit (www.agilent.com) on an Agilent 2100 Bioanalyzer.

[0268] In vitro transcription (IVT) of Cpd.1 and Cpd.8-Cpd.39 mRNA For the pMA-T and pMA-RQ vectors encoding Cpd.1 (SEQ ID NO: 40; before subcloning into the pVAX.A120 vector) and Cpd.8 to Cpd.39, a homologous primer pair (SEQ ID NO: 22 and 23) was used for PCR-based IVT-mRNA production (Figure 15). The reverse primer contained a 120 bp polyA to include a polyA tail in the mature mRNA. The PCR amplicon was used as a template for IVT performed by T7 RNA polymerase in the MEGAscript T7 kit (www.ambion.com). All mRNAs were produced with an anti-reverse CAP analog at the 5' end (ARCA; [m7G(5')G]) and chemically modified with 100% N1-methylpseudo-UTP (www.trilink.com). In vitro transcribed mRNAs were purified using the MEGAclear kit (www.ambion.com) and analyzed for quality and concentration using RNA agarose gel electrophoresis.

[0269] In vitro transfection of HEK293T, C2C12 and HepG2 cells Human embryonic kidney cells 293 (HEK293T; ATCC, CRL-1573, Rockville, MD, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM, www.biochrom.com) supplemented with 10% (v / v) fetal bovine serum (FBS), and penicillin-streptomycin-amphotericin B mixture (882087, Biozym, Oldendorf, Germany). Cells were seeded at 7,000–20,000 cells / well in 96-well culture plates and incubated at 37 °C in a humidified atmosphere containing 5% CO2 for 24 h before transfection. Cells were grown in DMEM growth medium containing 10% FBS without antibiotics to reach a confluency <60% before transfection.

[0270] The human hepatoma cell line HepG2 (cat. no. 85011430, ECACC UK) was grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and penicillin-streptomycin-amphotericin B mixture (882087, Biozym, Oldendorf, Germany) at 37 °C in a humidified atmosphere containing 5% CO2. HepG2 cells were subcultured every 2 and 5 days at split ratios of 1:2 and 1:4, respectively. Cells were seeded in 96-well microtiter plates at a density of 20,000–40,000 cells / well 24 h prior to transfection. Cells were grown in DMEM growth medium containing 10% FBS without antibiotics to reach 30–40% confluency prior to transfection.

[0271] The mouse myoblast cell line C2C12 (ATCC, CRL-1772, Rockville, MD, USA) was grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and penicillin-streptomycin-amphotericin B mixture (882087, Biozym, Oldendorf, Germany) at 37 °C in a humidified atmosphere containing 5% CO2. C2C12 cells were subcultured every 2 and 5 days at split ratios of 1:2 and 1:4, respectively. Cells were plated in 96-well microtiter plates at a density of 20,000 cells / well 24 h before transfection. Cells were grown in DMEM growth medium containing 2% FBS without antibiotics to reach 80–90% confluency before transfection.

[0272] The cells were then transfected with 0.3 μg of the various mRNA variants using Lipofectamine 2000 (www.invitrogen.com) according to the manufacturer's instructions. 100 μl of DMEM was removed and replaced with 50 μl Opti-MEM and 50 μl mRNA in Opti-MEM and Lipofectamine 2000 complex (www.thermofisher.com). After 5 hours, the medium was replaced with fresh medium and the plates were incubated for 24 hours at 37° C. in a humidified atmosphere containing 5% CO2.

[0273] In vitro transfection of HSkMC cells HSkMC cells were plated in SkM growth medium (PromoCell, Heidelberg, Germany) at a density of 40.000 cells per 96-well microtiter plate. Cells were grown for 1 day in a humidified atmosphere in a 37°C incubator and 5% CO2 until >90% confluence. On the day of transfection, cells were treated with 2 μg of the different mRNA variants (Cpd.1 or 4) using Lipofectamine 2000 (www.invitrogen.com). Therefore, 100 μl medium was removed and 1 μl Lipofectamine / well was added with 2 μg mRNA / well in OPTIMEM medium (www.thermofisher.com). Cells were then incubated for 24 h at 37°C and 5% CO2 in a humidified atmosphere.

[0274] In vitro transfection of IMR32 cells 24 hours prior to transfection, human white neuroblastoma IMR32 cells (cat. no. 86041809, ECACC, UK) were plated at a density of 60,000 cells per well of a 96-precoated BRAND microtiter plate (cat. no. 782082) in Eagle's Minimum Essential Medium (EMEM, Bioconcept cat. no. 1-31S01-I, www.bioconcept.ch) supplemented with 10% (v / v) heat-inactivated fetal bovine serum (FBS), L-glutamine (2 mM) and non-essential amino acids (NEAA, 1x). Cells were grown overnight at 37°C in a humidified atmosphere containing 5% CO2. Cells were transfected with 0.3 μg of mRNA constructs using JetMessenger (www.polyplus-transfection.com) according to the manufacturer's instructions. Briefly, 0.25 μl JetMessenger reagent was mixed per 0.1 μg mRNA construct to form mRNA / JetMessenger complexes. After 15 min incubation at room temperature, JetMessenger complexes were added in 10 μl. 5 h post-transfection, medium / mRNA / JetMessenger was removed from the wells and replaced with 100 μl fresh growth medium, and plates were incubated at 37°C in a humidified atmosphere containing 5% CO2 for 24 h.

[0275] In vitro transfection of A549 cells Human lung cancer cell lines (Sigma-Aldrich, Buchs Switzerland, Cat. No. 6012804) were maintained in Dulbecco's modified Eagle's medium-high glucose (DMEM, Sigma-Aldrich, Buchs Switzerland, Cat. No. D0822) supplemented with 10% FBS (Thermofischer, Basel, Switzerland, Cat. No. 10500-064). 24 h prior to transfection, A549 cells were plated at a density of 10,000 cells / well in regular growth medium. Afterwards, cells were transfected with the various mRNAs (0.3–0.6 μg) using Lipofectamine 2000 (www.invitrogen.com) according to the manufacturer's instructions. 100 μl of DMEM was removed. 50 μl of Opti-MEM (www.thermofisher.com) was added to each well, followed by 50 μl mRNA in Opti-MEM and Lipofectamine 2000 complex. After 5 h of incubation, the medium was replaced with fresh growth medium and the plates were incubated for 24 h at 37° C. in a humidified atmosphere containing 5% CO2.

[0276] In vitro transfection of THP-1 cells The human monocytic leukemia cell line THP-1 (Sigma-Aldrich, Buchs-Switzerland, Cat. No. 88081201) was maintained in growth medium (RPMI 1640 supplemented with 10% FBS and 2 mM glutamine). 72 h prior to transfection, cells were seeded with 30,000 THP-1 cells in 96-well cell culture plates and activated with 50 nM phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, Buchs-Switzerland, Cat. No. P8139) diluted in growth medium. Cells were transfected with mRNA (300–600 ng / well) using Lipofectamine 2000 (www.thermofisher.com) and 100 μl of DMEM was removed. 50 μl of Opti-MEM (www.thermofisher.com) was added to each well, followed by 50 μl of Opti-MEM. The mRNA and Lipofectamine 2000 complexes were added. After 5 hours, the medium was replaced with fresh growth medium supplemented with 50 nM PMA, and the plates were incubated for 24 hours at 37° C. in a humidified atmosphere containing 5% CO2.

[0277] Rat primary spinal cord neurons Pregnant female wild-type Wistar rats (Janvier labs, France) or SOD1G93A Sprague Dawley rats (Taconic Bioscience) at 14 days of gestation were sacrificed using deep anesthesia with CO2 and cervical dislocation. Fetuses were removed from the uterus and immediately placed in ice-cold Leibovitz medium supplemented with 2% penicillin (10,000 U / mL) and streptomycin (10 mg / mL) solution (PS) and 1% bovine serum albumin (BSA). Spinal cords were cut and treated with 0.05% trypsin-0.02% EDTA for 20 min at 37 °C. Dissociation was stopped by the addition of Dulbecco's modified Eagle's medium (DMEM) supplemented with 4.5 g / l glucose, 0.5 mg / mL DNAase I and II, and 10% fetal calf serum (FCS). Cells were mechanically dissociated by forcibly passing the tip of a 10 mL pipette three times. Further, cells were centrifuged at 515 g for 10 min at 4 °C. The resulting pellet was resuspended in chemically defined medium consisting of neurobasal medium containing 2% solution of B27 supplement, 2 mmol / l glutamine, 2% PS solution, and 10 ng / ml brain-derived neurotrophic factor (BDNF). Cells were seeded at 20,000 cells per well in 96-well poly-D-lysine precoated plates and cultured at 37 °C in a humidified atmosphere containing 5% CO2. The medium was replaced every 2 days. After 11–12 days in culture, the cells were transfected with mRNA constructs (0.3 μg) using JetMessenger (www.polyplus-transfection.com) according to the manufacturer's instructions.

[0278] In vitro transfection of human differentiated chondrocytes Human articular chondrocytes (Sigma / Cell Applications, Buchs, Switzerland Cat. No. 402-05A) were maintained in Chondrocyte Growth Medium (Sigma Aldrich, Buchs, Switzerland Cat. No. 411-500). Cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2. Cells were differentiated by growing them on alginate beads (Sigma Aldrich, Buchs, Switzerland Cat. No. A411D-250) in differentiation medium for a minimum of 3 weeks. For the preparation of alginate beads, 4 × 10 6One ml of 1.2% sterile alginate solution (1.2% alginate in 0.9% NaCl Sigma Aldrich, Buchs Switzerland Cat. No. A-2033) was used per chondrocyte. Cells were resuspended in the corresponding volume of 1.2% alginate solution and dispensed dropwise through a 22-gauge needle into 100 mM CaCl2 solution in 6-well untreated cell culture plates. After 15 min, the polymerized beads were washed 5 times with 0.9% NaCl and twice with differentiation medium. The chondrocyte / alginate beads were incubated for differentiation at 37°C in a humidified atmosphere containing 5% CO2 for a minimum of 3 weeks, with medium changed every 2 days. 24 hours prior to transfection, differentiated chondrocytes were washed 2x with 0.9% NaCl and incubated for approximately 5 minutes in alginate lysis buffer (55 mM sodium citrate, 150 mM NaCl, 30 mM EDTA pH 6.8) to release the differentiated chondrocytes from the alginate beads. Cells were washed 2x with 0.9% NaCl. 30,000 cells per well were seeded in 100 μl growth medium in a 96-well TPP plate (Sigma Aldrich, Buchs, Switzerland Cat. No. 92096) and grown overnight. Cells were transfected with 0.6 μg of mRNA construct using JetMessenger (www.polyplus-transfection.com) according to the manufacturer's instructions. 10 μl of mRNA / JetMessenger complex was added in quadruplicates. The mRNA / JetMessenger complexes were formed by mixing 0.25 μl JetMessenger reagent per 0.1 μg mRNA construct and incubating for 15 min at room temperature. Five hours after transfection, the transfection complexes (medium / mRNA / JetMessenger) were removed from the wells and replaced with 100 μl growth medium. The plates were incubated for 24 h at 37°C in a humidified atmosphere containing 5% CO2.

[0279] Analysis of protein levels in cell culture supernatants At 24 h post-transfection, supernatants from transfected cells were collected, frozen and stored at 20°C until quantitative analysis by ELISA according to the manufacturer's instructions for IGF1 (cat. no. E20, Mediagnost, Reutlingen, Germany), erythropoietin (EPO; cat. no. BMS2035, ThermoFisher, Basel, Switzerland), insulin (INS, cat. no. RAB0327, Sigma-Aldrich, Buchs, Switzerland), interleukin-4 (IL-4, cat. no. 88-7046-22, ThermoFisher, Basel, Switzerland) and interleukin-10 (IL-10, cat. no. Kit 10947 Sino Biological, China). After dilution with the respective ELISA buffer, cell supernatants were analyzed.

[0280] Data analysis For estimation of protein (IGF1, EPO, INS, IL-4, IL-10) levels in standards or samples, the average absorbance value of the blank was subtracted from the average absorbance of the standards or samples. Standard curves were generated and plotted using four parameter nonlinear regression according to the manufacturer's protocol. To determine the concentration of protein (IGF1, EPO, INS, IL-4, IL-10) in each sample, the concentrations of the various proteins were interpolated from the standard curve. The final protein concentrations of the samples were calculated by multiplying by the dilution factor. All calculations were performed using GraphPad Prism 8 (San Diego, USA). For the display of fold increase compared to the endogenous signaling peptide construct, the level of protein produced by the individual construct was divided by the level of protein produced by the endogenous signaling peptide construct at the same concentration.

[0281] result Cloning of IGF1 Successful cloning of all inserts into pVAX.A120 was confirmed by Sanger sequencing. All tested clones yielded the correct orientation of the IGF1 insert with 100% sequence accuracy. Positive clones were selected for IVT mRNA production.

[0282] Average hydrophobicity and polarity of Cpd.1-39 The average hydrophobicity of Cpd.1-39 relative to amino acids 1-9, 1-7, and 1-5 at the N-terminus and the last 9 amino acids at the C-terminus of the amino acid sequence of the signal peptide, and the average polarity of Cpd.1-39 relative to amino acids 1-9 at the N-terminus are as shown in Tables 2-5 below. TIFF2024156665000005.tif254170TIFF2024156665000006.tif254170TIFF2024156665000007.tif254170TIFF2024156665000008.tif254170

[0283] In vitro transcription of mRNA The IGF1_pVAX.A120 plasmid was linearized with XhoI and IGF1 mRNA (Cpd.1) was produced using the IVT system. Similarly, IGF1 mRNA with altered predomains (signaling peptides), Cpd.2-Cpd.7 (FIG. 16) encoded by vectors pMA-T and pMA-RQ, were produced in the 50-200 μg range for in vitro transfection experiments using PCR-based IVT. Similarly, IGF1 mRNA with altered signaling peptides, for Cpd.1 (SEQ ID NO: 40) and Cpd.8-26 encoded by pMA-T and pMA-RQ vectors, were produced in the 50-200 μg range for in vitro transfection experiments using PCR-based IVT. In addition to IGF1 mRNA, mRNAs for erythropoietin (EPO, Cpd.27-29), insulin (INS, Cpd.30-32), interleukin 4 (IL4, Cpd.33-35), and interleukin 10 (IL10, Cpd.36-38), with endogenous or altered signaling peptides, were produced in the in vitro transfection experiments using PCR-based IVT. A range of 50-200 μg was produced for vitro transfection experiments.

[0284] In vitro transfection of HEK293T cells to test IGF1 secretion After incubation of HEK293T cells with Cpd.1-Cpd.7 mRNA for 24 hours, secreted IGF1 levels were evaluated in the cell culture supernatant (Figure 17). Cpd.1 was able to induce IGF1 secretion up to 50ng / ml. Cpd.4 induced significantly higher IGF1 secretion than Cpd.1 (3.3-fold, 0.001). To evaluate the concentration dependency of Cpd.1 and Cpd.4, various concentrations (0.02-2μg / well) of both Cpd.1 and Cpd.4 were tested for induction of IGF1 secretion into the supernatant (Figure 18). Cpd.1 had an EC of 0.89μg. 50 and an EC of 0.13 μg for Cpd.4. 50 17 and 18, demonstrating that Cpd.4 was 6.8-fold more potent in inducing IGF1 secretion from HEK293T cells. Collectively, the data in Figures 17 and 18 demonstrate that Cpd.4 induced IGF1 secretion in HEK293T cells more strongly and potently than Cpd.1, suggesting that this signaling peptide facilitates cellular export of produced IGF1 in this cell type.

[0285] In vitro transfection of C2C12 cells for testing IGF1 secretion After incubation of C2C12 cells with Cpd.1–Cpd.7 mRNA for 24 h, secreted IGF1 levels were evaluated in the cell culture supernatants (Figure 19). Cpd.1 was able to induce IGF1 secretion up to 60 ng / ml. Cpd.4 induced significantly higher IGF1 secretion than Cpd.1 (6.1-fold, 0.001). The data demonstrate that Cpd.4 induced stronger IGF1 secretion in C2C12 cells than Cpd.1, suggesting that this signaling peptide facilitates cellular export of produced IGF1 also in this cell type.

[0286] In vitro transfection of HSkMC cells for testing IGF1 secretion After incubation of HSkMC cells with Cpd.1 or Cpd.4 mRNA for 24 hours, secreted IGF1 levels were assessed in the cell culture supernatants (Figure 20). Cpd.1 was able to induce IGF1 secretion up to 30ng / ml. Cpd.4 induced significantly higher IGF1 secretion than Cpd.1 (3.1-fold, p<0.05). The data demonstrate that Cpd.4 induced stronger IGF1 secretion in primary HSkMC cells than Cpd.1, suggesting that this signaling peptide facilitates cellular export of produced IGF1 in this cell type as well.

[0287] In vitro transfection of additional mRNA into HEK293T cells to test IGF1 secretion In another set of tests, Cpd.8–Cpd.26 were analyzed for their potential for regulating IGF1 secretion from HEK293T cells. After 24 h of incubation with Cpd.1 as a control and Cpd.8–Cpd.26 as test mRNAs, secreted IGF1 levels were assessed in cell culture supernatants (Figure 22). Cpd.1 responses were normalized to 1 and data were expressed as fold change of Cpd.1. Whereas Cpd.8, Cpd.9, Cpd.10, Cpd.11, Cpd.12 and Cpd13 showed a decrease in IGF1 secretion, Cpd.14, Cpd.15, Cpd.16, Cpd.17, Cpd.18, Cpd.19, Cpd.20, Cpd.21, Cpd.23, Cpd.24, Cpd.25 and Cpd.26 were able to induce significantly higher IGF1 secretion up to 2.6-fold compared to Cpd.1. In that regard, Cpd.15 and Cpd.21 showed a similar induction as Cpd.4 (see FIG. 17). Taken together, the data demonstrate that Cpd.14, Cpd.15, Cpd.16, Cpd.17, Cpd.18, Cpd.19, Cpd.20, Cpd.21, Cpd.23, Cpd.24, Cpd.25 and Cpd.26 induced stronger and more potent IGF1 secretion in HEK293T cells than Cpd.1, suggesting that these signaling peptides facilitate cellular export of produced IGF1 in this cell type.

[0288] In vitro transfection of HepG2 cells for testing IGF1 secretion After 24 h incubation of HepG2 cells with Cpd.1 as a control and Cpd.4–Cpd.26 as test mRNAs, secreted IGF1 levels were assessed in the cell culture supernatants (Figure 23). Cpd.1 responses were normalized to 1 and data were expressed as fold change of Cpd.1. Whereas Cpd.8, Cpd.9, and Cpd.12 showed reduced IGF1 secretion, Cpd.4, Cpd.14, Cpd.15, Cpd.16, Cpd.17, Cpd.18, Cpd.19, Cpd.20, Cpd.21, Cpd.22, Cpd.23, Cpd.24, Cpd.25, and Cpd.26 were able to induce significantly higher IGF1 secretion up to 8.3-fold compared to Cpd.1. Taken together, the data demonstrate that Cpd.4, Cpd.14, Cpd.15, Cpd.16, Cpd.17, Cpd.18, Cpd.19, Cpd.20, Cpd.21, Cpd.22, Cpd.23, Cpd.24, Cpd.25 and Cpd.26 induced stronger IGF1 secretion in HepG2 cells than Cpd.1, suggesting that these signaling peptides facilitate cellular export of produced IGF1 in this cell type.

[0289] In vitro transfection of IMR32 neuronal cells to test IGF1 secretion After 24 h incubation of IMR324 neuronal cells with Cpd.1 as a control and Cpd.4–Cpd.24 as test mRNAs, secreted IGF1 levels were assessed in cell culture supernatants (Figure 24). Cpd.1 responses were normalized to 1 and data were expressed as fold change of Cpd.1. Cpd.4, Cpd.14, Cpd.15, Cpd.16, Cpd.17, Cpd.20, Cpd.22, Cpd.23 and Cpd.24 were able to induce significantly higher IGF1 secretion up to 2.6-fold compared to Cpd.1. Taken together, the data demonstrate that Cpd.4, Cpd.14, Cpd.15, Cpd.16, Cpd.17, Cpd.20, Cpd.22, Cpd.23 and Cpd.24 induced stronger IGF1 secretion in IMR32 neuronal cells than Cpd.1, suggesting that these signaling peptides facilitate cellular export of produced IGF1 in this cell type.

[0290] In vitro transfection of human chondrocytes to test for IGF1 secretion After 24 h incubation of chondrocytes with Cpd.1 as control and Cpd.4–Cpd.25 as test mRNAs, secreted IGF1 levels were assessed in cell culture supernatants (Figure 25). Cpd.1 responses were normalized to 1 and data were expressed as fold change of Cpd.1. Cpd.4, Cpd.14, Cpd.15, Cpd.16, Cpd.20, Cpd.21, Cpd.22, Cpd.24 and Cpd.25 were able to induce significantly higher IGF1 secretion compared to Cpd.1 by up to 1.9-fold. Taken together, the data demonstrate that Cpd.4, Cpd.14, Cpd.15, Cpd.16, Cpd.20, Cpd.21, Cpd.22, Cpd.24 and Cpd.25 induced stronger IGF1 secretion in chondrocytes than Cpd.1, suggesting that these signaling peptides facilitate cellular export of produced IGF1 in this cell type.

[0291] In vitro transfection of rat motoneurons for testing IGF1 secretion. Rat motor neurons or rat transgenic / recombinant SOD1 G93A (FIG. 26B) were compared with Cpd.1 as a control and Cpd.4, Cpd.14 and Cpd.17 (FIG. 26A) versus wild type or transgenic / recombinant SOD1 as test mRNAs. G93A Secreted IGF1 levels were assessed in cell culture supernatants after 48 h incubation with Cpd.14 and Cpd.17 against SOD1G (Figure 26B). Cpd.1 responses were normalized to 1 and data were expressed as fold change of Cpd.1. Cpd.4, Cpd.14 and Cpd.17 increased IGF1 secretion up to 4.3-fold in wild type or 1.2-fold in transgenic / recombinant SOD1G compared to Cpd.1. S93A We were able to induce IGF1 secretion in motor neurons up to 9.3-fold with Cpd.4, Cpd.14, and Cpd.17. Collectively, the data demonstrate that Cpd.4, Cpd.14, and Cpd.17 induced IGF1 secretion in motor neurons more strongly than Cpd.1, suggesting that these signaling peptides facilitate the cellular export of produced IGF1 in this cell type.

[0292] In vitro transfection of HEK293T, HepG2 and A549 cells for testing EPO secretion After 24-hour incubation of HEK293T, HepG2 or A549 cells with Cpd.27 as a control and Cpd.28 and Cpd.29 as test mRNAs, secreted erythropoietin (EPO) levels were assessed in cell culture supernatants (Figure 27). Cpd.27 responses were normalized to 1, and data were expressed as fold changes of Cpd.27. Cpd.28 could induce EPO secretion up to 1.8-fold compared to Cpd.27 in HEK293T cells (Figure 27A), HepG2 cells (Figure 27B) and A549 cells (Figure 27C), and Cpd.29 induced EPO secretion up to 1.4-fold compared to Cpd.27 in HEK293T cells (Figure 27A) and HepG2 cells (Figure 27B). Taken together, the data demonstrate that Cpd.28 and Cpd.29 induced stronger EPO secretion than Cpd.27, suggesting that these signaling peptides facilitate cellular export of produced EPO in these cell types.

[0293] In vitro transfection of HEK293T cells to test INS secretion After 24 hours of incubation of HEK293T cells with Cpd.30 as a control and Cpd.31 and Cpd.32 as test mRNAs, secreted insulin (INS) levels were assessed in cell culture supernatants (Figure 28). Cpd.30 responses were normalized to 1, and data were expressed as fold changes of Cpd.30. Cpd.31 and Cpd.32 were able to induce INS secretion up to 3.9-fold compared to Cpd.30 in HEK293T cells. Taken together, the data demonstrated that Cpd.31 and Cpd.32 induced stronger INS secretion than Cpd.30, suggesting that these signaling peptides facilitate cellular export of produced INS in this cell type.

[0294] In vitro transfection of HEK293T, HepG2, THP-1 and A549 cells for testing IL4 secretion After 24-hour incubation of HEK293T, HepG2, THP-1 or A549 cells with Cpd.33 as a control and Cpd.34 and Cpd.35 as test mRNAs, secreted interleukin 4 (IL4) levels were assessed in cell culture supernatants (Figure 29). Cpd.33 responses were normalized to 1 and data were expressed as fold changes of Cpd.33. Cpd.34 could induce IL4 secretion up to 2.2-fold compared to Cpd.33 in HEK293T cells (Figure 29A), HepG2 cells (Figure 29B), THP-1 cells (Figure 29C) and A549 cells (Figure 29D), and Cpd.35 induced IL4 secretion up to 1.3-fold compared to Cpd.33 in HepG2 cells (Figure 29B) and THP-1 cells (Figure 29C), respectively. Taken together, the data demonstrate that Cpd.34 and Cpd.35 induced stronger IL4 secretion than Cpd.33, suggesting that these signaling peptides facilitate cellular export of produced IL4 in these cell types.

[0295] In vitro transfection of HEK293T, HepG2 and THP-1 cells for testing IL10 secretion After 24-hour incubation of HEK293T, HepG2 or THP-1 cells with Cpd.36 as a control and Cpd.37 and Cpd.38 as test mRNAs, secreted interleukin 10 (IL10) levels were assessed in cell culture supernatants (Figure 30). Cpd.36 responses were normalized to 1 and data were expressed as fold changes of Cpd.36. Cpd.37 could induce IL10 secretion up to 2.2-fold compared to Cpd.36 in HEK293T cells (Figure 30A), HepG2 cells (Figure 30B) and THP-1 cells (Figure 30C), and Cpd.38 induced IL10 secretion 1.4-fold compared to Cpd.36 in THP-1 cells (Figure 30C). Taken together, the data demonstrate that Cpd.37 and Cpd.38 induced stronger IL10 secretion than Cpd.36, suggesting that these signaling peptides facilitate cellular export of produced IL10 in these cell types.

[0296] In vitro transfection of Cpd.39 into HepG2 and human primary chondrocytes to test IGF1 secretion After 24-hour incubation of HepG2 or chondrocytes with Cpd.1 as a control and Cpd.39 as a test mRNA, secreted IGF1 levels were assessed in the cell culture supernatants (Figure 31). Cpd.1 responses were normalized to 1, and data were expressed as fold changes of Cpd.1. Cpd.39 was able to induce significantly higher IGF1 secretion compared to Cpd.1 up to 1.4-fold in HepG2 (Figure 31A) and human primary chondrocytes (Figure 31B). Taken together, the data demonstrated that Cpd.39 induced stronger IGF1 secretion than Cpd.1, suggesting that this signaling peptide facilitates cellular export of produced IGF1 in these cell types.

[0297] Example 2 To test the efficacy of locally applied IGF-I mRNA in a mouse model of skeletal muscle injury, 8-10 week old male C57BL6 / J mice were subjected to notexin-induced myotoxic injury of the tibialis anterior (TA) muscle on day 0. On day 1 post-injury, vehicle or 1 µg mRNA (Cpd.4) was applied by intramuscular injection into the injured muscle and repeated on day 4 post-injury. TA muscle function was measured on days 1, 4, 7, 10, 14, 21 and 28 post-injury. A subset of contralateral TA muscles was also evaluated throughout the study to assess healthy control levels of TA muscle function.

[0298] Methods and Materials Cloning of IGF-1 and in vitro transcription of IGF-1 mRNA Cloning of IGF-1 and in vitro transcription of IGF-1 mRNA was performed as described in Example 1. Codon-optimized DNA of Cpd.4 (Figure 4) was used to clone into the pMA-T vector, resulting in the construct shown in Figure 11. This construct was used to produce in vitro transcribed mRNA used for mRNA treatments.

[0299] Notexin damage Notexin (Latoxan, Balance, France) was prepared at a concentration of 0.4 μg in 40 μl saline per mouse. Mice were anesthetized by induction in a chamber (approximately 4–5% isoflurane, until effective) and maintained by a nose cone (approximately 2–3% isoflurane, until effective). Mice were then maintained on a heated (37°C) operating table. The skin over the mid-ventral portion of the TA muscle was prepared with a depilatory cream (Nair Hair Remover for 45 seconds, followed by three rinses with water) and further prepared by three alternating washes with betadine and 70% alcohol to prevent dissemination of skin bacteria to the soft tissue. Using a tuberculin syringe, 0.04 ml of the prepared notexin was injected intramuscularly into the ventral portion of the right TA. During the procedure, the animals suffered no observable pain and were subsequently administered the appropriate anti-pain treatment (buprenorphine 0.05–0.1 mg / kg every 12 hours for 48 hours after injection). The first dose of analgesic was administered at the time of anesthetic induction to ensure its presence during recovery. After the first 48 hours, animals were examined at least twice weekly to ensure proper healing and return of normal ambulation.

[0300] mRNA treatment Mice were randomized to receive mRNA or vehicle treatment. Mice were anesthetized using isoflurane as described above and the injured TA muscle received a single intramuscular injection of mRNA or vehicle treatment in the middle of the muscle.

[0301] Assessment of in vivo TA function Muscle performance was measured in vivo with a 305C muscle lever system (Aurora Scientific Inc., Aurora, Canada) at 1, 4, 7, 10, 14, 21 and 28 days after injury. Mice were anesthetized as described above and placed on a thermostatically controlled platform. The knee was insulated using a pin pressed against the tibial head and the foot was firmly fixed to the footplate of the motor shaft. Contractions of the dorsiflexor muscles were induced by percutaneous electrical stimulation of the peroneal nerve. Optimal isometric twitch torque was determined by increasing current with a minimum of 30 seconds between contractions to avoid fatigue. A train of stimuli was then delivered at increasing stimulation frequencies (0.2 ms pulses, 500 ms train duration): 1, 10, 20, 40, 60, 80, 100, 150 Hz, followed by a final stimulus of 1 Hz. Maximum peak isometric muscle force was plotted.

[0302] Data analysis Data were grouped and means and standard errors were calculated. Statistical analysis was performed using GraphPad Prism 8 (San Diego, USA). Comparisons were made using Student's t-test.

[0303] result Example 2 shows that in a mouse model of toxin (notexin)-induced TA muscle injury, intramuscular IGF-I mRNA treatment on days 1 and 4 early after muscle injury resulted in accelerated and complete recovery of muscle function (Figure 21). Animals treated with 1 μg Cpd.4 reached a functional level in the healthy range over the course of 16 days. In contrast, vehicle-treated control animals and low-dose treated mice did not achieve complete functional recovery even by day 28. The data therefore indicate that IGF-I mRNA treatment can accelerate healing after muscle injury and potentially prevent chronic disorders by fully restoring muscle function. Surprisingly, it only requires two early doses after injury.

Claims

1. An mRNA comprising a nucleic acid sequence encoding a protein and a signal peptide, The amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. The mRNA is selected from the group consisting of:

2. The mRNA of claim 1, wherein amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide have an average polarity of 6.1 or less.

3. The mRNA according to claim 1 or 2, wherein the average hydrophobicity score of the last nine amino acids at the C-terminus of the amino acid sequence of the signal peptide is at least 1.0 unit lower than the average hydrophobicity score of amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide.

4. The mRNA according to any one of claims 1 to 3, wherein amino acids 1 to 9, amino acids 2 to 10, amino acids 3 to 11, amino acids 4 to 12, and amino acids 5 to 13 at the N-terminus of the amino acid sequence of the signal peptide each have an average hydrophobicity score of greater than 1.

5.

5. 5. The mRNA according to claim 1, wherein the average hydrophobicity score of the amino acids 8 to 16 at the N-terminus of the amino acid sequence of the signal peptide is equal to or lower than the average hydrophobicity score of the amino acids 3 to 11 at the N-terminus of the amino acid sequence of the signal peptide.

6. 5. The mRNA according to claim 1, wherein the signal peptide comprises an amino acid sequence of 18 to 40 amino acids in length, and the average hydrophobicity score of the N-terminal amino acids 10 to 18 of the amino acid sequence of the signal peptide is at least 0.5 units lower than the average hydrophobicity score of the N-terminal amino acids 3 to 11 of the amino acid sequence of the signal peptide.

7. 7. The mRNA according to any one of claims 1 to 6, wherein the average hydrophobicity score of the last 9 amino acids at the C-terminus of the amino acid sequence of the signal peptide is at least 1.5 units lower than the average hydrophobicity score of amino acids 3 to 11 at the N-terminus of the amino acid sequence of the signal peptide.

8. 8. The mRNA of claim 1 , wherein the average hydrophobicity score of any nine consecutive amino acids in the amino acid sequence of the signal peptide does not exceed 4.

1.

9. 9. An mRNA according to any one of claims 1 to 8, wherein the last nine amino acids at the C-terminus of the amino acid sequence of the signal peptide contain at least one amino acid having a negative hydrophobicity score.

10. 10. The mRNA of claim 9, wherein at least one amino acid having a negative hydrophobicity score is selected from the group consisting of G, Q, N, T, S, R, K, H, D, E, P, Y and W.

11. The mRNA according to any one of claims 1 to 10, wherein the second amino acid of amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide is selected from the group consisting of P, Y, W, S, T, G, A, M, C, F, L, V and I.

12. The mRNA according to any one of claims 1 to 10, wherein the second amino acid among amino acids 1 to 9 at the N-terminus of the amino acid sequence of the signal peptide is selected from the group consisting of A, L, S, T, V and W.

13. 13. The mRNA according to any one of claims 1 to 12, wherein the signal peptide is ii) a signal peptide homologous to said protein, which is modified by at least one amino acid insertion, deletion and / or substitution, and wherein the average hydrophobicity score of the N-terminal amino acids 1 to 9 of the amino acid sequence of the modified signal peptide homologous to said protein is at least 1.0 unit higher than the average hydrophobicity score of the N-terminal amino acids 1 to 9 of the amino acid sequence of the signal peptide without the modification.

14. 14. The mRNA of any one of claims 1 to 13 or 2 to 13, wherein the hydrophobicity score is calculated according to the Kyte-Durial scale and the polarity is calculated according to the Zimmerman polarity index.

15. 15. The mRNA of any one of claims 1 to 14, wherein the signal peptide is i) a heterologous signal peptide to said protein, selected from the group consisting of the signal peptide of brain-derived neurotrophic factor (BDNF), the signal peptide of neurotrophin-3 (NTF-3), the signal peptide of fibroblast growth factor 5 (FGF5), the signal peptide of insulin-like growth factor binding protein 5 (IBP5), the signal peptide of prostate- and testis-expressed protein 2 (PATE2), the signal peptide of extracellular superoxide dismutase (SOD3), and the signal peptide of complement factor H-related protein 2 (FHR2).

16. 15. The mRNA of any one of claims 1 to 14, wherein the signal peptide is i) a signal peptide heterologous to said protein, wherein said signal peptide heterologous to said protein is modified by at least one amino acid insertion, deletion and / or substitution, and wherein said signal peptide heterologous to said protein is a signal peptide heterologous to said protein selected from the group consisting of the signal peptide of C-X-C motif chemokine ligand 12 (CXCL12), the signal peptide of insulin growth factor 2 (IGF2), the signal peptide of insulin (INS), and the signal peptide of brain-derived neurotrophic factor (BDNF).

17. 15. The mRNA of any one of claims 1 to 14, wherein the signal peptide is ii) a signal peptide homologous to said protein, which is modified by at least one amino acid insertion, deletion and / or substitution, and wherein said signal peptide homologous to said protein and said protein are selected from the group consisting of the signal peptide of insulin growth factor 1 (IGF1) and IGF1, the signal peptide of insulin and INS, the signal peptide of erythropoietin (EPO) and EPO, the signal peptide of interleukin 4 (IL-4) and IL-4, and the signal peptide of interleukin 10 (IL-10) and IL-10.

18. 15. The mRNA according to any one of claims 1 to 14, wherein the signal peptide is iii) a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature, the naturally occurring amino acid sequence being modified, as necessary, by insertion, deletion and / or substitution of at least one amino acid, the naturally occurring amino acid sequence being a naturally occurring amino acid sequence selected from the group consisting of the propeptide of insulin growth factor 1 (IGF1), the coding sequence of the glucagon receptor (GL-R) and the propeptide of intestinal alkaline phosphatase (ALPI).

19. 19. The mRNA of any one of claims 1 to 18, wherein the signal peptide is i) a signal peptide heterologous to the protein, optionally modified by insertion, deletion and / or substitution of at least one amino acid, and wherein the amount of secreted protein when a signal peptide heterologous to the protein is used is greater than the amount of secreted protein when a signal peptide homologous to the protein is used.

20. 19. The mRNA of any one of claims 1 to 18, wherein the signal peptide is ii) a signal peptide homologous to the protein, wherein the signal peptide homologous to the protein is modified by the insertion, deletion and / or substitution of at least one amino acid, and wherein the amount of secreted protein when the modified signal peptide homologous to the protein is used is greater than the amount of the secreted protein when a signal peptide homologous to the protein without the modification is used.

21. 19. The mRNA according to any one of claims 1 to 18, wherein the signal peptide is iii) a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature, which naturally occurring amino acid sequence is modified, as necessary, by the insertion, deletion and / or substitution of at least one amino acid, and the amount of secreted protein when a naturally occurring amino acid sequence that does not have a function of a signal peptide in nature is used is greater than the amount of said secreted protein when a signal peptide homologous to said protein is used.

22. 22. The mRNA according to any one of claims 1 to 21, wherein the signal peptide is i) a signal peptide heterologous to said protein, optionally modified by insertion, deletion and / or substitution of less than 50% of the number of amino acids of the amino acid sequence of the signal peptide heterologous to said protein.

23. 22. The mRNA according to any one of claims 1 to 21, wherein the signal peptide is ii) a signal peptide homologous to said protein, which is modified by insertion, deletion and / or substitution of less than 50% of the number of amino acids of the amino acid sequence of the signal peptide homologous to said protein.

24. 22. The mRNA according to any one of claims 1 to 21, wherein the signal peptide is iii) a naturally occurring amino acid sequence that does not have the function of a signal peptide in nature, and which is optionally modified by insertion, deletion and / or substitution of less than 50% of the number of amino acids of the naturally occurring amino acid sequence.

25. 25. The mRNA of any one of claims 1 to 24, wherein the protein is selected from the group consisting of cytokines, growth factors and hormones.

26. 26. The mRNA of any one of claims 1 to 25, wherein the signal peptide is i) a signal peptide heterologous to said protein, said protein being selected from the group consisting of insulin growth factor 1 (IGF1), insulin (INS), erythropoietin (EPO), interleukin-4 (IL-4) and interleukin-10 (IL-10).

27. 26. The mRNA of any one of claims 1 to 25, wherein the signal peptide is i) a signal peptide heterologous to the protein, wherein the signal peptide heterologous to the protein is modified by the insertion, deletion and / or substitution of at least one amino acid, and wherein the protein is IGF1.

28. 28. The mRNA of any one of claims 1 to 27, wherein the signal peptide is iii) a naturally occurring amino acid sequence that does not have a signal peptide function in nature, the naturally occurring amino acid sequence being optionally modified by the insertion, deletion and / or substitution of at least one amino acid, and the protein is IGF1.

29. The mRNA according to any one of claims 1 to 5 and claims 7 to 28, wherein the signal peptide comprises an amino acid sequence of 16 to 40 amino acids in length.

30. A transcription unit, expression vector or gene therapy vector comprising a nucleic acid encoding a protein and a signal peptide, wherein the N-terminal amino acids 1-9 of the amino acid sequence of the signal peptide have an average hydrophobicity score of greater than 2, and the signal peptide comprises i) a signal peptide heterologous to said protein, optionally modified by the insertion, deletion and / or substitution of at least one amino acid, with the proviso that said protein is not an oxidoreductase; ii) a signal peptide homologous to said protein, the signal peptide being modified by the insertion, deletion and / or substitution of at least one amino acid; and iii) naturally occurring amino acid sequences which do not naturally have the function of a signal peptide, optionally modified by the insertion, deletion and / or substitution of at least one amino acid. A transcription unit, expression vector or gene therapy vector selected from the group consisting of:

31. A therapeutic composition comprising an mRNA according to any one of claims 1 to 29 and / or a transcription unit, expression vector or gene therapy vector according to claim 30.

32. A kit comprising an mRNA according to any one of claims 1 to 29 and / or a transcription unit, expression vector or gene therapy vector according to claim 30, and / or a therapeutic composition according to claim 31 and instructions for use, optionally a vector map, optionally host cells, optionally medium for culturing the host cells, and / or optionally a selection medium for selecting and culturing the transfected host cells.

33. i) a protein; and ii) a signal peptide heterologous to said protein An mRNA comprising a nucleic acid sequence encoding The signal peptide heterologous to said protein is the signal peptide of brain-derived neurotrophic factor (BDNF), and said protein is not an oxidoreductase, mRNA.

34. i) a protein; and ii) a signal peptide heterologous to said protein An mRNA comprising a nucleic acid sequence encoding The signal peptide heterologous to the protein is the signal peptide of brain-derived neurotrophic factor (BDNF), and the protein is an mRNA selected from the group consisting of carboxypeptidases; cytokines; extracellular ligands and transporters; extracellular matrix proteins; glucosidases; glycosyltransferases; growth factors; growth factor binding proteins; heparin binding proteins; hormones; hydrolases; immunoglobulins; isomerases; kinases; lyases; metalloenzyme inhibitors; metalloproteases; milk proteins; neuroactive proteins; proteases; protease inhibitors; protein phosphatases; esterases; transferases; and vasoactive proteins.

35. 35. The mRNA of claim 33 or 34, wherein the protein is selected from the group consisting of: cytokines; growth factors; growth factor binding proteins; heparin binding proteins; hormones; neuroactive proteins; and vasoactive proteins.

36. 35. The mRNA of claim 33 or 34, wherein the protein is a growth factor.

37. Growth factors include AMH, ARTN, BTC, CDNF, CFC1, CFC1B, CHRDL1, CHRDL2, CLEC11A, CNMD, EFEMP1, EGFL6, EGFL7, EGFL8, EPGN, EREG, EYS, FGF1, FGF10, FGF16, FGF17, FGF18, FGF19, FGF2, FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FRZB, GDNF, GFER, GKN1, HBEGF, IGF1, IGF2, INHA, INHBA, INHBB, INHBC, 37. The mRNA of claim 36, selected from the group consisting of INHBE, KITLG, MANF, MDK, MIA, NGF, NOV, NRG1, NRG2, NRG3, NRG4, NRTN, NTF3, NTF4, OGN, PDGFA, PDGFB, PDGFC, PDGFD, PGF, PROK1, PSPN, PTN, SDF1, SDF2, SFRP1, SFRP2, SFRP3, SFRP4, SFRP5, TDGF1, TFF1, TGFA, TGFB1, TGFB2, TGFB3, THBS4, TIMP1, VEGFA, VEGFB, VEGFC, VEGFD, and WISP3.

38. 35. The mRNA of claim 33 or 34, wherein the protein is IGF1.

39. 39. An mRNA according to any one of claims 33 to 38, wherein the signal peptide of brain-derived neurotrophic factor (BDNF) comprises the amino acid sequence set forth in SEQ ID NO:

31.

40. 40. The mRNA of any one of claims 33 to 39, wherein a nucleic acid sequence encoding a protein and a nucleic acid sequence encoding a signal peptide of brain-derived neurotrophic factor (BDNF) heterologous to the protein are operably linked.

41. From 5' to 3', in the following order: i) the signal peptide of brain-derived neurotrophic factor (BDNF); ii) optionally a prodomain of the protein; and iii) Mature Protein comprising a nucleic acid sequence encoding A nucleic acid sequence encoding the signal peptide of brain-derived neurotrophic factor (BDNF), optionally 41. The mRNA of any one of claims 33 to 40, wherein the nucleic acid sequence encoding the prodomain of the protein and the nucleic acid sequence encoding the mature protein are operably linked.

42. 42. An mRNA according to any one of claims 33 to 41, comprising a nucleic acid sequence encoding the propeptide of IGF1, a nucleic acid sequence encoding mature IGF1, and a nucleic acid sequence encoding the signal peptide of brain-derived neurotrophic factor (BDNF), but not including a nucleic acid sequence encoding the E peptide of IGF1.

43. 43. An mRNA according to any one of claims 33 to 42, wherein the signal peptide of brain-derived neurotrophic factor (BDNF) replaces the natural signal peptide of the protein.

44. 1. A transcription unit, expression vector or gene therapy vector comprising a nucleic acid sequence encoding a protein and a signal peptide heterologous to said protein, wherein the signal peptide heterologous to said protein is the signal peptide of brain-derived neurotrophic factor (BDNF), and said protein is not an oxidoreductase.

45. A transcription unit, expression vector or gene therapy vector comprising a nucleic acid sequence encoding a protein and a signal peptide heterologous to said protein, wherein the signal peptide heterologous to said protein is the signal peptide of brain-derived neurotrophic factor (BDNF), and said protein is selected from the group consisting of carboxypeptidases; cytokines; extracellular ligands and transporters; extracellular matrix proteins; glucosidases; glycosyltransferases; growth factors; growth factor binding proteins; heparin binding proteins; hormones; hydrolases; immunoglobulins; isomerases; kinases; lyases; metalloenzyme inhibitors; metalloproteases; milk proteins; neuroactive proteins; proteases; protease inhibitors; protein phosphatases; esterases; transferases; and vasoactive proteins.

46. A therapeutic composition comprising an mRNA according to any one of claims 33 to 43 and / or a transcription unit, expression vector or gene therapy vector according to claims 44 or 45.

47. A kit comprising an mRNA according to any one of claims 33 to 43 or a transcription unit according to claims 44 or 45, an expression vector or a gene therapy vector, and / or a therapeutic composition according to claim 46 and instructions for use, optionally a vector map, optionally host cells, optionally a medium for culturing the host cells, and / or optionally a selection medium for selecting and culturing the transfected host cells.

48. An mRNA according to any one of claims 1 to 28 or 33 to 43, a transcription unit, an expression vector or a gene therapy vector according to any one of claims 30 or 44 to 45, a therapeutic composition according to claim 31 or 46, or a kit according to claim 32 or 47 for use as a medicament.

49. 43. An mRNA according to any one of claims 1 to 29 or claims 38 or 42 for use in a method for treating skeletal muscle injury.

50. mRNA for use in a method for treating skeletal muscle injury.

51. A therapeutic composition comprising mRNA for use in a method for treating skeletal muscle injury.

52. 52. The mRNA or composition for use according to claim 50 or 51, wherein the mRNA is an mRNA encoding human insulin-like growth factor 1 (IGF1).

53. 53. The mRNA or composition for use according to claim 52, wherein the mRNA encoding human IGF1 comprises a nucleic acid sequence encoding a signal peptide, optionally a nucleic acid sequence encoding a propeptide of human IGF1, and a nucleic acid sequence encoding mature human IGF1.

54. 54. The mRNA or composition for use according to claim 53, wherein the nucleic acid sequence encoding a signal peptide encodes the signal peptide of brain-derived neurotrophic factor (BDNF).